6	XIAFLEX.xml:S1:4:1	O
ADVERSE	XIAFLEX.xml:S1:6:7	O
REACTIONS	XIAFLEX.xml:S1:14:9	O

The	XIAFLEX.xml:S1:27:3	O
following	XIAFLEX.xml:S1:31:9	O
serious	XIAFLEX.xml:S1:41:7	O
adverse	XIAFLEX.xml:S1:49:7	O
reactions	XIAFLEX.xml:S1:57:9	O
in	XIAFLEX.xml:S1:67:2	O
patients	XIAFLEX.xml:S1:70:8	O
with	XIAFLEX.xml:S1:79:4	O
Dupuytren	XIAFLEX.xml:S1:84:9	O
's	XIAFLEX.xml:S1:93:2	O
contracture	XIAFLEX.xml:S1:96:11	O
are	XIAFLEX.xml:S1:108:3	O
discussed	XIAFLEX.xml:S1:112:9	O
in	XIAFLEX.xml:S1:122:2	O
greater	XIAFLEX.xml:S1:125:7	O
detail	XIAFLEX.xml:S1:133:6	O
elsewhere	XIAFLEX.xml:S1:140:9	O
in	XIAFLEX.xml:S1:150:2	O
the	XIAFLEX.xml:S1:153:3	O
labeling	XIAFLEX.xml:S1:157:8	O
:	XIAFLEX.xml:S1:165:1	O

Tendon	XIAFLEX.xml:S1:174:6	B-AdverseReaction
ruptures	XIAFLEX.xml:S1:181:8	I-AdverseReaction
or	XIAFLEX.xml:S1:190:2	O
other	XIAFLEX.xml:S1:193:5	O
serious	XIAFLEX.xml:S1:199:7	B-Severity
injury	XIAFLEX.xml:S1:207:6	B-AdverseReaction
to	XIAFLEX.xml:S1:214:2	I-AdverseReaction
the	XIAFLEX.xml:S1:217:3	I-AdverseReaction
injected	XIAFLEX.xml:S1:221:8	I-AdverseReaction
extremity	XIAFLEX.xml:S1:230:9	I-AdverseReaction
[	XIAFLEX.xml:S1:242:1	O
see	XIAFLEX.xml:S1:243:3	O
Warnings	XIAFLEX.xml:S1:247:8	O
and	XIAFLEX.xml:S1:256:3	O
Precautions	XIAFLEX.xml:S1:260:11	O
(	XIAFLEX.xml:S1:272:1	O
5.1	XIAFLEX.xml:S1:273:3	O
)]	XIAFLEX.xml:S1:276:2	O

The	XIAFLEX.xml:S1:287:3	O
following	XIAFLEX.xml:S1:291:9	O
serious	XIAFLEX.xml:S1:301:7	O
adverse	XIAFLEX.xml:S1:309:7	O
reactions	XIAFLEX.xml:S1:317:9	O
in	XIAFLEX.xml:S1:327:2	O
patients	XIAFLEX.xml:S1:330:8	O
with	XIAFLEX.xml:S1:339:4	O
Peyronie	XIAFLEX.xml:S1:344:8	O
's	XIAFLEX.xml:S1:352:2	O
disease	XIAFLEX.xml:S1:355:7	O
are	XIAFLEX.xml:S1:363:3	O
discussed	XIAFLEX.xml:S1:367:9	O
in	XIAFLEX.xml:S1:377:2	O
greater	XIAFLEX.xml:S1:380:7	O
detail	XIAFLEX.xml:S1:388:6	O
elsewhere	XIAFLEX.xml:S1:395:9	O
in	XIAFLEX.xml:S1:405:2	O
the	XIAFLEX.xml:S1:408:3	O
labeling	XIAFLEX.xml:S1:412:8	O
:	XIAFLEX.xml:S1:420:1	O

Corporal	XIAFLEX.xml:S1:429:8	B-AdverseReaction

rupture	XIAFLEX.xml:S1:438:7	I-AdverseReaction
(	XIAFLEX.xml:S1:446:1	O
penile	XIAFLEX.xml:S1:447:6	B-AdverseReaction
fracture	XIAFLEX.xml:S1:454:8	I-AdverseReaction
)	XIAFLEX.xml:S1:462:1	O
and	XIAFLEX.xml:S1:464:3	O
severe	XIAFLEX.xml:S1:468:6	B-Severity
penile	XIAFLEX.xml:S1:475:6	B-AdverseReaction
hematoma	XIAFLEX.xml:S1:482:8	I-AdverseReaction
[	XIAFLEX.xml:S1:493:1	O
see	XIAFLEX.xml:S1:494:3	O
Warnings	XIAFLEX.xml:S1:498:8	O
and	XIAFLEX.xml:S1:507:3	O
Precautions	XIAFLEX.xml:S1:511:11	O
(	XIAFLEX.xml:S1:523:1	O
5.2	XIAFLEX.xml:S1:524:3	O
)]	XIAFLEX.xml:S1:527:2	O

In	XIAFLEX.xml:S1:538:2	O
other	XIAFLEX.xml:S1:541:5	O
XIAFLEX	XIAFLEX.xml:S1:547:7	O
-	XIAFLEX.xml:S1:554:1	O
treated	XIAFLEX.xml:S1:555:7	O
patients	XIAFLEX.xml:S1:563:8	O
,	XIAFLEX.xml:S1:571:1	O
a	XIAFLEX.xml:S1:573:1	O
combination	XIAFLEX.xml:S1:575:11	O
of	XIAFLEX.xml:S1:587:2	O
penile	XIAFLEX.xml:S1:590:6	B-AdverseReaction
ecchymoses	XIAFLEX.xml:S1:597:10	I-AdverseReaction
or	XIAFLEX.xml:S1:608:2	O
hematoma	XIAFLEX.xml:S1:611:8	I-AdverseReaction
,	XIAFLEX.xml:S1:619:1	O
sudden	XIAFLEX.xml:S1:621:6	O
penile	XIAFLEX.xml:S1:628:6	B-AdverseReaction
detumescence	XIAFLEX.xml:S1:635:12	I-AdverseReaction
,	XIAFLEX.xml:S1:647:1	O
and	XIAFLEX.xml:S1:649:3	O
or	XIAFLEX.xml:S1:653:2	O
a	XIAFLEX.xml:S1:656:1	O
penile	XIAFLEX.xml:S1:658:6	B-AdverseReaction
"	XIAFLEX.xml:S1:665:1	I-AdverseReaction
popping	XIAFLEX.xml:S1:666:7	I-AdverseReaction
"	XIAFLEX.xml:S1:673:1	I-AdverseReaction
sound	XIAFLEX.xml:S1:675:5	I-AdverseReaction
or	XIAFLEX.xml:S1:681:2	O
sensation	XIAFLEX.xml:S1:684:9	I-AdverseReaction
was	XIAFLEX.xml:S1:694:3	O
reported	XIAFLEX.xml:S1:698:8	O
,	XIAFLEX.xml:S1:706:1	O
and	XIAFLEX.xml:S1:708:3	O
in	XIAFLEX.xml:S1:712:2	O
these	XIAFLEX.xml:S1:715:5	O
cases	XIAFLEX.xml:S1:721:5	O
,	XIAFLEX.xml:S1:726:1	O
a	XIAFLEX.xml:S1:728:1	O
diagnosis	XIAFLEX.xml:S1:730:9	O
of	XIAFLEX.xml:S1:740:2	O
corporal	XIAFLEX.xml:S1:743:8	B-AdverseReaction
rupture	XIAFLEX.xml:S1:752:7	I-AdverseReaction
cannot	XIAFLEX.xml:S1:760:6	B-Factor
be	XIAFLEX.xml:S1:767:2	I-Factor
excluded	XIAFLEX.xml:S1:770:8	I-Factor
[	XIAFLEX.xml:S1:781:1	O
see	XIAFLEX.xml:S1:782:3	O
Warnings	XIAFLEX.xml:S1:786:8	O
and	XIAFLEX.xml:S1:795:3	O
Precautions	XIAFLEX.xml:S1:799:11	O
(	XIAFLEX.xml:S1:811:1	O
5.2	XIAFLEX.xml:S1:812:3	O
)]	XIAFLEX.xml:S1:815:2	O

EXCERPT	XIAFLEX.xml:S1:828:7	O
:	XIAFLEX.xml:S1:835:1	O
Dupuytren	XIAFLEX.xml:S1:841:9	O
's	XIAFLEX.xml:S1:850:2	O
Contracture	XIAFLEX.xml:S1:853:11	O
(	XIAFLEX.xml:S1:865:1	O
6.1	XIAFLEX.xml:S1:868:3	O
)	XIAFLEX.xml:S1:873:1	O

The	XIAFLEX.xml:S1:881:3	O

most	XIAFLEX.xml:S1:885:4	O
common	XIAFLEX.xml:S1:890:6	O
adverse	XIAFLEX.xml:S1:897:7	O
reactions	XIAFLEX.xml:S1:905:9	O
reported	XIAFLEX.xml:S1:915:8	O
in	XIAFLEX.xml:S1:924:2	O
25%	XIAFLEX.xml:S1:930:3	O
of	XIAFLEX.xml:S1:934:2	O
patients	XIAFLEX.xml:S1:937:8	O
treated	XIAFLEX.xml:S1:946:7	O
with	XIAFLEX.xml:S1:954:4	O
XIAFLEX	XIAFLEX.xml:S1:959:7	O
and	XIAFLEX.xml:S1:967:3	O
at	XIAFLEX.xml:S1:971:2	O
an	XIAFLEX.xml:S1:974:2	O
incidence	XIAFLEX.xml:S1:977:9	O
greater	XIAFLEX.xml:S1:987:7	O
than	XIAFLEX.xml:S1:995:4	O
placebo	XIAFLEX.xml:S1:1000:7	O
were	XIAFLEX.xml:S1:1008:4	O
edema	XIAFLEX.xml:S1:1013:5	B-AdverseReaction
peripheral	XIAFLEX.xml:S1:1019:10	I-AdverseReaction
(	XIAFLEX.xml:S1:1030:1	O
e	XIAFLEX.xml:S1:1031:1	O
.	XIAFLEX.xml:S1:1032:1	O
g	XIAFLEX.xml:S1:1033:1	O
.	XIAFLEX.xml:S1:1034:1	O
,	XIAFLEX.xml:S1:1035:1	O
swelling	XIAFLEX.xml:S1:1037:8	B-AdverseReaction
of	XIAFLEX.xml:S1:1046:2	I-AdverseReaction
the	XIAFLEX.xml:S1:1049:3	I-AdverseReaction
injected	XIAFLEX.xml:S1:1053:8	I-AdverseReaction
hand	XIAFLEX.xml:S1:1062:4	I-AdverseReaction
)	XIAFLEX.xml:S1:1066:1	O
,	XIAFLEX.xml:S1:1067:1	O
contusion	XIAFLEX.xml:S1:1069:9	B-AdverseReaction
,	XIAFLEX.xml:S1:1078:1	O
injection	XIAFLEX.xml:S1:1080:9	B-AdverseReaction
site	XIAFLEX.xml:S1:1090:4	I-AdverseReaction
hemorrhage	XIAFLEX.xml:S1:1095:10	I-AdverseReaction
,	XIAFLEX.xml:S1:1105:1	O
injection	XIAFLEX.xml:S1:1107:9	B-AdverseReaction
site	XIAFLEX.xml:S1:1117:4	I-AdverseReaction
reaction	XIAFLEX.xml:S1:1122:8	I-AdverseReaction
,	XIAFLEX.xml:S1:1130:1	O
and	XIAFLEX.xml:S1:1132:3	O
pain	XIAFLEX.xml:S1:1136:4	B-AdverseReaction
in	XIAFLEX.xml:S1:1141:2	I-AdverseReaction
the	XIAFLEX.xml:S1:1144:3	I-AdverseReaction
injected	XIAFLEX.xml:S1:1148:8	I-AdverseReaction
extremity	XIAFLEX.xml:S1:1157:9	I-AdverseReaction
.	XIAFLEX.xml:S1:1166:1	O

Peyronie	XIAFLEX.xml:S1:1174:8	O
's	XIAFLEX.xml:S1:1182:2	O
Disease	XIAFLEX.xml:S1:1185:7	O
(	XIAFLEX.xml:S1:1193:1	O
6.2	XIAFLEX.xml:S1:1196:3	O
)	XIAFLEX.xml:S1:1201:1	O

The	XIAFLEX.xml:S1:1209:3	O
most	XIAFLEX.xml:S1:1213:4	O
frequently	XIAFLEX.xml:S1:1218:10	O
reported	XIAFLEX.xml:S1:1229:8	O
adverse	XIAFLEX.xml:S1:1238:7	O
drug	XIAFLEX.xml:S1:1246:4	O
reactions	XIAFLEX.xml:S1:1251:9	O
reported	XIAFLEX.xml:S1:1261:8	O
with	XIAFLEX.xml:S1:1270:4	O
25%	XIAFLEX.xml:S1:1278:3	O
of	XIAFLEX.xml:S1:1282:2	O
patients	XIAFLEX.xml:S1:1285:8	O
treated	XIAFLEX.xml:S1:1294:7	O
with	XIAFLEX.xml:S1:1302:4	O
XIAFLEX	XIAFLEX.xml:S1:1307:7	O
and	XIAFLEX.xml:S1:1315:3	O
at	XIAFLEX.xml:S1:1319:2	O
an	XIAFLEX.xml:S1:1322:2	O
incidence	XIAFLEX.xml:S1:1325:9	O
greater	XIAFLEX.xml:S1:1335:7	O
than	XIAFLEX.xml:S1:1343:4	O
placebo	XIAFLEX.xml:S1:1348:7	O
were	XIAFLEX.xml:S1:1356:4	O
penile	XIAFLEX.xml:S1:1361:6	B-AdverseReaction
hematoma	XIAFLEX.xml:S1:1368:8	I-AdverseReaction
,	XIAFLEX.xml:S1:1376:1	O
penile	XIAFLEX.xml:S1:1378:6	B-AdverseReaction
swelling	XIAFLEX.xml:S1:1385:8	I-AdverseReaction
and	XIAFLEX.xml:S1:1394:3	O
penile	XIAFLEX.xml:S1:1398:6	B-AdverseReaction
pain	XIAFLEX.xml:S1:1405:4	I-AdverseReaction
.	XIAFLEX.xml:S1:1409:1	O

To	XIAFLEX.xml:S1:1417:2	O
report	XIAFLEX.xml:S1:1420:6	O
SUSPECTED	XIAFLEX.xml:S1:1427:9	O
ADVERSE	XIAFLEX.xml:S1:1437:7	O
REACTIONS	XIAFLEX.xml:S1:1445:9	O
,	XIAFLEX.xml:S1:1454:1	O
contact	XIAFLEX.xml:S1:1456:7	O
Auxilium	XIAFLEX.xml:S1:1464:8	O
Pharmaceuticals	XIAFLEX.xml:S1:1473:15	O
,	XIAFLEX.xml:S1:1488:1	O
Inc	XIAFLEX.xml:S1:1490:3	O
.	XIAFLEX.xml:S1:1493:1	O

at	XIAFLEX.xml:S1:1495:2	O
1	XIAFLEX.xml:S1:1498:1	O
-	XIAFLEX.xml:S1:1499:1	O
877	XIAFLEX.xml:S1:1500:3	O
-	XIAFLEX.xml:S1:1503:1	O
663	XIAFLEX.xml:S1:1504:3	O
-	XIAFLEX.xml:S1:1507:1	O
0412	XIAFLEX.xml:S1:1508:4	O
or	XIAFLEX.xml:S1:1513:2	O
FDA	XIAFLEX.xml:S1:1516:3	O
at	XIAFLEX.xml:S1:1520:2	O
1	XIAFLEX.xml:S1:1523:1	O
-	XIAFLEX.xml:S1:1524:1	O
800	XIAFLEX.xml:S1:1525:3	O
-	XIAFLEX.xml:S1:1528:1	O
FDA	XIAFLEX.xml:S1:1529:3	O
-	XIAFLEX.xml:S1:1532:1	O
1088	XIAFLEX.xml:S1:1533:4	O
or	XIAFLEX.xml:S1:1538:2	O
www	XIAFLEX.xml:S1:1542:3	O
.	XIAFLEX.xml:S1:1545:1	O
fda	XIAFLEX.xml:S1:1546:3	O
.	XIAFLEX.xml:S1:1549:1	O
gov	XIAFLEX.xml:S1:1550:3	O
medwatch	XIAFLEX.xml:S1:1554:8	O
.	XIAFLEX.xml:S1:1562:1	O

6.1	XIAFLEX.xml:S1:1576:3	O

Clinical	XIAFLEX.xml:S1:1580:8	O
Studies	XIAFLEX.xml:S1:1589:7	O
Experience	XIAFLEX.xml:S1:1597:10	O
in	XIAFLEX.xml:S1:1608:2	O
Patients	XIAFLEX.xml:S1:1611:8	O
with	XIAFLEX.xml:S1:1620:4	O
Dupuytren	XIAFLEX.xml:S1:1625:9	O
's	XIAFLEX.xml:S1:1634:2	O
Contracture	XIAFLEX.xml:S1:1637:11	O

Because	XIAFLEX.xml:S1:1652:7	O
clinical	XIAFLEX.xml:S1:1660:8	O
studies	XIAFLEX.xml:S1:1669:7	O
are	XIAFLEX.xml:S1:1677:3	O
conducted	XIAFLEX.xml:S1:1681:9	O
under	XIAFLEX.xml:S1:1691:5	O
widely	XIAFLEX.xml:S1:1697:6	O
varying	XIAFLEX.xml:S1:1704:7	O
conditions	XIAFLEX.xml:S1:1712:10	O
,	XIAFLEX.xml:S1:1722:1	O
adverse	XIAFLEX.xml:S1:1724:7	O
reaction	XIAFLEX.xml:S1:1732:8	O
rates	XIAFLEX.xml:S1:1741:5	O
observed	XIAFLEX.xml:S1:1747:8	O
in	XIAFLEX.xml:S1:1756:2	O
the	XIAFLEX.xml:S1:1759:3	O
clinical	XIAFLEX.xml:S1:1763:8	O
studies	XIAFLEX.xml:S1:1772:7	O
of	XIAFLEX.xml:S1:1780:2	O
a	XIAFLEX.xml:S1:1783:1	O
drug	XIAFLEX.xml:S1:1785:4	O
cannot	XIAFLEX.xml:S1:1790:6	O
be	XIAFLEX.xml:S1:1797:2	O
directly	XIAFLEX.xml:S1:1800:8	O
compared	XIAFLEX.xml:S1:1809:8	O
to	XIAFLEX.xml:S1:1818:2	O
rates	XIAFLEX.xml:S1:1821:5	O
in	XIAFLEX.xml:S1:1827:2	O
the	XIAFLEX.xml:S1:1830:3	O
clinical	XIAFLEX.xml:S1:1834:8	O
studies	XIAFLEX.xml:S1:1843:7	O
of	XIAFLEX.xml:S1:1851:2	O
another	XIAFLEX.xml:S1:1854:7	O
drug	XIAFLEX.xml:S1:1862:4	O
and	XIAFLEX.xml:S1:1867:3	O
may	XIAFLEX.xml:S1:1871:3	O
not	XIAFLEX.xml:S1:1875:3	O
reflect	XIAFLEX.xml:S1:1879:7	O
the	XIAFLEX.xml:S1:1887:3	O
rates	XIAFLEX.xml:S1:1891:5	O
observed	XIAFLEX.xml:S1:1897:8	O
in	XIAFLEX.xml:S1:1906:2	O
practice	XIAFLEX.xml:S1:1909:8	O
.	XIAFLEX.xml:S1:1917:1	O

Out	XIAFLEX.xml:S1:1923:3	O
of	XIAFLEX.xml:S1:1927:2	O
1082	XIAFLEX.xml:S1:1930:4	O
patients	XIAFLEX.xml:S1:1935:8	O
who	XIAFLEX.xml:S1:1944:3	O
received	XIAFLEX.xml:S1:1948:8	O
0.58	XIAFLEX.xml:S1:1957:4	O
mg	XIAFLEX.xml:S1:1962:2	O
of	XIAFLEX.xml:S1:1965:2	O
XIAFLEX	XIAFLEX.xml:S1:1968:7	O
in	XIAFLEX.xml:S1:1976:2	O
the	XIAFLEX.xml:S1:1979:3	O
controlled	XIAFLEX.xml:S1:1983:10	O
and	XIAFLEX.xml:S1:1994:3	O
uncontrolled	XIAFLEX.xml:S1:1998:12	O
portions	XIAFLEX.xml:S1:2011:8	O
of	XIAFLEX.xml:S1:2020:2	O
the	XIAFLEX.xml:S1:2023:3	O
XIAFLEX	XIAFLEX.xml:S1:2027:7	O
studies	XIAFLEX.xml:S1:2035:7	O
(	XIAFLEX.xml:S1:2043:1	O
2630	XIAFLEX.xml:S1:2044:4	O
XIAFLEX	XIAFLEX.xml:S1:2049:7	O
injections	XIAFLEX.xml:S1:2057:10	O
)	XIAFLEX.xml:S1:2067:1	O
,	XIAFLEX.xml:S1:2068:1	O
3	XIAFLEX.xml:S1:2070:1	O
(	XIAFLEX.xml:S1:2072:1	O
0.3%	XIAFLEX.xml:S1:2073:4	O
)	XIAFLEX.xml:S1:2077:1	O
patients	XIAFLEX.xml:S1:2079:8	O
had	XIAFLEX.xml:S1:2088:3	O
a	XIAFLEX.xml:S1:2092:1	O
flexor	XIAFLEX.xml:S1:2094:6	B-AdverseReaction
tendon	XIAFLEX.xml:S1:2101:6	I-AdverseReaction
rupture	XIAFLEX.xml:S1:2108:7	I-AdverseReaction
of	XIAFLEX.xml:S1:2116:2	I-AdverseReaction
the	XIAFLEX.xml:S1:2119:3	I-AdverseReaction
treated	XIAFLEX.xml:S1:2123:7	O
finger	XIAFLEX.xml:S1:2131:6	I-AdverseReaction
within	XIAFLEX.xml:S1:2138:6	O
7	XIAFLEX.xml:S1:2145:1	O
days	XIAFLEX.xml:S1:2147:4	O
of	XIAFLEX.xml:S1:2152:2	O
the	XIAFLEX.xml:S1:2155:3	O
injection	XIAFLEX.xml:S1:2159:9	O
.	XIAFLEX.xml:S1:2168:1	O

The	XIAFLEX.xml:S1:2174:3	O
data	XIAFLEX.xml:S1:2178:4	O
described	XIAFLEX.xml:S1:2183:9	O
below	XIAFLEX.xml:S1:2193:5	O
are	XIAFLEX.xml:S1:2199:3	O
based	XIAFLEX.xml:S1:2203:5	O
on	XIAFLEX.xml:S1:2209:2	O
two	XIAFLEX.xml:S1:2212:3	O
pooled	XIAFLEX.xml:S1:2216:6	O
randomized	XIAFLEX.xml:S1:2223:10	O
,	XIAFLEX.xml:S1:2233:1	O
double	XIAFLEX.xml:S1:2235:6	O
-	XIAFLEX.xml:S1:2241:1	O
blind	XIAFLEX.xml:S1:2242:5	O
,	XIAFLEX.xml:S1:2247:1	O
placebo	XIAFLEX.xml:S1:2249:7	O
-	XIAFLEX.xml:S1:2256:1	O
controlled	XIAFLEX.xml:S1:2257:10	O
trials	XIAFLEX.xml:S1:2268:6	O
through	XIAFLEX.xml:S1:2275:7	O
Day	XIAFLEX.xml:S1:2283:3	O
90	XIAFLEX.xml:S1:2287:2	O
in	XIAFLEX.xml:S1:2290:2	O
patients	XIAFLEX.xml:S1:2293:8	O
with	XIAFLEX.xml:S1:2302:4	O
Dupuytren	XIAFLEX.xml:S1:2307:9	O
's	XIAFLEX.xml:S1:2316:2	O
contracture	XIAFLEX.xml:S1:2319:11	O
(	XIAFLEX.xml:S1:2331:1	O
Studies	XIAFLEX.xml:S1:2332:7	O
1	XIAFLEX.xml:S1:2340:1	O
and	XIAFLEX.xml:S1:2342:3	O
2	XIAFLEX.xml:S1:2346:1	O
)	XIAFLEX.xml:S1:2347:1	O
.	XIAFLEX.xml:S1:2348:1	O

In	XIAFLEX.xml:S1:2350:2	O
these	XIAFLEX.xml:S1:2353:5	O
trials	XIAFLEX.xml:S1:2359:6	O
,	XIAFLEX.xml:S1:2365:1	O
patients	XIAFLEX.xml:S1:2367:8	O
were	XIAFLEX.xml:S1:2376:4	O
treated	XIAFLEX.xml:S1:2381:7	O
with	XIAFLEX.xml:S1:2389:4	O
up	XIAFLEX.xml:S1:2394:2	O
to	XIAFLEX.xml:S1:2397:2	O
3	XIAFLEX.xml:S1:2400:1	O
injections	XIAFLEX.xml:S1:2402:10	O
of	XIAFLEX.xml:S1:2413:2	O
0.58	XIAFLEX.xml:S1:2416:4	O
mg	XIAFLEX.xml:S1:2421:2	O
of	XIAFLEX.xml:S1:2424:2	O
XIAFLEX	XIAFLEX.xml:S1:2427:7	O
or	XIAFLEX.xml:S1:2435:2	O
placebo	XIAFLEX.xml:S1:2438:7	O
with	XIAFLEX.xml:S1:2446:4	O
approximately	XIAFLEX.xml:S1:2451:13	O
4	XIAFLEX.xml:S1:2465:1	O
-	XIAFLEX.xml:S1:2466:1	O
week	XIAFLEX.xml:S1:2467:4	O
intervals	XIAFLEX.xml:S1:2472:9	O
between	XIAFLEX.xml:S1:2482:7	O
injections	XIAFLEX.xml:S1:2490:10	O
and	XIAFLEX.xml:S1:2501:3	O
the	XIAFLEX.xml:S1:2505:3	O
patients	XIAFLEX.xml:S1:2509:8	O
had	XIAFLEX.xml:S1:2518:3	O
finger	XIAFLEX.xml:S1:2522:6	O
extension	XIAFLEX.xml:S1:2529:9	O
procedures	XIAFLEX.xml:S1:2539:10	O
the	XIAFLEX.xml:S1:2550:3	O
day	XIAFLEX.xml:S1:2554:3	O
after	XIAFLEX.xml:S1:2558:5	O
injection	XIAFLEX.xml:S1:2564:9	O
,	XIAFLEX.xml:S1:2573:1	O
if	XIAFLEX.xml:S1:2575:2	O
needed	XIAFLEX.xml:S1:2578:6	O
,	XIAFLEX.xml:S1:2584:1	O
to	XIAFLEX.xml:S1:2586:2	O
facilitate	XIAFLEX.xml:S1:2589:10	O
disruption	XIAFLEX.xml:S1:2600:10	O
of	XIAFLEX.xml:S1:2611:2	O
the	XIAFLEX.xml:S1:2614:3	O
cord	XIAFLEX.xml:S1:2618:4	O
[	XIAFLEX.xml:S1:2626:1	O
see	XIAFLEX.xml:S1:2627:3	O
Clinical	XIAFLEX.xml:S1:2631:8	O
Studies	XIAFLEX.xml:S1:2640:7	O
(	XIAFLEX.xml:S1:2648:1	O
14	XIAFLEX.xml:S1:2649:2	O
)]	XIAFLEX.xml:S1:2651:2	O
.	XIAFLEX.xml:S1:2657:1	O

These	XIAFLEX.xml:S1:2659:5	O
trials	XIAFLEX.xml:S1:2665:6	O
were	XIAFLEX.xml:S1:2672:4	O
comprised	XIAFLEX.xml:S1:2677:9	O
of	XIAFLEX.xml:S1:2687:2	O
374	XIAFLEX.xml:S1:2690:3	O
patients	XIAFLEX.xml:S1:2694:8	O
of	XIAFLEX.xml:S1:2703:2	O
whom	XIAFLEX.xml:S1:2706:4	O
249	XIAFLEX.xml:S1:2711:3	O
and	XIAFLEX.xml:S1:2715:3	O
125	XIAFLEX.xml:S1:2719:3	O
received	XIAFLEX.xml:S1:2723:8	O
0.58	XIAFLEX.xml:S1:2732:4	O
mg	XIAFLEX.xml:S1:2737:2	O
of	XIAFLEX.xml:S1:2740:2	O
XIAFLEX	XIAFLEX.xml:S1:2743:7	O
and	XIAFLEX.xml:S1:2751:3	O
placebo	XIAFLEX.xml:S1:2755:7	O
,	XIAFLEX.xml:S1:2762:1	O
respectively	XIAFLEX.xml:S1:2764:12	O
.	XIAFLEX.xml:S1:2776:1	O

The	XIAFLEX.xml:S1:2778:3	O
mean	XIAFLEX.xml:S1:2782:4	O
age	XIAFLEX.xml:S1:2787:3	O
was	XIAFLEX.xml:S1:2791:3	O
63	XIAFLEX.xml:S1:2795:2	O
years	XIAFLEX.xml:S1:2798:5	O
,	XIAFLEX.xml:S1:2803:1	O
80%	XIAFLEX.xml:S1:2805:3	O
were	XIAFLEX.xml:S1:2809:4	O
male	XIAFLEX.xml:S1:2814:4	O
and	XIAFLEX.xml:S1:2819:3	O
20%	XIAFLEX.xml:S1:2823:3	O
were	XIAFLEX.xml:S1:2827:4	O
female	XIAFLEX.xml:S1:2832:6	O
,	XIAFLEX.xml:S1:2838:1	O
and	XIAFLEX.xml:S1:2840:3	O
100%	XIAFLEX.xml:S1:2844:4	O
were	XIAFLEX.xml:S1:2849:4	O
white	XIAFLEX.xml:S1:2854:5	O
.	XIAFLEX.xml:S1:2859:1	O

In	XIAFLEX.xml:S1:2865:2	O
the	XIAFLEX.xml:S1:2868:3	O
placebo	XIAFLEX.xml:S1:2872:7	O
-	XIAFLEX.xml:S1:2879:1	O
controlled	XIAFLEX.xml:S1:2880:10	O
portions	XIAFLEX.xml:S1:2891:8	O
of	XIAFLEX.xml:S1:2900:2	O
Studies	XIAFLEX.xml:S1:2903:7	O
1	XIAFLEX.xml:S1:2911:1	O
and	XIAFLEX.xml:S1:2913:3	O
2	XIAFLEX.xml:S1:2917:1	O
through	XIAFLEX.xml:S1:2919:7	O
Day	XIAFLEX.xml:S1:2927:3	O
90	XIAFLEX.xml:S1:2931:2	O
,	XIAFLEX.xml:S1:2933:1	O
98%	XIAFLEX.xml:S1:2935:3	O
and	XIAFLEX.xml:S1:2939:3	O
51%	XIAFLEX.xml:S1:2943:3	O
of	XIAFLEX.xml:S1:2947:2	O
XIAFLEX	XIAFLEX.xml:S1:2950:7	O
-	XIAFLEX.xml:S1:2957:1	O
treated	XIAFLEX.xml:S1:2958:7	O
and	XIAFLEX.xml:S1:2966:3	O
placebo	XIAFLEX.xml:S1:2970:7	O
-	XIAFLEX.xml:S1:2977:1	O
treated	XIAFLEX.xml:S1:2978:7	O
patients	XIAFLEX.xml:S1:2986:8	O
had	XIAFLEX.xml:S1:2995:3	O
an	XIAFLEX.xml:S1:2999:2	O
adverse	XIAFLEX.xml:S1:3002:7	O
reaction	XIAFLEX.xml:S1:3010:8	O
after	XIAFLEX.xml:S1:3019:5	O
up	XIAFLEX.xml:S1:3025:2	O
to	XIAFLEX.xml:S1:3028:2	O
3	XIAFLEX.xml:S1:3031:1	O
injections	XIAFLEX.xml:S1:3033:10	O
,	XIAFLEX.xml:S1:3043:1	O
respectively	XIAFLEX.xml:S1:3045:12	O
.	XIAFLEX.xml:S1:3057:1	O

Over	XIAFLEX.xml:S1:3059:4	O
95%	XIAFLEX.xml:S1:3064:3	O
of	XIAFLEX.xml:S1:3068:2	O
XIAFLEX	XIAFLEX.xml:S1:3071:7	O
-	XIAFLEX.xml:S1:3078:1	O
treated	XIAFLEX.xml:S1:3079:7	O
patients	XIAFLEX.xml:S1:3087:8	O
had	XIAFLEX.xml:S1:3096:3	O
an	XIAFLEX.xml:S1:3100:2	O
adverse	XIAFLEX.xml:S1:3103:7	B-AdverseReaction
reaction	XIAFLEX.xml:S1:3111:8	I-AdverseReaction
of	XIAFLEX.xml:S1:3120:2	I-AdverseReaction
the	XIAFLEX.xml:S1:3123:3	I-AdverseReaction
injected	XIAFLEX.xml:S1:3127:8	I-AdverseReaction
extremity	XIAFLEX.xml:S1:3136:9	I-AdverseReaction
after	XIAFLEX.xml:S1:3146:5	O
up	XIAFLEX.xml:S1:3152:2	O
to	XIAFLEX.xml:S1:3155:2	O
3	XIAFLEX.xml:S1:3158:1	O
injections	XIAFLEX.xml:S1:3160:10	O
.	XIAFLEX.xml:S1:3170:1	O

Approximately	XIAFLEX.xml:S1:3172:13	O
81%	XIAFLEX.xml:S1:3186:3	O
of	XIAFLEX.xml:S1:3190:2	O
these	XIAFLEX.xml:S1:3193:5	O
local	XIAFLEX.xml:S1:3199:5	O
reactions	XIAFLEX.xml:S1:3205:9	O
resolved	XIAFLEX.xml:S1:3215:8	O
without	XIAFLEX.xml:S1:3224:7	O
intervention	XIAFLEX.xml:S1:3232:12	O
within	XIAFLEX.xml:S1:3245:6	O
4	XIAFLEX.xml:S1:3252:1	O
weeks	XIAFLEX.xml:S1:3254:5	O
of	XIAFLEX.xml:S1:3260:2	O
XIAFLEX	XIAFLEX.xml:S1:3263:7	O
injections	XIAFLEX.xml:S1:3271:10	O
.	XIAFLEX.xml:S1:3281:1	O

The	XIAFLEX.xml:S1:3283:3	O
adverse	XIAFLEX.xml:S1:3287:7	O
reaction	XIAFLEX.xml:S1:3295:8	O
profile	XIAFLEX.xml:S1:3304:7	O
was	XIAFLEX.xml:S1:3312:3	O
similar	XIAFLEX.xml:S1:3316:7	O
for	XIAFLEX.xml:S1:3324:3	O
each	XIAFLEX.xml:S1:3328:4	O
injection	XIAFLEX.xml:S1:3333:9	O
,	XIAFLEX.xml:S1:3342:1	O
regardless	XIAFLEX.xml:S1:3344:10	O
of	XIAFLEX.xml:S1:3355:2	O
the	XIAFLEX.xml:S1:3358:3	O
number	XIAFLEX.xml:S1:3362:6	O
of	XIAFLEX.xml:S1:3369:2	O
injections	XIAFLEX.xml:S1:3372:10	O
administered	XIAFLEX.xml:S1:3383:12	O
.	XIAFLEX.xml:S1:3395:1	O

However	XIAFLEX.xml:S1:3397:7	O
,	XIAFLEX.xml:S1:3404:1	O
the	XIAFLEX.xml:S1:3406:3	O
incidence	XIAFLEX.xml:S1:3410:9	O
of	XIAFLEX.xml:S1:3420:2	O
pruritus	XIAFLEX.xml:S1:3423:8	B-AdverseReaction
increased	XIAFLEX.xml:S1:3432:9	O
with	XIAFLEX.xml:S1:3442:4	O
more	XIAFLEX.xml:S1:3447:4	O
injections	XIAFLEX.xml:S1:3452:10	O
[	XIAFLEX.xml:S1:3466:1	O
see	XIAFLEX.xml:S1:3467:3	O
Warnings	XIAFLEX.xml:S1:3471:8	O
and	XIAFLEX.xml:S1:3480:3	O
Precautions	XIAFLEX.xml:S1:3484:11	O
(	XIAFLEX.xml:S1:3496:1	O
5.4	XIAFLEX.xml:S1:3497:3	O
)]	XIAFLEX.xml:S1:3500:2	O
.	XIAFLEX.xml:S1:3502:1	O

The	XIAFLEX.xml:S1:3512:3	O
most	XIAFLEX.xml:S1:3516:4	O
frequently	XIAFLEX.xml:S1:3521:10	O
reported	XIAFLEX.xml:S1:3532:8	O
adverse	XIAFLEX.xml:S1:3541:7	O
drug	XIAFLEX.xml:S1:3549:4	O
reactions	XIAFLEX.xml:S1:3554:9	O
(	XIAFLEX.xml:S1:3564:1	O
25%	XIAFLEX.xml:S1:3568:3	O
)	XIAFLEX.xml:S1:3571:1	O
in	XIAFLEX.xml:S1:3573:2	O
the	XIAFLEX.xml:S1:3576:3	O
XIAFLEX	XIAFLEX.xml:S1:3580:7	O
clinical	XIAFLEX.xml:S1:3588:8	O
trials	XIAFLEX.xml:S1:3597:6	O
in	XIAFLEX.xml:S1:3604:2	O
patients	XIAFLEX.xml:S1:3607:8	O
with	XIAFLEX.xml:S1:3616:4	O
Dupuytren	XIAFLEX.xml:S1:3621:9	O
's	XIAFLEX.xml:S1:3630:2	O
contracture	XIAFLEX.xml:S1:3633:11	O
included	XIAFLEX.xml:S1:3645:8	O
edema	XIAFLEX.xml:S1:3654:5	B-AdverseReaction
peripheral	XIAFLEX.xml:S1:3660:10	I-AdverseReaction
(	XIAFLEX.xml:S1:3671:1	O
mostly	XIAFLEX.xml:S1:3672:6	O
swelling	XIAFLEX.xml:S1:3679:8	B-AdverseReaction
of	XIAFLEX.xml:S1:3688:2	I-AdverseReaction
the	XIAFLEX.xml:S1:3691:3	I-AdverseReaction
injected	XIAFLEX.xml:S1:3695:8	I-AdverseReaction
hand	XIAFLEX.xml:S1:3704:4	I-AdverseReaction
)	XIAFLEX.xml:S1:3708:1	O
,	XIAFLEX.xml:S1:3709:1	O
contusion	XIAFLEX.xml:S1:3711:9	B-AdverseReaction
,	XIAFLEX.xml:S1:3720:1	O
injection	XIAFLEX.xml:S1:3722:9	B-AdverseReaction
site	XIAFLEX.xml:S1:3732:4	I-AdverseReaction
hemorrhage	XIAFLEX.xml:S1:3737:10	I-AdverseReaction
,	XIAFLEX.xml:S1:3747:1	O
injection	XIAFLEX.xml:S1:3749:9	B-AdverseReaction
site	XIAFLEX.xml:S1:3759:4	I-AdverseReaction
reaction	XIAFLEX.xml:S1:3764:8	I-AdverseReaction
,	XIAFLEX.xml:S1:3772:1	O
and	XIAFLEX.xml:S1:3774:3	O
pain	XIAFLEX.xml:S1:3778:4	B-AdverseReaction
in	XIAFLEX.xml:S1:3783:2	I-AdverseReaction
the	XIAFLEX.xml:S1:3786:3	I-AdverseReaction
treated	XIAFLEX.xml:S1:3790:7	I-AdverseReaction
extremity	XIAFLEX.xml:S1:3798:9	I-AdverseReaction
.	XIAFLEX.xml:S1:3807:1	O

Table	XIAFLEX.xml:S1:3809:5	O
3	XIAFLEX.xml:S1:3815:1	O
shows	XIAFLEX.xml:S1:3817:5	O
the	XIAFLEX.xml:S1:3823:3	O
incidence	XIAFLEX.xml:S1:3827:9	O
of	XIAFLEX.xml:S1:3837:2	O
adverse	XIAFLEX.xml:S1:3840:7	O
reactions	XIAFLEX.xml:S1:3848:9	O
that	XIAFLEX.xml:S1:3858:4	O
were	XIAFLEX.xml:S1:3863:4	O
reported	XIAFLEX.xml:S1:3868:8	O
in	XIAFLEX.xml:S1:3877:2	O
greater	XIAFLEX.xml:S1:3880:7	O
than	XIAFLEX.xml:S1:3888:4	O
or	XIAFLEX.xml:S1:3893:2	O
equal	XIAFLEX.xml:S1:3896:5	O
to	XIAFLEX.xml:S1:3902:2	O
5%	XIAFLEX.xml:S1:3905:2	O
of	XIAFLEX.xml:S1:3908:2	O
XIAFLEX	XIAFLEX.xml:S1:3911:7	O
-	XIAFLEX.xml:S1:3918:1	O
treated	XIAFLEX.xml:S1:3919:7	O
patients	XIAFLEX.xml:S1:3927:8	O
and	XIAFLEX.xml:S1:3936:3	O
at	XIAFLEX.xml:S1:3940:2	O
a	XIAFLEX.xml:S1:3943:1	O
frequency	XIAFLEX.xml:S1:3945:9	O
greater	XIAFLEX.xml:S1:3955:7	O
than	XIAFLEX.xml:S1:3963:4	O
placebo	XIAFLEX.xml:S1:3968:7	O
-	XIAFLEX.xml:S1:3975:1	O
treated	XIAFLEX.xml:S1:3976:7	O
patients	XIAFLEX.xml:S1:3984:8	O
after	XIAFLEX.xml:S1:3993:5	O
up	XIAFLEX.xml:S1:3999:2	O
to	XIAFLEX.xml:S1:4002:2	O
3	XIAFLEX.xml:S1:4005:1	O
injections	XIAFLEX.xml:S1:4007:10	O
in	XIAFLEX.xml:S1:4018:2	O
the	XIAFLEX.xml:S1:4021:3	O
pooled	XIAFLEX.xml:S1:4025:6	O
placebo	XIAFLEX.xml:S1:4032:7	O
-	XIAFLEX.xml:S1:4039:1	O
controlled	XIAFLEX.xml:S1:4040:10	O
trials	XIAFLEX.xml:S1:4051:6	O
through	XIAFLEX.xml:S1:4058:7	O
Day	XIAFLEX.xml:S1:4066:3	O
90	XIAFLEX.xml:S1:4070:2	O
(	XIAFLEX.xml:S1:4073:1	O
Studies	XIAFLEX.xml:S1:4074:7	O
1	XIAFLEX.xml:S1:4082:1	O
and	XIAFLEX.xml:S1:4084:3	O
2	XIAFLEX.xml:S1:4088:1	O
)	XIAFLEX.xml:S1:4089:1	O
.	XIAFLEX.xml:S1:4090:1	O

Table	XIAFLEX.xml:S1:4096:5	O
3	XIAFLEX.xml:S1:4102:1	O
.	XIAFLEX.xml:S1:4103:1	O

Adverse	XIAFLEX.xml:S1:4105:7	O
Reactions	XIAFLEX.xml:S1:4113:9	O
Occurring	XIAFLEX.xml:S1:4123:9	O
in	XIAFLEX.xml:S1:4133:2	O
5%	XIAFLEX.xml:S1:4139:2	O
of	XIAFLEX.xml:S1:4142:2	O
XIAFLEX	XIAFLEX.xml:S1:4145:7	O
-	XIAFLEX.xml:S1:4152:1	O
Treated	XIAFLEX.xml:S1:4153:7	O
Patients	XIAFLEX.xml:S1:4161:8	O
with	XIAFLEX.xml:S1:4170:4	O
Dupuytren	XIAFLEX.xml:S1:4175:9	O
's	XIAFLEX.xml:S1:4184:2	O
Contracture	XIAFLEX.xml:S1:4187:11	O
and	XIAFLEX.xml:S1:4199:3	O
at	XIAFLEX.xml:S1:4203:2	O
a	XIAFLEX.xml:S1:4206:1	O
Greater	XIAFLEX.xml:S1:4208:7	O
Incidence	XIAFLEX.xml:S1:4216:9	O
than	XIAFLEX.xml:S1:4226:4	O
Placebo	XIAFLEX.xml:S1:4231:7	O
in	XIAFLEX.xml:S1:4239:2	O
the	XIAFLEX.xml:S1:4242:3	O
Placebo	XIAFLEX.xml:S1:4246:7	O
-	XIAFLEX.xml:S1:4253:1	O
Controlled	XIAFLEX.xml:S1:4254:10	O
Trials	XIAFLEX.xml:S1:4265:6	O
Through	XIAFLEX.xml:S1:4272:7	O
Day	XIAFLEX.xml:S1:4280:3	O
90	XIAFLEX.xml:S1:4284:2	O
After	XIAFLEX.xml:S1:4287:5	O
Up	XIAFLEX.xml:S1:4293:2	O
to	XIAFLEX.xml:S1:4296:2	O
3	XIAFLEX.xml:S1:4299:1	O
Injections	XIAFLEX.xml:S1:4301:10	O

a	XIAFLEX.xml:S1:4317:1	O
Most	XIAFLEX.xml:S1:4320:4	O
of	XIAFLEX.xml:S1:4325:2	O
these	XIAFLEX.xml:S1:4328:5	O
events	XIAFLEX.xml:S1:4334:6	O
were	XIAFLEX.xml:S1:4341:4	O
swelling	XIAFLEX.xml:S1:4346:8	B-AdverseReaction
of	XIAFLEX.xml:S1:4355:2	I-AdverseReaction
the	XIAFLEX.xml:S1:4358:3	I-AdverseReaction
injected	XIAFLEX.xml:S1:4362:8	I-AdverseReaction
hand	XIAFLEX.xml:S1:4371:4	I-AdverseReaction
.	XIAFLEX.xml:S1:4375:1	O

b	XIAFLEX.xml:S1:4384:1	O
Includes	XIAFLEX.xml:S1:4387:8	O
the	XIAFLEX.xml:S1:4396:3	O
terms	XIAFLEX.xml:S1:4400:5	O
:	XIAFLEX.xml:S1:4405:1	O
contusion	XIAFLEX.xml:S1:4407:9	B-AdverseReaction
(	XIAFLEX.xml:S1:4417:1	O
any	XIAFLEX.xml:S1:4418:3	O
body	XIAFLEX.xml:S1:4422:4	O
system	XIAFLEX.xml:S1:4427:6	O
)	XIAFLEX.xml:S1:4433:1	O
and	XIAFLEX.xml:S1:4435:3	O
ecchymosis	XIAFLEX.xml:S1:4439:10	B-AdverseReaction

c	XIAFLEX.xml:S1:4457:1	O
Includes	XIAFLEX.xml:S1:4460:8	O
the	XIAFLEX.xml:S1:4469:3	O
terms	XIAFLEX.xml:S1:4473:5	O
:	XIAFLEX.xml:S1:4478:1	O
injection	XIAFLEX.xml:S1:4480:9	B-AdverseReaction
site	XIAFLEX.xml:S1:4490:4	I-AdverseReaction
reaction	XIAFLEX.xml:S1:4495:8	I-AdverseReaction
,	XIAFLEX.xml:S1:4503:1	O
injection	XIAFLEX.xml:S1:4505:9	B-AdverseReaction
site	XIAFLEX.xml:S1:4515:4	I-AdverseReaction
erythema	XIAFLEX.xml:S1:4520:8	I-AdverseReaction
,	XIAFLEX.xml:S1:4528:1	O
injection	XIAFLEX.xml:S1:4530:9	B-AdverseReaction
site	XIAFLEX.xml:S1:4540:4	I-AdverseReaction
inflammation	XIAFLEX.xml:S1:4545:12	I-AdverseReaction
,	XIAFLEX.xml:S1:4557:1	O
injection	XIAFLEX.xml:S1:4559:9	B-AdverseReaction
site	XIAFLEX.xml:S1:4569:4	I-AdverseReaction
irritation	XIAFLEX.xml:S1:4574:10	I-AdverseReaction
,	XIAFLEX.xml:S1:4584:1	O
injection	XIAFLEX.xml:S1:4586:9	B-AdverseReaction
site	XIAFLEX.xml:S1:4596:4	I-AdverseReaction
pain	XIAFLEX.xml:S1:4601:4	I-AdverseReaction
,	XIAFLEX.xml:S1:4605:1	O
and	XIAFLEX.xml:S1:4607:3	O
injection	XIAFLEX.xml:S1:4611:9	B-AdverseReaction
site	XIAFLEX.xml:S1:4621:4	I-AdverseReaction
warmth	XIAFLEX.xml:S1:4626:6	I-AdverseReaction

d	XIAFLEX.xml:S1:4640:1	O
Includes	XIAFLEX.xml:S1:4643:8	O
the	XIAFLEX.xml:S1:4652:3	O
terms	XIAFLEX.xml:S1:4656:5	O
:	XIAFLEX.xml:S1:4661:1	O
injection	XIAFLEX.xml:S1:4663:9	B-AdverseReaction
site	XIAFLEX.xml:S1:4673:4	I-AdverseReaction
swelling	XIAFLEX.xml:S1:4678:8	I-AdverseReaction
and	XIAFLEX.xml:S1:4687:3	O
injection	XIAFLEX.xml:S1:4691:9	B-AdverseReaction
site	XIAFLEX.xml:S1:4701:4	I-AdverseReaction
edema	XIAFLEX.xml:S1:4706:5	I-AdverseReaction

e	XIAFLEX.xml:S1:4719:1	O
Includes	XIAFLEX.xml:S1:4722:8	O
the	XIAFLEX.xml:S1:4731:3	O
terms	XIAFLEX.xml:S1:4735:5	O
:	XIAFLEX.xml:S1:4740:1	O
pruritus	XIAFLEX.xml:S1:4742:8	B-AdverseReaction
and	XIAFLEX.xml:S1:4751:3	O
injection	XIAFLEX.xml:S1:4755:9	B-AdverseReaction
site	XIAFLEX.xml:S1:4765:4	I-AdverseReaction
pruritus	XIAFLEX.xml:S1:4770:8	I-AdverseReaction

f	XIAFLEX.xml:S1:4786:1	O
Includes	XIAFLEX.xml:S1:4789:8	O
the	XIAFLEX.xml:S1:4798:3	O
terms	XIAFLEX.xml:S1:4802:5	O
:	XIAFLEX.xml:S1:4807:1	O
lymphadenopathy	XIAFLEX.xml:S1:4809:15	B-AdverseReaction
and	XIAFLEX.xml:S1:4825:3	O
axillary	XIAFLEX.xml:S1:4829:8	B-AdverseReaction
mass	XIAFLEX.xml:S1:4838:4	I-AdverseReaction

Adverse	XIAFLEX.xml:S1:4853:7	O

Reaction	XIAFLEX.xml:S1:4861:8	O
XIAFLEXN	XIAFLEX.xml:S1:4876:8	O
249	XIAFLEX.xml:S1:4885:3	O
PlaceboN	XIAFLEX.xml:S1:4895:8	O
125	XIAFLEX.xml:S1:4904:3	O

All	XIAFLEX.xml:S1:4915:3	O
Adverse	XIAFLEX.xml:S1:4919:7	O
Reactions	XIAFLEX.xml:S1:4927:9	O
98%	XIAFLEX.xml:S1:4939:3	O
51%	XIAFLEX.xml:S1:4945:3	O

Edema	XIAFLEX.xml:S1:4954:5	B-AdverseReaction
Peripheral	XIAFLEX.xml:S1:4960:10	I-AdverseReaction
a	XIAFLEX.xml:S1:4972:1	O
73%	XIAFLEX.xml:S1:4978:3	O
5%	XIAFLEX.xml:S1:4984:2	O

Contusion	XIAFLEX.xml:S1:4992:9	B-AdverseReaction
b	XIAFLEX.xml:S1:5003:1	O
70%	XIAFLEX.xml:S1:5009:3	O
3%	XIAFLEX.xml:S1:5015:2	O

Injection	XIAFLEX.xml:S1:5023:9	B-AdverseReaction
Site	XIAFLEX.xml:S1:5033:4	I-AdverseReaction
Hemorrhage	XIAFLEX.xml:S1:5038:10	I-AdverseReaction
38%	XIAFLEX.xml:S1:5051:3	O
3%	XIAFLEX.xml:S1:5057:2	O

Injection	XIAFLEX.xml:S1:5065:9	B-AdverseReaction
Site	XIAFLEX.xml:S1:5075:4	I-AdverseReaction
Reaction	XIAFLEX.xml:S1:5080:8	I-AdverseReaction
c	XIAFLEX.xml:S1:5090:1	O
35%	XIAFLEX.xml:S1:5096:3	O
6%	XIAFLEX.xml:S1:5102:2	O

Pain	XIAFLEX.xml:S1:5110:4	B-AdverseReaction
in	XIAFLEX.xml:S1:5115:2	I-AdverseReaction
Extremity	XIAFLEX.xml:S1:5118:9	I-AdverseReaction
35%	XIAFLEX.xml:S1:5130:3	O
4%	XIAFLEX.xml:S1:5136:2	O

Tenderness	XIAFLEX.xml:S1:5144:10	B-AdverseReaction
24%	XIAFLEX.xml:S1:5157:3	O
0%	XIAFLEX.xml:S1:5163:2	O

Injection	XIAFLEX.xml:S1:5171:9	B-AdverseReaction
Site	XIAFLEX.xml:S1:5181:4	I-AdverseReaction
Swelling	XIAFLEX.xml:S1:5186:8	I-AdverseReaction
d	XIAFLEX.xml:S1:5196:1	O
24%	XIAFLEX.xml:S1:5202:3	O
6%	XIAFLEX.xml:S1:5208:2	O

Pruritus	XIAFLEX.xml:S1:5216:8	B-AdverseReaction
e	XIAFLEX.xml:S1:5226:1	O
15%	XIAFLEX.xml:S1:5232:3	O
1%	XIAFLEX.xml:S1:5238:2	O

Lymphadenopathy	XIAFLEX.xml:S1:5246:15	B-AdverseReaction
f	XIAFLEX.xml:S1:5263:1	O
13%	XIAFLEX.xml:S1:5269:3	O
0%	XIAFLEX.xml:S1:5275:2	O

Skin	XIAFLEX.xml:S1:5283:4	B-AdverseReaction
Laceration	XIAFLEX.xml:S1:5288:10	I-AdverseReaction
9%	XIAFLEX.xml:S1:5301:2	O
0%	XIAFLEX.xml:S1:5306:2	O

Lymph	XIAFLEX.xml:S1:5314:5	B-AdverseReaction
Node	XIAFLEX.xml:S1:5320:4	I-AdverseReaction
Pain	XIAFLEX.xml:S1:5325:4	I-AdverseReaction
8%	XIAFLEX.xml:S1:5332:2	O
0%	XIAFLEX.xml:S1:5337:2	O

Erythema	XIAFLEX.xml:S1:5345:8	B-AdverseReaction
6%	XIAFLEX.xml:S1:5356:2	O
0%	XIAFLEX.xml:S1:5361:2	O

Axillary	XIAFLEX.xml:S1:5369:8	B-AdverseReaction
Pain	XIAFLEX.xml:S1:5378:4	I-AdverseReaction
6%	XIAFLEX.xml:S1:5385:2	O
0%	XIAFLEX.xml:S1:5390:2	O

Some	XIAFLEX.xml:S1:5405:4	O
patients	XIAFLEX.xml:S1:5410:8	O
developed	XIAFLEX.xml:S1:5419:9	O
vasovagal	XIAFLEX.xml:S1:5429:9	B-AdverseReaction
syncope	XIAFLEX.xml:S1:5439:7	I-AdverseReaction
after	XIAFLEX.xml:S1:5447:5	O
finger	XIAFLEX.xml:S1:5453:6	O
extension	XIAFLEX.xml:S1:5460:9	O
procedures	XIAFLEX.xml:S1:5470:10	O
.	XIAFLEX.xml:S1:5480:1	O

The	XIAFLEX.xml:S1:5486:3	O

safety	XIAFLEX.xml:S1:5490:6	O
of	XIAFLEX.xml:S1:5497:2	O
two	XIAFLEX.xml:S1:5500:3	O
concurrent	XIAFLEX.xml:S1:5504:10	O
injections	XIAFLEX.xml:S1:5515:10	O
of	XIAFLEX.xml:S1:5526:2	O
XIAFLEX	XIAFLEX.xml:S1:5529:7	O
0.58	XIAFLEX.xml:S1:5537:4	O
mg	XIAFLEX.xml:S1:5542:2	O
into	XIAFLEX.xml:S1:5545:4	O
Dupuytren	XIAFLEX.xml:S1:5550:9	O
's	XIAFLEX.xml:S1:5559:2	O
cords	XIAFLEX.xml:S1:5562:5	O
in	XIAFLEX.xml:S1:5568:2	O
the	XIAFLEX.xml:S1:5571:3	O
same	XIAFLEX.xml:S1:5575:4	O
hand	XIAFLEX.xml:S1:5580:4	O
was	XIAFLEX.xml:S1:5585:3	O
evaluated	XIAFLEX.xml:S1:5589:9	O
in	XIAFLEX.xml:S1:5599:2	O
a	XIAFLEX.xml:S1:5602:1	O
historically	XIAFLEX.xml:S1:5604:12	O
-	XIAFLEX.xml:S1:5616:1	O
controlled	XIAFLEX.xml:S1:5617:10	O
,	XIAFLEX.xml:S1:5627:1	O
open	XIAFLEX.xml:S1:5629:4	O
-	XIAFLEX.xml:S1:5633:1	O
label	XIAFLEX.xml:S1:5634:5	O
multi	XIAFLEX.xml:S1:5640:5	O
-	XIAFLEX.xml:S1:5645:1	O
center	XIAFLEX.xml:S1:5646:6	O
trial	XIAFLEX.xml:S1:5653:5	O
in	XIAFLEX.xml:S1:5659:2	O
715	XIAFLEX.xml:S1:5662:3	O
adult	XIAFLEX.xml:S1:5666:5	O
subjects	XIAFLEX.xml:S1:5672:8	O
with	XIAFLEX.xml:S1:5681:4	O
Dupuytren	XIAFLEX.xml:S1:5686:9	O
's	XIAFLEX.xml:S1:5695:2	O
contracture	XIAFLEX.xml:S1:5698:11	O
(	XIAFLEX.xml:S1:5710:1	O
Study	XIAFLEX.xml:S1:5711:5	O
3	XIAFLEX.xml:S1:5717:1	O
)	XIAFLEX.xml:S1:5718:1	O
.	XIAFLEX.xml:S1:5719:1	O

In	XIAFLEX.xml:S1:5721:2	O
Study	XIAFLEX.xml:S1:5724:5	O
3	XIAFLEX.xml:S1:5730:1	O
,	XIAFLEX.xml:S1:5731:1	O
finger	XIAFLEX.xml:S1:5733:6	O
extension	XIAFLEX.xml:S1:5740:9	O
procedures	XIAFLEX.xml:S1:5750:10	O
were	XIAFLEX.xml:S1:5761:4	O
performed	XIAFLEX.xml:S1:5766:9	O
approximately	XIAFLEX.xml:S1:5776:13	O
24	XIAFLEX.xml:S1:5790:2	O
to	XIAFLEX.xml:S1:5793:2	O
72	XIAFLEX.xml:S1:5796:2	O
hours	XIAFLEX.xml:S1:5799:5	O
after	XIAFLEX.xml:S1:5805:5	O
injection	XIAFLEX.xml:S1:5811:9	O
.	XIAFLEX.xml:S1:5820:1	O

The	XIAFLEX.xml:S1:5822:3	O
patient	XIAFLEX.xml:S1:5826:7	O
demographics	XIAFLEX.xml:S1:5834:12	O
were	XIAFLEX.xml:S1:5847:4	O
similar	XIAFLEX.xml:S1:5852:7	O
to	XIAFLEX.xml:S1:5860:2	O
Studies	XIAFLEX.xml:S1:5863:7	O
1	XIAFLEX.xml:S1:5871:1	O
and	XIAFLEX.xml:S1:5873:3	O
2	XIAFLEX.xml:S1:5877:1	O
.	XIAFLEX.xml:S1:5878:1	O

Out	XIAFLEX.xml:S1:5884:3	O
of	XIAFLEX.xml:S1:5888:2	O
715	XIAFLEX.xml:S1:5891:3	O
patients	XIAFLEX.xml:S1:5895:8	O
who	XIAFLEX.xml:S1:5904:3	O
received	XIAFLEX.xml:S1:5908:8	O
two	XIAFLEX.xml:S1:5917:3	O
concurrent	XIAFLEX.xml:S1:5921:10	O
injections	XIAFLEX.xml:S1:5932:10	O
of	XIAFLEX.xml:S1:5943:2	O
XIAFLEX	XIAFLEX.xml:S1:5946:7	O
0.58	XIAFLEX.xml:S1:5954:4	O
mg	XIAFLEX.xml:S1:5959:2	O
in	XIAFLEX.xml:S1:5962:2	O
the	XIAFLEX.xml:S1:5965:3	O
same	XIAFLEX.xml:S1:5969:4	O
hand	XIAFLEX.xml:S1:5974:4	O
(	XIAFLEX.xml:S1:5979:1	O
1450	XIAFLEX.xml:S1:5980:4	O
XIAFLEX	XIAFLEX.xml:S1:5985:7	O
injections	XIAFLEX.xml:S1:5993:10	O
)	XIAFLEX.xml:S1:6003:1	O
in	XIAFLEX.xml:S1:6005:2	O
Study	XIAFLEX.xml:S1:6008:5	O
3	XIAFLEX.xml:S1:6014:1	O
,	XIAFLEX.xml:S1:6015:1	O
one	XIAFLEX.xml:S1:6017:3	O
(	XIAFLEX.xml:S1:6021:1	O
0.1%	XIAFLEX.xml:S1:6022:4	O
)	XIAFLEX.xml:S1:6026:1	O
patient	XIAFLEX.xml:S1:6028:7	O
experienced	XIAFLEX.xml:S1:6036:11	O
a	XIAFLEX.xml:S1:6048:1	O
tendon	XIAFLEX.xml:S1:6050:6	B-AdverseReaction
rupture	XIAFLEX.xml:S1:6057:7	I-AdverseReaction
of	XIAFLEX.xml:S1:6065:2	I-AdverseReaction
the	XIAFLEX.xml:S1:6068:3	I-AdverseReaction
treated	XIAFLEX.xml:S1:6072:7	O
finger	XIAFLEX.xml:S1:6080:6	I-AdverseReaction
within	XIAFLEX.xml:S1:6087:6	O
3	XIAFLEX.xml:S1:6094:1	O
days	XIAFLEX.xml:S1:6096:4	O
of	XIAFLEX.xml:S1:6101:2	O
the	XIAFLEX.xml:S1:6104:3	O
injection	XIAFLEX.xml:S1:6108:9	O
.	XIAFLEX.xml:S1:6117:1	O

Table	XIAFLEX.xml:S1:6123:5	O
4	XIAFLEX.xml:S1:6129:1	O
shows	XIAFLEX.xml:S1:6131:5	O
the	XIAFLEX.xml:S1:6137:3	O
incidence	XIAFLEX.xml:S1:6141:9	O
of	XIAFLEX.xml:S1:6151:2	O
adverse	XIAFLEX.xml:S1:6154:7	O
reactions	XIAFLEX.xml:S1:6162:9	O
that	XIAFLEX.xml:S1:6172:4	O
were	XIAFLEX.xml:S1:6177:4	O
reported	XIAFLEX.xml:S1:6182:8	O
in	XIAFLEX.xml:S1:6191:2	O
greater	XIAFLEX.xml:S1:6194:7	O
than	XIAFLEX.xml:S1:6202:4	O
or	XIAFLEX.xml:S1:6207:2	O
equal	XIAFLEX.xml:S1:6210:5	O
to	XIAFLEX.xml:S1:6216:2	O
5%	XIAFLEX.xml:S1:6219:2	O
of	XIAFLEX.xml:S1:6222:2	O
XIAFLEX	XIAFLEX.xml:S1:6225:7	O
-	XIAFLEX.xml:S1:6232:1	O
treated	XIAFLEX.xml:S1:6233:7	O
patients	XIAFLEX.xml:S1:6241:8	O
after	XIAFLEX.xml:S1:6250:5	O
two	XIAFLEX.xml:S1:6256:3	O
concurrent	XIAFLEX.xml:S1:6260:10	O
injections	XIAFLEX.xml:S1:6271:10	O
of	XIAFLEX.xml:S1:6282:2	O
XIAFLEX	XIAFLEX.xml:S1:6285:7	O
in	XIAFLEX.xml:S1:6293:2	O
the	XIAFLEX.xml:S1:6296:3	O
same	XIAFLEX.xml:S1:6300:4	O
hand	XIAFLEX.xml:S1:6305:4	O
through	XIAFLEX.xml:S1:6310:7	O
Day	XIAFLEX.xml:S1:6318:3	O
60	XIAFLEX.xml:S1:6322:2	O
in	XIAFLEX.xml:S1:6325:2	O
Study	XIAFLEX.xml:S1:6328:5	O
3	XIAFLEX.xml:S1:6334:1	O
.	XIAFLEX.xml:S1:6335:1	O

Table	XIAFLEX.xml:S1:6341:5	O
4	XIAFLEX.xml:S1:6347:1	O
.	XIAFLEX.xml:S1:6348:1	O

Adverse	XIAFLEX.xml:S1:6350:7	O
Reactions	XIAFLEX.xml:S1:6358:9	O
Occurring	XIAFLEX.xml:S1:6368:9	O
in	XIAFLEX.xml:S1:6378:2	O
5.0%	XIAFLEX.xml:S1:6383:4	O
of	XIAFLEX.xml:S1:6388:2	O
Subjects	XIAFLEX.xml:S1:6391:8	O
Who	XIAFLEX.xml:S1:6400:3	O
Received	XIAFLEX.xml:S1:6404:8	O
Two	XIAFLEX.xml:S1:6413:3	O
Concurrent	XIAFLEX.xml:S1:6417:10	O
Injections	XIAFLEX.xml:S1:6428:10	O
of	XIAFLEX.xml:S1:6439:2	O
XIAFLEX	XIAFLEX.xml:S1:6442:7	O
in	XIAFLEX.xml:S1:6450:2	O
Study	XIAFLEX.xml:S1:6453:5	O
3	XIAFLEX.xml:S1:6459:1	O

Adverse	XIAFLEX.xml:S1:6465:7	O
Reaction	XIAFLEX.xml:S1:6473:8	O
XIAFLEXN	XIAFLEX.xml:S1:6537:8	O
715	XIAFLEX.xml:S1:6546:3	O

Subjects	XIAFLEX.xml:S1:6570:8	O
with	XIAFLEX.xml:S1:6579:4	O
1	XIAFLEX.xml:S1:6586:1	O
adverse	XIAFLEX.xml:S1:6588:7	O
reaction	XIAFLEX.xml:S1:6596:8	O
95%	XIAFLEX.xml:S1:6642:3	O

Edema	XIAFLEX.xml:S1:6677:5	B-AdverseReaction
peripheral	XIAFLEX.xml:S1:6683:10	I-AdverseReaction
77%	XIAFLEX.xml:S1:6749:3	O

Contusion	XIAFLEX.xml:S1:6784:9	B-AdverseReaction
59%	XIAFLEX.xml:S1:6856:3	O

Pain	XIAFLEX.xml:S1:6891:4	B-AdverseReaction
in	XIAFLEX.xml:S1:6896:2	I-AdverseReaction
extremity	XIAFLEX.xml:S1:6899:9	I-AdverseReaction
51%	XIAFLEX.xml:S1:6963:3	O

Laceration	XIAFLEX.xml:S1:6998:10	B-AdverseReaction
22%	XIAFLEX.xml:S1:7070:3	O

Pruritus	XIAFLEX.xml:S1:7105:8	B-AdverseReaction
15%	XIAFLEX.xml:S1:7177:3	O

Injection	XIAFLEX.xml:S1:7212:9	B-AdverseReaction
site	XIAFLEX.xml:S1:7222:4	I-AdverseReaction
pain	XIAFLEX.xml:S1:7227:4	I-AdverseReaction
14%	XIAFLEX.xml:S1:7284:3	O

Lymphadenopathy	XIAFLEX.xml:S1:7319:15	B-AdverseReaction
13%	XIAFLEX.xml:S1:7391:3	O

Blood	XIAFLEX.xml:S1:7426:5	B-AdverseReaction
blister	XIAFLEX.xml:S1:7432:7	I-AdverseReaction
12%	XIAFLEX.xml:S1:7498:3	O

Injection	XIAFLEX.xml:S1:7533:9	B-AdverseReaction
site	XIAFLEX.xml:S1:7543:4	I-AdverseReaction
hematoma	XIAFLEX.xml:S1:7548:8	I-AdverseReaction
8%	XIAFLEX.xml:S1:7605:2	O

Axillary	XIAFLEX.xml:S1:7640:8	B-AdverseReaction
pain	XIAFLEX.xml:S1:7649:4	I-AdverseReaction
7%	XIAFLEX.xml:S1:7712:2	O

Injection	XIAFLEX.xml:S1:7747:9	B-AdverseReaction
site	XIAFLEX.xml:S1:7757:4	I-AdverseReaction
hemorrhage	XIAFLEX.xml:S1:7762:10	I-AdverseReaction
6%	XIAFLEX.xml:S1:7819:2	O

Injection	XIAFLEX.xml:S1:7854:9	B-AdverseReaction
site	XIAFLEX.xml:S1:7864:4	I-AdverseReaction
swelling	XIAFLEX.xml:S1:7869:8	I-AdverseReaction
5%	XIAFLEX.xml:S1:7926:2	O

Ecchymosis	XIAFLEX.xml:S1:7961:10	B-AdverseReaction
5%	XIAFLEX.xml:S1:8033:2	O

Safety	XIAFLEX.xml:S1:8077:6	O
of	XIAFLEX.xml:S1:8084:2	O
Retreatment	XIAFLEX.xml:S1:8087:11	O
of	XIAFLEX.xml:S1:8099:2	O
Recurrent	XIAFLEX.xml:S1:8102:9	O
Contractures	XIAFLEX.xml:S1:8112:12	O

An	XIAFLEX.xml:S1:8131:2	O

observational	XIAFLEX.xml:S1:8134:13	O
,	XIAFLEX.xml:S1:8147:1	O
open	XIAFLEX.xml:S1:8149:4	O
label	XIAFLEX.xml:S1:8154:5	O
study	XIAFLEX.xml:S1:8160:5	O
was	XIAFLEX.xml:S1:8166:3	O
conducted	XIAFLEX.xml:S1:8170:9	O
in	XIAFLEX.xml:S1:8180:2	O
subjects	XIAFLEX.xml:S1:8183:8	O
who	XIAFLEX.xml:S1:8192:3	O
had	XIAFLEX.xml:S1:8196:3	O
participated	XIAFLEX.xml:S1:8200:12	O
in	XIAFLEX.xml:S1:8213:2	O
XIAFLEX	XIAFLEX.xml:S1:8216:7	O
clinical	XIAFLEX.xml:S1:8224:8	O
trials	XIAFLEX.xml:S1:8233:6	O
for	XIAFLEX.xml:S1:8240:3	O
Dupuytren	XIAFLEX.xml:S1:8244:9	O
's	XIAFLEX.xml:S1:8253:2	O
contracture	XIAFLEX.xml:S1:8256:11	O
(	XIAFLEX.xml:S1:8268:1	O
Study	XIAFLEX.xml:S1:8269:5	O
4	XIAFLEX.xml:S1:8275:1	O
)	XIAFLEX.xml:S1:8276:1	O
.	XIAFLEX.xml:S1:8277:1	O

A	XIAFLEX.xml:S1:8280:1	O
subset	XIAFLEX.xml:S1:8282:6	O
of	XIAFLEX.xml:S1:8289:2	O
patients	XIAFLEX.xml:S1:8292:8	O
who	XIAFLEX.xml:S1:8301:3	O
had	XIAFLEX.xml:S1:8305:3	O
recurrence	XIAFLEX.xml:S1:8309:10	O
of	XIAFLEX.xml:S1:8320:2	O
contracture	XIAFLEX.xml:S1:8323:11	O
in	XIAFLEX.xml:S1:8335:2	O
a	XIAFLEX.xml:S1:8338:1	O
joint	XIAFLEX.xml:S1:8340:5	O
that	XIAFLEX.xml:S1:8346:4	O
was	XIAFLEX.xml:S1:8351:3	O
previously	XIAFLEX.xml:S1:8355:10	O
successfully	XIAFLEX.xml:S1:8366:12	O
treated	XIAFLEX.xml:S1:8379:7	O
with	XIAFLEX.xml:S1:8387:4	O
XIAFLEX	XIAFLEX.xml:S1:8392:7	O
in	XIAFLEX.xml:S1:8400:2	O
Study	XIAFLEX.xml:S1:8403:5	O
4	XIAFLEX.xml:S1:8409:1	O
were	XIAFLEX.xml:S1:8411:4	O
retreated	XIAFLEX.xml:S1:8416:9	O
(	XIAFLEX.xml:S1:8426:1	O
Study	XIAFLEX.xml:S1:8427:5	O
5	XIAFLEX.xml:S1:8433:1	O
)	XIAFLEX.xml:S1:8434:1	O
.	XIAFLEX.xml:S1:8435:1	O

No	XIAFLEX.xml:S1:8438:2	O
new	XIAFLEX.xml:S1:8441:3	O
safety	XIAFLEX.xml:S1:8445:6	O
signals	XIAFLEX.xml:S1:8452:7	O
were	XIAFLEX.xml:S1:8460:4	O
identified	XIAFLEX.xml:S1:8465:10	O
among	XIAFLEX.xml:S1:8476:5	O
subjects	XIAFLEX.xml:S1:8482:8	O
who	XIAFLEX.xml:S1:8491:3	O
were	XIAFLEX.xml:S1:8495:4	O
retreated	XIAFLEX.xml:S1:8500:9	O
with	XIAFLEX.xml:S1:8510:4	O
XIAFLEX	XIAFLEX.xml:S1:8515:7	O
.	XIAFLEX.xml:S1:8522:1	O

6.2	XIAFLEX.xml:S1:8530:3	O
Clinical	XIAFLEX.xml:S1:8534:8	O
Studies	XIAFLEX.xml:S1:8543:7	O
Experience	XIAFLEX.xml:S1:8551:10	O
in	XIAFLEX.xml:S1:8562:2	O
Patients	XIAFLEX.xml:S1:8565:8	O
with	XIAFLEX.xml:S1:8574:4	O
Peyronie	XIAFLEX.xml:S1:8579:8	O
's	XIAFLEX.xml:S1:8587:2	O
Disease	XIAFLEX.xml:S1:8590:7	O

Because	XIAFLEX.xml:S1:8601:7	O
clinical	XIAFLEX.xml:S1:8609:8	O
studies	XIAFLEX.xml:S1:8618:7	O
are	XIAFLEX.xml:S1:8626:3	O
conducted	XIAFLEX.xml:S1:8630:9	O
under	XIAFLEX.xml:S1:8640:5	O
widely	XIAFLEX.xml:S1:8646:6	O
varying	XIAFLEX.xml:S1:8653:7	O
conditions	XIAFLEX.xml:S1:8661:10	O
,	XIAFLEX.xml:S1:8671:1	O
adverse	XIAFLEX.xml:S1:8673:7	O
reaction	XIAFLEX.xml:S1:8681:8	O
rates	XIAFLEX.xml:S1:8690:5	O
observed	XIAFLEX.xml:S1:8696:8	O
in	XIAFLEX.xml:S1:8705:2	O
the	XIAFLEX.xml:S1:8708:3	O
clinical	XIAFLEX.xml:S1:8712:8	O
studies	XIAFLEX.xml:S1:8721:7	O
of	XIAFLEX.xml:S1:8729:2	O
a	XIAFLEX.xml:S1:8732:1	O
drug	XIAFLEX.xml:S1:8734:4	O
cannot	XIAFLEX.xml:S1:8739:6	O
be	XIAFLEX.xml:S1:8746:2	O
directly	XIAFLEX.xml:S1:8749:8	O
compared	XIAFLEX.xml:S1:8758:8	O
to	XIAFLEX.xml:S1:8767:2	O
rates	XIAFLEX.xml:S1:8770:5	O
in	XIAFLEX.xml:S1:8776:2	O
the	XIAFLEX.xml:S1:8779:3	O
clinical	XIAFLEX.xml:S1:8783:8	O
studies	XIAFLEX.xml:S1:8792:7	O
of	XIAFLEX.xml:S1:8800:2	O
another	XIAFLEX.xml:S1:8803:7	O
drug	XIAFLEX.xml:S1:8811:4	O
and	XIAFLEX.xml:S1:8816:3	O
may	XIAFLEX.xml:S1:8820:3	O
not	XIAFLEX.xml:S1:8824:3	O
reflect	XIAFLEX.xml:S1:8828:7	O
the	XIAFLEX.xml:S1:8836:3	O
rates	XIAFLEX.xml:S1:8840:5	O
observed	XIAFLEX.xml:S1:8846:8	O
in	XIAFLEX.xml:S1:8855:2	O
practice	XIAFLEX.xml:S1:8858:8	O
.	XIAFLEX.xml:S1:8866:1	O

In	XIAFLEX.xml:S1:8872:2	O
the	XIAFLEX.xml:S1:8875:3	O
controlled	XIAFLEX.xml:S1:8879:10	O
and	XIAFLEX.xml:S1:8890:3	O
uncontrolled	XIAFLEX.xml:S1:8894:12	O
clinical	XIAFLEX.xml:S1:8907:8	O
studies	XIAFLEX.xml:S1:8916:7	O
of	XIAFLEX.xml:S1:8924:2	O
XIAFLEX	XIAFLEX.xml:S1:8927:7	O
in	XIAFLEX.xml:S1:8935:2	O
Peyronie	XIAFLEX.xml:S1:8938:8	O
's	XIAFLEX.xml:S1:8946:2	O
disease	XIAFLEX.xml:S1:8949:7	O
,	XIAFLEX.xml:S1:8956:1	O
1044	XIAFLEX.xml:S1:8958:4	O
patients	XIAFLEX.xml:S1:8963:8	O
received	XIAFLEX.xml:S1:8972:8	O
a	XIAFLEX.xml:S1:8981:1	O
total	XIAFLEX.xml:S1:8983:5	O
of	XIAFLEX.xml:S1:8989:2	O
7466	XIAFLEX.xml:S1:8992:4	O
XIAFLEX	XIAFLEX.xml:S1:8997:7	O
injections	XIAFLEX.xml:S1:9005:10	O
.	XIAFLEX.xml:S1:9015:1	O

Corporal	XIAFLEX.xml:S1:9023:8	O
Rupture	XIAFLEX.xml:S1:9032:7	O
and	XIAFLEX.xml:S1:9040:3	O
Other	XIAFLEX.xml:S1:9044:5	O
Serious	XIAFLEX.xml:S1:9050:7	O
Penile	XIAFLEX.xml:S1:9058:6	O
Injury	XIAFLEX.xml:S1:9065:6	O

Corporal	XIAFLEX.xml:S1:9081:8	B-AdverseReaction
rupture	XIAFLEX.xml:S1:9090:7	I-AdverseReaction
was	XIAFLEX.xml:S1:9098:3	O
reported	XIAFLEX.xml:S1:9102:8	O
as	XIAFLEX.xml:S1:9111:2	O
an	XIAFLEX.xml:S1:9114:2	O
adverse	XIAFLEX.xml:S1:9117:7	O
reaction	XIAFLEX.xml:S1:9125:8	O
after	XIAFLEX.xml:S1:9134:5	O
XIAFLEX	XIAFLEX.xml:S1:9140:7	O
injections	XIAFLEX.xml:S1:9148:10	O
in	XIAFLEX.xml:S1:9159:2	O
5	XIAFLEX.xml:S1:9162:1	O
of	XIAFLEX.xml:S1:9164:2	O
1044	XIAFLEX.xml:S1:9167:4	O
(	XIAFLEX.xml:S1:9172:1	O
0.5%	XIAFLEX.xml:S1:9173:4	O
)	XIAFLEX.xml:S1:9177:1	O
XIAFLEX	XIAFLEX.xml:S1:9179:7	O
treated	XIAFLEX.xml:S1:9187:7	O
patients	XIAFLEX.xml:S1:9195:8	O
.	XIAFLEX.xml:S1:9203:1	O

In	XIAFLEX.xml:S1:9210:2	O
other	XIAFLEX.xml:S1:9213:5	O
XIAFLEX	XIAFLEX.xml:S1:9219:7	O
-	XIAFLEX.xml:S1:9226:1	O
treated	XIAFLEX.xml:S1:9227:7	O
patients	XIAFLEX.xml:S1:9235:8	O
(	XIAFLEX.xml:S1:9244:1	O
9	XIAFLEX.xml:S1:9245:1	O
of	XIAFLEX.xml:S1:9247:2	O
1044	XIAFLEX.xml:S1:9250:4	O
;	XIAFLEX.xml:S1:9254:1	O
0.9%	XIAFLEX.xml:S1:9256:4	O
)	XIAFLEX.xml:S1:9260:1	O
,	XIAFLEX.xml:S1:9261:1	O
a	XIAFLEX.xml:S1:9263:1	O
combination	XIAFLEX.xml:S1:9265:11	O
of	XIAFLEX.xml:S1:9277:2	O
penile	XIAFLEX.xml:S1:9280:6	B-AdverseReaction
ecchymoses	XIAFLEX.xml:S1:9287:10	I-AdverseReaction
or	XIAFLEX.xml:S1:9298:2	O
hematoma	XIAFLEX.xml:S1:9301:8	I-AdverseReaction
,	XIAFLEX.xml:S1:9309:1	O
sudden	XIAFLEX.xml:S1:9311:6	O
penile	XIAFLEX.xml:S1:9318:6	B-AdverseReaction
detumescence	XIAFLEX.xml:S1:9325:12	I-AdverseReaction
,	XIAFLEX.xml:S1:9337:1	O
and	XIAFLEX.xml:S1:9339:3	O
or	XIAFLEX.xml:S1:9343:2	O
a	XIAFLEX.xml:S1:9346:1	O
penile	XIAFLEX.xml:S1:9348:6	B-AdverseReaction
"	XIAFLEX.xml:S1:9355:1	I-AdverseReaction
popping	XIAFLEX.xml:S1:9356:7	I-AdverseReaction
"	XIAFLEX.xml:S1:9363:1	I-AdverseReaction
sound	XIAFLEX.xml:S1:9365:5	I-AdverseReaction
or	XIAFLEX.xml:S1:9371:2	O
sensation	XIAFLEX.xml:S1:9374:9	I-AdverseReaction
was	XIAFLEX.xml:S1:9384:3	O
reported	XIAFLEX.xml:S1:9388:8	O
,	XIAFLEX.xml:S1:9396:1	O
and	XIAFLEX.xml:S1:9398:3	O
in	XIAFLEX.xml:S1:9402:2	O
these	XIAFLEX.xml:S1:9405:5	O
cases	XIAFLEX.xml:S1:9411:5	O
,	XIAFLEX.xml:S1:9416:1	O
a	XIAFLEX.xml:S1:9418:1	O
diagnosis	XIAFLEX.xml:S1:9420:9	O
of	XIAFLEX.xml:S1:9430:2	O
corporal	XIAFLEX.xml:S1:9433:8	B-AdverseReaction
rupture	XIAFLEX.xml:S1:9442:7	I-AdverseReaction
cannot	XIAFLEX.xml:S1:9450:6	B-Factor
be	XIAFLEX.xml:S1:9457:2	I-Factor
excluded	XIAFLEX.xml:S1:9460:8	I-Factor
.	XIAFLEX.xml:S1:9468:1	O

These	XIAFLEX.xml:S1:9470:5	O
patients	XIAFLEX.xml:S1:9476:8	O
were	XIAFLEX.xml:S1:9485:4	O
managed	XIAFLEX.xml:S1:9490:7	O
without	XIAFLEX.xml:S1:9498:7	O
surgical	XIAFLEX.xml:S1:9506:8	O
intervention	XIAFLEX.xml:S1:9515:12	O
,	XIAFLEX.xml:S1:9527:1	O
but	XIAFLEX.xml:S1:9529:3	O
the	XIAFLEX.xml:S1:9533:3	O
long	XIAFLEX.xml:S1:9537:4	O
-	XIAFLEX.xml:S1:9541:1	O
term	XIAFLEX.xml:S1:9542:4	O
consequences	XIAFLEX.xml:S1:9547:12	O
are	XIAFLEX.xml:S1:9560:3	O
unknown	XIAFLEX.xml:S1:9564:7	O
.	XIAFLEX.xml:S1:9571:1	O

Severe	XIAFLEX.xml:S1:9578:6	B-Severity
penile	XIAFLEX.xml:S1:9585:6	B-AdverseReaction
hematoma	XIAFLEX.xml:S1:9592:8	I-AdverseReaction
was	XIAFLEX.xml:S1:9601:3	O
also	XIAFLEX.xml:S1:9605:4	O
reported	XIAFLEX.xml:S1:9610:8	O
as	XIAFLEX.xml:S1:9619:2	O
an	XIAFLEX.xml:S1:9622:2	O
adverse	XIAFLEX.xml:S1:9625:7	O
reaction	XIAFLEX.xml:S1:9633:8	O
in	XIAFLEX.xml:S1:9642:2	O
39	XIAFLEX.xml:S1:9645:2	O
of	XIAFLEX.xml:S1:9648:2	O
1044	XIAFLEX.xml:S1:9651:4	O
patients	XIAFLEX.xml:S1:9656:8	O
(	XIAFLEX.xml:S1:9665:1	O
3.7%	XIAFLEX.xml:S1:9666:4	O
)	XIAFLEX.xml:S1:9670:1	O
in	XIAFLEX.xml:S1:9672:2	O
the	XIAFLEX.xml:S1:9675:3	O
controlled	XIAFLEX.xml:S1:9679:10	O
and	XIAFLEX.xml:S1:9690:3	O
uncontrolled	XIAFLEX.xml:S1:9694:12	O
clinical	XIAFLEX.xml:S1:9707:8	O
trials	XIAFLEX.xml:S1:9716:6	O
in	XIAFLEX.xml:S1:9723:2	O
Peyronie	XIAFLEX.xml:S1:9726:8	O
's	XIAFLEX.xml:S1:9734:2	O
disease	XIAFLEX.xml:S1:9737:7	O
[	XIAFLEX.xml:S1:9747:1	O
see	XIAFLEX.xml:S1:9748:3	O
Adverse	XIAFLEX.xml:S1:9752:7	O
Reactions	XIAFLEX.xml:S1:9760:9	O
(	XIAFLEX.xml:S1:9770:1	O
6	XIAFLEX.xml:S1:9771:1	O
)]	XIAFLEX.xml:S1:9772:2	O
.	XIAFLEX.xml:S1:9774:1	O

The	XIAFLEX.xml:S1:9784:3	O
data	XIAFLEX.xml:S1:9788:4	O
described	XIAFLEX.xml:S1:9793:9	O
below	XIAFLEX.xml:S1:9803:5	O
are	XIAFLEX.xml:S1:9809:3	O
based	XIAFLEX.xml:S1:9813:5	O
on	XIAFLEX.xml:S1:9819:2	O
two	XIAFLEX.xml:S1:9822:3	O
identical	XIAFLEX.xml:S1:9826:9	O
,	XIAFLEX.xml:S1:9835:1	O
pooled	XIAFLEX.xml:S1:9837:6	O
,	XIAFLEX.xml:S1:9843:1	O
randomized	XIAFLEX.xml:S1:9845:10	O
,	XIAFLEX.xml:S1:9855:1	O
double	XIAFLEX.xml:S1:9857:6	O
-	XIAFLEX.xml:S1:9863:1	O
blind	XIAFLEX.xml:S1:9864:5	O
,	XIAFLEX.xml:S1:9869:1	O
placebo	XIAFLEX.xml:S1:9871:7	O
-	XIAFLEX.xml:S1:9878:1	O
controlled	XIAFLEX.xml:S1:9879:10	O
,	XIAFLEX.xml:S1:9889:1	O
multi	XIAFLEX.xml:S1:9891:5	O
-	XIAFLEX.xml:S1:9896:1	O
center	XIAFLEX.xml:S1:9897:6	O
trials	XIAFLEX.xml:S1:9904:6	O
through	XIAFLEX.xml:S1:9911:7	O
Day	XIAFLEX.xml:S1:9919:3	O
365	XIAFLEX.xml:S1:9923:3	O
in	XIAFLEX.xml:S1:9927:2	O
patients	XIAFLEX.xml:S1:9930:8	O
with	XIAFLEX.xml:S1:9939:4	O
Peyronie	XIAFLEX.xml:S1:9944:8	O
's	XIAFLEX.xml:S1:9952:2	O
disease	XIAFLEX.xml:S1:9955:7	O
(	XIAFLEX.xml:S1:9963:1	O
Studies	XIAFLEX.xml:S1:9964:7	O
1	XIAFLEX.xml:S1:9972:1	O
and	XIAFLEX.xml:S1:9974:3	O
2	XIAFLEX.xml:S1:9978:1	O
)	XIAFLEX.xml:S1:9979:1	O
.	XIAFLEX.xml:S1:9980:1	O

These	XIAFLEX.xml:S1:9982:5	O
trials	XIAFLEX.xml:S1:9988:6	O
included	XIAFLEX.xml:S1:9995:8	O
832	XIAFLEX.xml:S1:10004:3	O
patients	XIAFLEX.xml:S1:10008:8	O
of	XIAFLEX.xml:S1:10017:2	O
whom	XIAFLEX.xml:S1:10020:4	O
551	XIAFLEX.xml:S1:10025:3	O
and	XIAFLEX.xml:S1:10029:3	O
281	XIAFLEX.xml:S1:10033:3	O
received	XIAFLEX.xml:S1:10037:8	O
XIAFLEX	XIAFLEX.xml:S1:10046:7	O
and	XIAFLEX.xml:S1:10054:3	O
placebo	XIAFLEX.xml:S1:10058:7	O
,	XIAFLEX.xml:S1:10065:1	O
respectively	XIAFLEX.xml:S1:10067:12	O
.	XIAFLEX.xml:S1:10079:1	O

In	XIAFLEX.xml:S1:10081:2	O
these	XIAFLEX.xml:S1:10084:5	O
trials	XIAFLEX.xml:S1:10090:6	O
,	XIAFLEX.xml:S1:10096:1	O
patients	XIAFLEX.xml:S1:10098:8	O
were	XIAFLEX.xml:S1:10107:4	O
given	XIAFLEX.xml:S1:10112:5	O
up	XIAFLEX.xml:S1:10118:2	O
to	XIAFLEX.xml:S1:10121:2	O
4	XIAFLEX.xml:S1:10124:1	O
treatment	XIAFLEX.xml:S1:10126:9	O
cycles	XIAFLEX.xml:S1:10136:6	O
of	XIAFLEX.xml:S1:10143:2	O
XIAFLEX	XIAFLEX.xml:S1:10146:7	O
or	XIAFLEX.xml:S1:10154:2	O
placebo	XIAFLEX.xml:S1:10157:7	O
.	XIAFLEX.xml:S1:10164:1	O

In	XIAFLEX.xml:S1:10166:2	O
each	XIAFLEX.xml:S1:10169:4	O
cycle	XIAFLEX.xml:S1:10174:5	O
,	XIAFLEX.xml:S1:10179:1	O
two	XIAFLEX.xml:S1:10181:3	O
injections	XIAFLEX.xml:S1:10185:10	O
of	XIAFLEX.xml:S1:10196:2	O
XIAFLEX	XIAFLEX.xml:S1:10199:7	O
or	XIAFLEX.xml:S1:10207:2	O
two	XIAFLEX.xml:S1:10210:3	O
injections	XIAFLEX.xml:S1:10214:10	O
of	XIAFLEX.xml:S1:10225:2	O
placebo	XIAFLEX.xml:S1:10228:7	O
were	XIAFLEX.xml:S1:10236:4	O
administered	XIAFLEX.xml:S1:10241:12	O
1	XIAFLEX.xml:S1:10254:1	O
to	XIAFLEX.xml:S1:10256:2	O
3	XIAFLEX.xml:S1:10259:1	O
days	XIAFLEX.xml:S1:10261:4	O
apart	XIAFLEX.xml:S1:10266:5	O
.	XIAFLEX.xml:S1:10271:1	O

A	XIAFLEX.xml:S1:10273:1	O
penile	XIAFLEX.xml:S1:10275:6	O
modeling	XIAFLEX.xml:S1:10282:8	O
procedure	XIAFLEX.xml:S1:10291:9	O
was	XIAFLEX.xml:S1:10301:3	O
performed	XIAFLEX.xml:S1:10305:9	O
at	XIAFLEX.xml:S1:10315:2	O
the	XIAFLEX.xml:S1:10318:3	O
study	XIAFLEX.xml:S1:10322:5	O
site	XIAFLEX.xml:S1:10328:4	O
on	XIAFLEX.xml:S1:10333:2	O
patients	XIAFLEX.xml:S1:10336:8	O
1	XIAFLEX.xml:S1:10345:1	O
to	XIAFLEX.xml:S1:10347:2	O
3	XIAFLEX.xml:S1:10350:1	O
days	XIAFLEX.xml:S1:10352:4	O
after	XIAFLEX.xml:S1:10357:5	O
the	XIAFLEX.xml:S1:10363:3	O
second	XIAFLEX.xml:S1:10367:6	O
injection	XIAFLEX.xml:S1:10374:9	O
of	XIAFLEX.xml:S1:10384:2	O
the	XIAFLEX.xml:S1:10387:3	O
cycle	XIAFLEX.xml:S1:10391:5	O
.	XIAFLEX.xml:S1:10396:1	O

The	XIAFLEX.xml:S1:10398:3	O
treatment	XIAFLEX.xml:S1:10402:9	O
cycle	XIAFLEX.xml:S1:10412:5	O
was	XIAFLEX.xml:S1:10418:3	O
repeated	XIAFLEX.xml:S1:10422:8	O
at	XIAFLEX.xml:S1:10431:2	O
approximately	XIAFLEX.xml:S1:10434:13	O
6	XIAFLEX.xml:S1:10448:1	O
-	XIAFLEX.xml:S1:10449:1	O
week	XIAFLEX.xml:S1:10450:4	O
intervals	XIAFLEX.xml:S1:10455:9	O
up	XIAFLEX.xml:S1:10465:2	O
to	XIAFLEX.xml:S1:10468:2	O
three	XIAFLEX.xml:S1:10471:5	O
additional	XIAFLEX.xml:S1:10477:10	O
times	XIAFLEX.xml:S1:10488:5	O
,	XIAFLEX.xml:S1:10493:1	O
for	XIAFLEX.xml:S1:10495:3	O
a	XIAFLEX.xml:S1:10499:1	O
maximum	XIAFLEX.xml:S1:10501:7	O
of	XIAFLEX.xml:S1:10509:2	O
8	XIAFLEX.xml:S1:10512:1	O
total	XIAFLEX.xml:S1:10514:5	O
injection	XIAFLEX.xml:S1:10520:9	O
procedures	XIAFLEX.xml:S1:10530:10	O
and	XIAFLEX.xml:S1:10541:3	O
4	XIAFLEX.xml:S1:10545:1	O
total	XIAFLEX.xml:S1:10547:5	O
modeling	XIAFLEX.xml:S1:10553:8	O
procedures	XIAFLEX.xml:S1:10562:10	O
[	XIAFLEX.xml:S1:10576:1	O
see	XIAFLEX.xml:S1:10577:3	O
Clinical	XIAFLEX.xml:S1:10581:8	O
Studies	XIAFLEX.xml:S1:10590:7	O
(	XIAFLEX.xml:S1:10598:1	O
14.2	XIAFLEX.xml:S1:10599:4	O
)]	XIAFLEX.xml:S1:10603:2	O
.	XIAFLEX.xml:S1:10605:1	O

The	XIAFLEX.xml:S1:10615:3	O

majority	XIAFLEX.xml:S1:10619:8	O
of	XIAFLEX.xml:S1:10628:2	O
Peyronie	XIAFLEX.xml:S1:10631:8	O
's	XIAFLEX.xml:S1:10639:2	O
patients	XIAFLEX.xml:S1:10642:8	O
experienced	XIAFLEX.xml:S1:10651:11	O
at	XIAFLEX.xml:S1:10663:2	O
least	XIAFLEX.xml:S1:10666:5	O
one	XIAFLEX.xml:S1:10672:3	O
adverse	XIAFLEX.xml:S1:10676:7	O
reaction	XIAFLEX.xml:S1:10684:8	O
(	XIAFLEX.xml:S1:10693:1	O
92%	XIAFLEX.xml:S1:10694:3	O
XIAFLEX	XIAFLEX.xml:S1:10698:7	O
-	XIAFLEX.xml:S1:10705:1	O
treated	XIAFLEX.xml:S1:10706:7	O
patients	XIAFLEX.xml:S1:10714:8	O
,	XIAFLEX.xml:S1:10722:1	O
61%	XIAFLEX.xml:S1:10724:3	O
placebo	XIAFLEX.xml:S1:10728:7	O
-	XIAFLEX.xml:S1:10735:1	O
treated	XIAFLEX.xml:S1:10736:7	O
)	XIAFLEX.xml:S1:10743:1	O
.	XIAFLEX.xml:S1:10744:1	O

Most	XIAFLEX.xml:S1:10746:4	O
adverse	XIAFLEX.xml:S1:10751:7	B-AdverseReaction
reactions	XIAFLEX.xml:S1:10759:9	I-AdverseReaction
were	XIAFLEX.xml:S1:10769:4	O
local	XIAFLEX.xml:S1:10774:5	O
events	XIAFLEX.xml:S1:10780:6	O
of	XIAFLEX.xml:S1:10787:2	I-AdverseReaction
the	XIAFLEX.xml:S1:10790:3	I-AdverseReaction
penis	XIAFLEX.xml:S1:10794:5	I-AdverseReaction
and	XIAFLEX.xml:S1:10800:3	O
groin	XIAFLEX.xml:S1:10804:5	I-AdverseReaction
and	XIAFLEX.xml:S1:10810:3	O
the	XIAFLEX.xml:S1:10814:3	O
majority	XIAFLEX.xml:S1:10818:8	O
of	XIAFLEX.xml:S1:10827:2	O
these	XIAFLEX.xml:S1:10830:5	O
events	XIAFLEX.xml:S1:10836:6	O
were	XIAFLEX.xml:S1:10843:4	O
of	XIAFLEX.xml:S1:10848:2	O
mild	XIAFLEX.xml:S1:10851:4	B-Severity
or	XIAFLEX.xml:S1:10856:2	O
moderate	XIAFLEX.xml:S1:10859:8	B-Severity
severity	XIAFLEX.xml:S1:10868:8	O
,	XIAFLEX.xml:S1:10876:1	O
and	XIAFLEX.xml:S1:10878:3	O
most	XIAFLEX.xml:S1:10882:4	O
(	XIAFLEX.xml:S1:10887:1	O
79%	XIAFLEX.xml:S1:10888:3	O
)	XIAFLEX.xml:S1:10891:1	O
resolved	XIAFLEX.xml:S1:10893:8	O
within	XIAFLEX.xml:S1:10902:6	O
14	XIAFLEX.xml:S1:10909:2	O
days	XIAFLEX.xml:S1:10912:4	O
of	XIAFLEX.xml:S1:10917:2	O
the	XIAFLEX.xml:S1:10920:3	O
injection	XIAFLEX.xml:S1:10924:9	O
.	XIAFLEX.xml:S1:10933:1	O

The	XIAFLEX.xml:S1:10935:3	O
adverse	XIAFLEX.xml:S1:10939:7	O
reaction	XIAFLEX.xml:S1:10947:8	O
profile	XIAFLEX.xml:S1:10956:7	O
was	XIAFLEX.xml:S1:10964:3	O
similar	XIAFLEX.xml:S1:10968:7	O
after	XIAFLEX.xml:S1:10976:5	O
each	XIAFLEX.xml:S1:10982:4	O
injection	XIAFLEX.xml:S1:10987:9	O
,	XIAFLEX.xml:S1:10996:1	O
regardless	XIAFLEX.xml:S1:10998:10	O
of	XIAFLEX.xml:S1:11009:2	O
the	XIAFLEX.xml:S1:11012:3	O
number	XIAFLEX.xml:S1:11016:6	O
of	XIAFLEX.xml:S1:11023:2	O
injections	XIAFLEX.xml:S1:11026:10	O
administered	XIAFLEX.xml:S1:11037:12	O
.	XIAFLEX.xml:S1:11049:1	O

The	XIAFLEX.xml:S1:11055:3	O
most	XIAFLEX.xml:S1:11059:4	O
frequently	XIAFLEX.xml:S1:11064:10	O
reported	XIAFLEX.xml:S1:11075:8	O
adverse	XIAFLEX.xml:S1:11084:7	O
drug	XIAFLEX.xml:S1:11092:4	O
reactions	XIAFLEX.xml:S1:11097:9	O
(	XIAFLEX.xml:S1:11107:1	O
25%	XIAFLEX.xml:S1:11111:3	O
)	XIAFLEX.xml:S1:11114:1	O
in	XIAFLEX.xml:S1:11116:2	O
the	XIAFLEX.xml:S1:11119:3	O
XIAFLEX	XIAFLEX.xml:S1:11123:7	O
clinical	XIAFLEX.xml:S1:11131:8	O
trials	XIAFLEX.xml:S1:11140:6	O
in	XIAFLEX.xml:S1:11147:2	O
patients	XIAFLEX.xml:S1:11150:8	O
with	XIAFLEX.xml:S1:11159:4	O
Peyronie	XIAFLEX.xml:S1:11164:8	O
's	XIAFLEX.xml:S1:11172:2	O
disease	XIAFLEX.xml:S1:11175:7	O
were	XIAFLEX.xml:S1:11183:4	O
penile	XIAFLEX.xml:S1:11188:6	B-AdverseReaction
hematoma	XIAFLEX.xml:S1:11195:8	I-AdverseReaction
,	XIAFLEX.xml:S1:11203:1	O
penile	XIAFLEX.xml:S1:11205:6	B-AdverseReaction
swelling	XIAFLEX.xml:S1:11212:8	I-AdverseReaction
,	XIAFLEX.xml:S1:11220:1	O
and	XIAFLEX.xml:S1:11222:3	O
penile	XIAFLEX.xml:S1:11226:6	B-AdverseReaction
pain	XIAFLEX.xml:S1:11233:4	I-AdverseReaction
.	XIAFLEX.xml:S1:11237:1	O

Table	XIAFLEX.xml:S1:11239:5	O
5	XIAFLEX.xml:S1:11245:1	O
shows	XIAFLEX.xml:S1:11247:5	O
the	XIAFLEX.xml:S1:11253:3	O
incidence	XIAFLEX.xml:S1:11257:9	O
of	XIAFLEX.xml:S1:11267:2	O
adverse	XIAFLEX.xml:S1:11270:7	O
reactions	XIAFLEX.xml:S1:11278:9	O
that	XIAFLEX.xml:S1:11288:4	O
were	XIAFLEX.xml:S1:11293:4	O
reported	XIAFLEX.xml:S1:11298:8	O
in	XIAFLEX.xml:S1:11307:2	O
greater	XIAFLEX.xml:S1:11310:7	O
than	XIAFLEX.xml:S1:11318:4	O
or	XIAFLEX.xml:S1:11323:2	O
equal	XIAFLEX.xml:S1:11326:5	O
to	XIAFLEX.xml:S1:11332:2	O
1%	XIAFLEX.xml:S1:11335:2	O
of	XIAFLEX.xml:S1:11338:2	O
XIAFLEX	XIAFLEX.xml:S1:11341:7	O
-	XIAFLEX.xml:S1:11348:1	O
treated	XIAFLEX.xml:S1:11349:7	O
patients	XIAFLEX.xml:S1:11357:8	O
and	XIAFLEX.xml:S1:11366:3	O
at	XIAFLEX.xml:S1:11370:2	O
a	XIAFLEX.xml:S1:11373:1	O
frequency	XIAFLEX.xml:S1:11375:9	O
greater	XIAFLEX.xml:S1:11385:7	O
than	XIAFLEX.xml:S1:11393:4	O
placebo	XIAFLEX.xml:S1:11398:7	O
-	XIAFLEX.xml:S1:11405:1	O
treated	XIAFLEX.xml:S1:11406:7	O
patients	XIAFLEX.xml:S1:11414:8	O
after	XIAFLEX.xml:S1:11423:5	O
up	XIAFLEX.xml:S1:11429:2	O
to	XIAFLEX.xml:S1:11432:2	O
8	XIAFLEX.xml:S1:11435:1	O
injections	XIAFLEX.xml:S1:11437:10	O
in	XIAFLEX.xml:S1:11448:2	O
the	XIAFLEX.xml:S1:11451:3	O
pooled	XIAFLEX.xml:S1:11455:6	O
placebo	XIAFLEX.xml:S1:11462:7	O
-	XIAFLEX.xml:S1:11469:1	O
controlled	XIAFLEX.xml:S1:11470:10	O
trials	XIAFLEX.xml:S1:11481:6	O
through	XIAFLEX.xml:S1:11488:7	O
Day	XIAFLEX.xml:S1:11496:3	O
365	XIAFLEX.xml:S1:11500:3	O
.	XIAFLEX.xml:S1:11503:1	O

Table	XIAFLEX.xml:S1:11509:5	O
5	XIAFLEX.xml:S1:11515:1	O
.	XIAFLEX.xml:S1:11516:1	O

Adverse	XIAFLEX.xml:S1:11518:7	O
Reactions	XIAFLEX.xml:S1:11526:9	O
Occurring	XIAFLEX.xml:S1:11536:9	O
in	XIAFLEX.xml:S1:11546:2	O
1%	XIAFLEX.xml:S1:11552:2	O
of	XIAFLEX.xml:S1:11555:2	O
XIAFLEX	XIAFLEX.xml:S1:11558:7	O
-	XIAFLEX.xml:S1:11565:1	O
Treated	XIAFLEX.xml:S1:11566:7	O
Patients	XIAFLEX.xml:S1:11574:8	O
with	XIAFLEX.xml:S1:11583:4	O
Peyronie	XIAFLEX.xml:S1:11588:8	O
's	XIAFLEX.xml:S1:11596:2	O
disease	XIAFLEX.xml:S1:11599:7	O
and	XIAFLEX.xml:S1:11607:3	O
at	XIAFLEX.xml:S1:11611:2	O
a	XIAFLEX.xml:S1:11614:1	O
Greater	XIAFLEX.xml:S1:11616:7	O
Incidence	XIAFLEX.xml:S1:11624:9	O
than	XIAFLEX.xml:S1:11634:4	O
Placebo	XIAFLEX.xml:S1:11639:7	O
After	XIAFLEX.xml:S1:11647:5	O
Up	XIAFLEX.xml:S1:11653:2	O
to	XIAFLEX.xml:S1:11656:2	O
Four	XIAFLEX.xml:S1:11659:4	O
Treatment	XIAFLEX.xml:S1:11664:9	O
Cycles	XIAFLEX.xml:S1:11674:6	O
in	XIAFLEX.xml:S1:11681:2	O
Studies	XIAFLEX.xml:S1:11684:7	O
1	XIAFLEX.xml:S1:11692:1	O
and	XIAFLEX.xml:S1:11694:3	O
2	XIAFLEX.xml:S1:11698:1	O
Combined	XIAFLEX.xml:S1:11700:8	O

a	XIAFLEX.xml:S1:11714:1	O
Includes	XIAFLEX.xml:S1:11717:8	O
:	XIAFLEX.xml:S1:11725:1	O
injection	XIAFLEX.xml:S1:11727:9	B-AdverseReaction
site	XIAFLEX.xml:S1:11737:4	I-AdverseReaction
hematoma	XIAFLEX.xml:S1:11742:8	I-AdverseReaction
and	XIAFLEX.xml:S1:11751:3	O
penile	XIAFLEX.xml:S1:11755:6	B-AdverseReaction
hematoma	XIAFLEX.xml:S1:11762:8	I-AdverseReaction
were	XIAFLEX.xml:S1:11771:4	O
reported	XIAFLEX.xml:S1:11776:8	O
with	XIAFLEX.xml:S1:11785:4	O
the	XIAFLEX.xml:S1:11790:3	O
verbatim	XIAFLEX.xml:S1:11794:8	O
term	XIAFLEX.xml:S1:11803:4	O
of	XIAFLEX.xml:S1:11808:2	O
penile	XIAFLEX.xml:S1:11811:6	B-AdverseReaction
bruising	XIAFLEX.xml:S1:11818:8	I-AdverseReaction
or	XIAFLEX.xml:S1:11827:2	O
injection	XIAFLEX.xml:S1:11830:9	B-AdverseReaction
site	XIAFLEX.xml:S1:11840:4	I-AdverseReaction
bruising	XIAFLEX.xml:S1:11845:8	I-AdverseReaction
in	XIAFLEX.xml:S1:11854:2	O
87%	XIAFLEX.xml:S1:11857:3	O
of	XIAFLEX.xml:S1:11861:2	O
subjects	XIAFLEX.xml:S1:11864:8	O
.	XIAFLEX.xml:S1:11872:1	O

b	XIAFLEX.xml:S1:11881:1	O
Includes	XIAFLEX.xml:S1:11884:8	O
:	XIAFLEX.xml:S1:11892:1	O
injection	XIAFLEX.xml:S1:11894:9	B-AdverseReaction
site	XIAFLEX.xml:S1:11904:4	I-AdverseReaction
swelling	XIAFLEX.xml:S1:11909:8	I-AdverseReaction
,	XIAFLEX.xml:S1:11917:1	O
penile	XIAFLEX.xml:S1:11919:6	B-AdverseReaction
edema	XIAFLEX.xml:S1:11926:5	I-AdverseReaction
,	XIAFLEX.xml:S1:11931:1	O
penile	XIAFLEX.xml:S1:11933:6	B-AdverseReaction
swelling	XIAFLEX.xml:S1:11940:8	I-AdverseReaction
,	XIAFLEX.xml:S1:11948:1	O
local	XIAFLEX.xml:S1:11950:5	B-AdverseReaction
swelling	XIAFLEX.xml:S1:11956:8	I-AdverseReaction
,	XIAFLEX.xml:S1:11964:1	O
scrotal	XIAFLEX.xml:S1:11966:7	B-AdverseReaction
swelling	XIAFLEX.xml:S1:11974:8	I-AdverseReaction
,	XIAFLEX.xml:S1:11982:1	O
and	XIAFLEX.xml:S1:11984:3	O
injection	XIAFLEX.xml:S1:11988:9	B-AdverseReaction
site	XIAFLEX.xml:S1:11998:4	I-AdverseReaction
edema	XIAFLEX.xml:S1:12003:5	I-AdverseReaction
.	XIAFLEX.xml:S1:12008:1	O

c	XIAFLEX.xml:S1:12017:1	O
Includes	XIAFLEX.xml:S1:12020:8	O
:	XIAFLEX.xml:S1:12028:1	O
injection	XIAFLEX.xml:S1:12030:9	B-AdverseReaction
site	XIAFLEX.xml:S1:12040:4	I-AdverseReaction
pain	XIAFLEX.xml:S1:12045:4	I-AdverseReaction
,	XIAFLEX.xml:S1:12049:1	O
penile	XIAFLEX.xml:S1:12051:6	B-AdverseReaction
pain	XIAFLEX.xml:S1:12058:4	I-AdverseReaction
,	XIAFLEX.xml:S1:12062:1	O
and	XIAFLEX.xml:S1:12064:3	O
injection	XIAFLEX.xml:S1:12068:9	B-AdverseReaction
site	XIAFLEX.xml:S1:12078:4	I-AdverseReaction
discomfort	XIAFLEX.xml:S1:12083:10	I-AdverseReaction
.	XIAFLEX.xml:S1:12093:1	O

d	XIAFLEX.xml:S1:12102:1	O
Includes	XIAFLEX.xml:S1:12105:8	O
:	XIAFLEX.xml:S1:12113:1	O
contusion	XIAFLEX.xml:S1:12115:9	B-AdverseReaction
,	XIAFLEX.xml:S1:12124:1	O
ecchymoses	XIAFLEX.xml:S1:12126:10	B-AdverseReaction
,	XIAFLEX.xml:S1:12136:1	O
penile	XIAFLEX.xml:S1:12138:6	B-AdverseReaction
hemorrhage	XIAFLEX.xml:S1:12145:10	I-AdverseReaction
,	XIAFLEX.xml:S1:12155:1	O
and	XIAFLEX.xml:S1:12157:3	O
injection	XIAFLEX.xml:S1:12161:9	B-AdverseReaction
site	XIAFLEX.xml:S1:12171:4	I-AdverseReaction
hemorrhage	XIAFLEX.xml:S1:12176:10	I-AdverseReaction
.	XIAFLEX.xml:S1:12186:1	O

Adverse	XIAFLEX.xml:S1:12198:7	O

Reaction	XIAFLEX.xml:S1:12206:8	O
XIAFLEXN	XIAFLEX.xml:S1:12240:8	O
551	XIAFLEX.xml:S1:12249:3	O
PlaceboN	XIAFLEX.xml:S1:12262:8	O
281	XIAFLEX.xml:S1:12271:3	O

All	XIAFLEX.xml:S1:12305:3	O
Adverse	XIAFLEX.xml:S1:12309:7	O
Reactions	XIAFLEX.xml:S1:12317:9	O
84.2%	XIAFLEX.xml:S1:12347:5	O
36.3%	XIAFLEX.xml:S1:12369:5	O

Penile	XIAFLEX.xml:S1:12414:6	B-AdverseReaction
hematoma	XIAFLEX.xml:S1:12421:8	I-AdverseReaction
a	XIAFLEX.xml:S1:12431:1	O
65.5%	XIAFLEX.xml:S1:12456:5	O
19.2%	XIAFLEX.xml:S1:12478:5	O

Penile	XIAFLEX.xml:S1:12523:6	B-AdverseReaction
swelling	XIAFLEX.xml:S1:12530:8	I-AdverseReaction
b	XIAFLEX.xml:S1:12540:1	O
55.0%	XIAFLEX.xml:S1:12565:5	O
3.2%	XIAFLEX.xml:S1:12587:4	O

Penile	XIAFLEX.xml:S1:12632:6	B-AdverseReaction
pain	XIAFLEX.xml:S1:12639:4	I-AdverseReaction
c	XIAFLEX.xml:S1:12645:1	O
45.4%	XIAFLEX.xml:S1:12674:5	O
9.3%	XIAFLEX.xml:S1:12696:4	O

Penile	XIAFLEX.xml:S1:12741:6	B-AdverseReaction
ecchymoses	XIAFLEX.xml:S1:12748:10	I-AdverseReaction
d	XIAFLEX.xml:S1:12760:1	O
14.5%	XIAFLEX.xml:S1:12783:5	O
6.8%	XIAFLEX.xml:S1:12805:4	O

Blood	XIAFLEX.xml:S1:12850:5	B-AdverseReaction
blister	XIAFLEX.xml:S1:12856:7	I-AdverseReaction
4.5%	XIAFLEX.xml:S1:12892:4	O
0	XIAFLEX.xml:S1:12914:1	O

Penile	XIAFLEX.xml:S1:12959:6	B-AdverseReaction
blister	XIAFLEX.xml:S1:12966:7	I-AdverseReaction
3.3%	XIAFLEX.xml:S1:13001:4	O
0	XIAFLEX.xml:S1:13023:1	O

Pruritus	XIAFLEX.xml:S1:13068:8	B-AdverseReaction
genital	XIAFLEX.xml:S1:13077:7	I-AdverseReaction
3.1%	XIAFLEX.xml:S1:13110:4	O
0	XIAFLEX.xml:S1:13132:1	O

Painful	XIAFLEX.xml:S1:13177:7	B-AdverseReaction
erection	XIAFLEX.xml:S1:13185:8	I-AdverseReaction
2.9%	XIAFLEX.xml:S1:13219:4	O
0	XIAFLEX.xml:S1:13241:1	O

Erectile	XIAFLEX.xml:S1:13286:8	B-AdverseReaction
dysfunction	XIAFLEX.xml:S1:13295:11	I-AdverseReaction
1.8%	XIAFLEX.xml:S1:13328:4	O
0.4%	XIAFLEX.xml:S1:13350:4	O

Skin	XIAFLEX.xml:S1:13395:4	B-AdverseReaction
discoloration	XIAFLEX.xml:S1:13400:13	I-AdverseReaction
1.8%	XIAFLEX.xml:S1:13437:4	O
0	XIAFLEX.xml:S1:13459:1	O

Procedural	XIAFLEX.xml:S1:13504:10	B-AdverseReaction
pain	XIAFLEX.xml:S1:13515:4	I-AdverseReaction
1.6%	XIAFLEX.xml:S1:13546:4	O
0.7%	XIAFLEX.xml:S1:13568:4	O

Injection	XIAFLEX.xml:S1:13613:9	B-AdverseReaction
site	XIAFLEX.xml:S1:13623:4	I-AdverseReaction
vesicles	XIAFLEX.xml:S1:13628:8	I-AdverseReaction
1.3%	XIAFLEX.xml:S1:13655:4	O
0	XIAFLEX.xml:S1:13677:1	O

Localized	XIAFLEX.xml:S1:13722:9	B-AdverseReaction
edema	XIAFLEX.xml:S1:13732:5	I-AdverseReaction
1.3%	XIAFLEX.xml:S1:13764:4	O
0	XIAFLEX.xml:S1:13786:1	O

Dyspareunia	XIAFLEX.xml:S1:13831:11	B-AdverseReaction
1.1%	XIAFLEX.xml:S1:13873:4	O
0	XIAFLEX.xml:S1:13895:1	O

Injection	XIAFLEX.xml:S1:13940:9	B-AdverseReaction
site	XIAFLEX.xml:S1:13950:4	I-AdverseReaction
pruritus	XIAFLEX.xml:S1:13955:8	I-AdverseReaction
1.1%	XIAFLEX.xml:S1:13982:4	O
0	XIAFLEX.xml:S1:14004:1	O

Nodule	XIAFLEX.xml:S1:14049:6	B-AdverseReaction
1.1%	XIAFLEX.xml:S1:14091:4	O
0	XIAFLEX.xml:S1:14113:1	O

Suprapubic	XIAFLEX.xml:S1:14158:10	B-AdverseReaction
pain	XIAFLEX.xml:S1:14169:4	I-AdverseReaction
1.1%	XIAFLEX.xml:S1:14200:4	O
0	XIAFLEX.xml:S1:14222:1	O

Severe	XIAFLEX.xml:S1:14274:6	B-Severity
penile	XIAFLEX.xml:S1:14281:6	B-AdverseReaction
hematoma	XIAFLEX.xml:S1:14288:8	I-AdverseReaction
or	XIAFLEX.xml:S1:14297:2	O
severe	XIAFLEX.xml:S1:14300:6	B-Severity
injection	XIAFLEX.xml:S1:14307:9	B-AdverseReaction
site	XIAFLEX.xml:S1:14317:4	I-AdverseReaction
hematoma	XIAFLEX.xml:S1:14322:8	I-AdverseReaction
were	XIAFLEX.xml:S1:14331:4	O
reported	XIAFLEX.xml:S1:14336:8	O
in	XIAFLEX.xml:S1:14345:2	O
33	XIAFLEX.xml:S1:14348:2	O
551	XIAFLEX.xml:S1:14351:3	O
(	XIAFLEX.xml:S1:14355:1	O
6.0%	XIAFLEX.xml:S1:14356:4	O
)	XIAFLEX.xml:S1:14360:1	O
of	XIAFLEX.xml:S1:14362:2	O
XIAFLEX	XIAFLEX.xml:S1:14365:7	O
-	XIAFLEX.xml:S1:14372:1	O
treated	XIAFLEX.xml:S1:14373:7	O
patients	XIAFLEX.xml:S1:14381:8	O
and	XIAFLEX.xml:S1:14390:3	O
0	XIAFLEX.xml:S1:14394:1	O
281	XIAFLEX.xml:S1:14396:3	O
(	XIAFLEX.xml:S1:14400:1	O
0%	XIAFLEX.xml:S1:14401:2	O
)	XIAFLEX.xml:S1:14403:1	O
of	XIAFLEX.xml:S1:14405:2	O
placebo	XIAFLEX.xml:S1:14408:7	O
-	XIAFLEX.xml:S1:14415:1	O
treated	XIAFLEX.xml:S1:14416:7	O
patients	XIAFLEX.xml:S1:14424:8	O
,	XIAFLEX.xml:S1:14432:1	O
in	XIAFLEX.xml:S1:14434:2	O
Studies	XIAFLEX.xml:S1:14437:7	O
1	XIAFLEX.xml:S1:14445:1	O
and	XIAFLEX.xml:S1:14447:3	O
2	XIAFLEX.xml:S1:14451:1	O
combined	XIAFLEX.xml:S1:14453:8	O
.	XIAFLEX.xml:S1:14461:1	O

Reports	XIAFLEX.xml:S1:14471:7	O

of	XIAFLEX.xml:S1:14479:2	O
penile	XIAFLEX.xml:S1:14482:6	O
"	XIAFLEX.xml:S1:14489:1	O
popping	XIAFLEX.xml:S1:14490:7	O
"	XIAFLEX.xml:S1:14497:1	O
sounds	XIAFLEX.xml:S1:14499:6	O
or	XIAFLEX.xml:S1:14506:2	O
sensations	XIAFLEX.xml:S1:14509:10	O
A	XIAFLEX.xml:S1:14523:1	O
popping	XIAFLEX.xml:S1:14525:7	B-AdverseReaction
noise	XIAFLEX.xml:S1:14533:5	I-AdverseReaction
or	XIAFLEX.xml:S1:14539:2	O
popping	XIAFLEX.xml:S1:14542:7	B-AdverseReaction
sensation	XIAFLEX.xml:S1:14550:9	I-AdverseReaction
in	XIAFLEX.xml:S1:14560:2	I-AdverseReaction
the	XIAFLEX.xml:S1:14563:3	I-AdverseReaction
penis	XIAFLEX.xml:S1:14567:5	I-AdverseReaction
,	XIAFLEX.xml:S1:14572:1	O
sometimes	XIAFLEX.xml:S1:14574:9	O
described	XIAFLEX.xml:S1:14584:9	O
as	XIAFLEX.xml:S1:14594:2	O
"	XIAFLEX.xml:S1:14597:1	O
snapping	XIAFLEX.xml:S1:14598:8	I-AdverseReaction
"	XIAFLEX.xml:S1:14606:1	O
or	XIAFLEX.xml:S1:14608:2	O
"	XIAFLEX.xml:S1:14611:1	O
cracking	XIAFLEX.xml:S1:14612:8	I-AdverseReaction
"	XIAFLEX.xml:S1:14620:1	O
,	XIAFLEX.xml:S1:14621:1	O
and	XIAFLEX.xml:S1:14623:3	O
sometimes	XIAFLEX.xml:S1:14627:9	O
accompanied	XIAFLEX.xml:S1:14637:11	O
by	XIAFLEX.xml:S1:14649:2	O
detumescence	XIAFLEX.xml:S1:14652:12	B-AdverseReaction
,	XIAFLEX.xml:S1:14664:1	O
hematoma	XIAFLEX.xml:S1:14666:8	B-AdverseReaction
and	XIAFLEX.xml:S1:14675:3	O
or	XIAFLEX.xml:S1:14679:2	O
pain	XIAFLEX.xml:S1:14682:4	B-AdverseReaction
,	XIAFLEX.xml:S1:14686:1	O
were	XIAFLEX.xml:S1:14688:4	O
reported	XIAFLEX.xml:S1:14693:8	O
in	XIAFLEX.xml:S1:14702:2	O
73	XIAFLEX.xml:S1:14705:2	O
551	XIAFLEX.xml:S1:14708:3	O
(	XIAFLEX.xml:S1:14712:1	O
13.2%	XIAFLEX.xml:S1:14713:5	O
)	XIAFLEX.xml:S1:14718:1	O
XIAFLEX	XIAFLEX.xml:S1:14720:7	O
-	XIAFLEX.xml:S1:14727:1	O
treated	XIAFLEX.xml:S1:14728:7	O
patients	XIAFLEX.xml:S1:14736:8	O
and	XIAFLEX.xml:S1:14745:3	O
1	XIAFLEX.xml:S1:14749:1	O
281	XIAFLEX.xml:S1:14751:3	O
(	XIAFLEX.xml:S1:14755:1	O
0.3%	XIAFLEX.xml:S1:14756:4	O
)	XIAFLEX.xml:S1:14760:1	O
placebo	XIAFLEX.xml:S1:14762:7	O
-	XIAFLEX.xml:S1:14769:1	O
treated	XIAFLEX.xml:S1:14770:7	O
patients	XIAFLEX.xml:S1:14778:8	O
.	XIAFLEX.xml:S1:14786:1	O

There	XIAFLEX.xml:S1:14792:5	O
were	XIAFLEX.xml:S1:14798:4	O
no	XIAFLEX.xml:S1:14803:2	O
clinically	XIAFLEX.xml:S1:14806:10	O
meaningful	XIAFLEX.xml:S1:14817:10	O
differences	XIAFLEX.xml:S1:14828:11	O
in	XIAFLEX.xml:S1:14840:2	O
the	XIAFLEX.xml:S1:14843:3	O
incidence	XIAFLEX.xml:S1:14847:9	O
of	XIAFLEX.xml:S1:14857:2	O
adverse	XIAFLEX.xml:S1:14860:7	O
events	XIAFLEX.xml:S1:14868:6	O
following	XIAFLEX.xml:S1:14875:9	O
treatment	XIAFLEX.xml:S1:14885:9	O
with	XIAFLEX.xml:S1:14895:4	O
XIAFLEX	XIAFLEX.xml:S1:14900:7	O
based	XIAFLEX.xml:S1:14908:5	O
on	XIAFLEX.xml:S1:14914:2	O
the	XIAFLEX.xml:S1:14917:3	O
severity	XIAFLEX.xml:S1:14921:8	O
of	XIAFLEX.xml:S1:14930:2	O
baseline	XIAFLEX.xml:S1:14933:8	O
erectile	XIAFLEX.xml:S1:14942:8	O
dysfunction	XIAFLEX.xml:S1:14951:11	O
or	XIAFLEX.xml:S1:14963:2	O
concomitant	XIAFLEX.xml:S1:14966:11	O
phosphodiesterase	XIAFLEX.xml:S1:14978:17	O
type	XIAFLEX.xml:S1:14996:4	O
5	XIAFLEX.xml:S1:15001:1	O
(	XIAFLEX.xml:S1:15003:1	O
PDE5	XIAFLEX.xml:S1:15004:4	O
)	XIAFLEX.xml:S1:15008:1	O
inhibitor	XIAFLEX.xml:S1:15010:9	O
use	XIAFLEX.xml:S1:15020:3	O
.	XIAFLEX.xml:S1:15023:1	O

XIAFLEX	XIAFLEX.xml:S1:15029:7	O
was	XIAFLEX.xml:S1:15037:3	O
not	XIAFLEX.xml:S1:15041:3	B-Negation
associated	XIAFLEX.xml:S1:15045:10	O
with	XIAFLEX.xml:S1:15056:4	O
shortening	XIAFLEX.xml:S1:15061:10	B-AdverseReaction
of	XIAFLEX.xml:S1:15072:2	I-AdverseReaction
penile	XIAFLEX.xml:S1:15075:6	I-AdverseReaction
length	XIAFLEX.xml:S1:15082:6	I-AdverseReaction
in	XIAFLEX.xml:S1:15089:2	O
clinical	XIAFLEX.xml:S1:15092:8	O
trials	XIAFLEX.xml:S1:15101:6	O
in	XIAFLEX.xml:S1:15108:2	O
the	XIAFLEX.xml:S1:15111:3	O
treatment	XIAFLEX.xml:S1:15115:9	O
of	XIAFLEX.xml:S1:15125:2	O
Peyronie	XIAFLEX.xml:S1:15128:8	O
's	XIAFLEX.xml:S1:15136:2	O
disease	XIAFLEX.xml:S1:15139:7	O
.	XIAFLEX.xml:S1:15146:1	O

6.3	XIAFLEX.xml:S1:15154:3	O
Immunogenicity	XIAFLEX.xml:S1:15158:14	O

During	XIAFLEX.xml:S1:15176:6	O
clinical	XIAFLEX.xml:S1:15183:8	O
studies	XIAFLEX.xml:S1:15192:7	O
in	XIAFLEX.xml:S1:15200:2	O
Dupuytren	XIAFLEX.xml:S1:15203:9	O
's	XIAFLEX.xml:S1:15212:2	O
contracture	XIAFLEX.xml:S1:15215:11	O
and	XIAFLEX.xml:S1:15227:3	O
Peyronie	XIAFLEX.xml:S1:15231:8	O
's	XIAFLEX.xml:S1:15239:2	O
disease	XIAFLEX.xml:S1:15242:7	O
,	XIAFLEX.xml:S1:15249:1	O
patients	XIAFLEX.xml:S1:15251:8	O
were	XIAFLEX.xml:S1:15260:4	O
tested	XIAFLEX.xml:S1:15265:6	O
at	XIAFLEX.xml:S1:15272:2	O
multiple	XIAFLEX.xml:S1:15275:8	O
time	XIAFLEX.xml:S1:15284:4	O
points	XIAFLEX.xml:S1:15289:6	O
for	XIAFLEX.xml:S1:15296:3	O
antibodies	XIAFLEX.xml:S1:15300:10	O
to	XIAFLEX.xml:S1:15311:2	O
the	XIAFLEX.xml:S1:15314:3	O
protein	XIAFLEX.xml:S1:15318:7	O
components	XIAFLEX.xml:S1:15326:10	O
of	XIAFLEX.xml:S1:15337:2	O
XIAFLEX	XIAFLEX.xml:S1:15340:7	O
(	XIAFLEX.xml:S1:15348:1	O
AUX	XIAFLEX.xml:S1:15349:3	O
-	XIAFLEX.xml:S1:15352:1	O
I	XIAFLEX.xml:S1:15353:1	O
and	XIAFLEX.xml:S1:15355:3	O
AUX	XIAFLEX.xml:S1:15359:3	O
-	XIAFLEX.xml:S1:15362:1	O
II	XIAFLEX.xml:S1:15363:2	O
)	XIAFLEX.xml:S1:15365:1	O
.	XIAFLEX.xml:S1:15366:1	O

In	XIAFLEX.xml:S1:15372:2	O
the	XIAFLEX.xml:S1:15375:3	O
Dupuytren	XIAFLEX.xml:S1:15379:9	O
's	XIAFLEX.xml:S1:15388:2	O
contracture	XIAFLEX.xml:S1:15391:11	O
clinical	XIAFLEX.xml:S1:15403:8	O
studies	XIAFLEX.xml:S1:15412:7	O
(	XIAFLEX.xml:S1:15420:1	O
Studies	XIAFLEX.xml:S1:15421:7	O
1	XIAFLEX.xml:S1:15429:1	O
and	XIAFLEX.xml:S1:15431:3	O
2	XIAFLEX.xml:S1:15435:1	O
)	XIAFLEX.xml:S1:15436:1	O
,	XIAFLEX.xml:S1:15437:1	O
at	XIAFLEX.xml:S1:15439:2	O
30	XIAFLEX.xml:S1:15442:2	O
days	XIAFLEX.xml:S1:15445:4	O
post	XIAFLEX.xml:S1:15450:4	O
the	XIAFLEX.xml:S1:15455:3	O
first	XIAFLEX.xml:S1:15459:5	O
injection	XIAFLEX.xml:S1:15465:9	O
of	XIAFLEX.xml:S1:15475:2	O
XIAFLEX	XIAFLEX.xml:S1:15478:7	O
0.58	XIAFLEX.xml:S1:15486:4	O
mg	XIAFLEX.xml:S1:15491:2	O
,	XIAFLEX.xml:S1:15493:1	O
92%	XIAFLEX.xml:S1:15495:3	O
of	XIAFLEX.xml:S1:15499:2	O
patients	XIAFLEX.xml:S1:15502:8	O
had	XIAFLEX.xml:S1:15511:3	O
antibodies	XIAFLEX.xml:S1:15515:10	O
against	XIAFLEX.xml:S1:15526:7	O
AUX	XIAFLEX.xml:S1:15534:3	O
-	XIAFLEX.xml:S1:15537:1	O
I	XIAFLEX.xml:S1:15538:1	O
detected	XIAFLEX.xml:S1:15540:8	O
and	XIAFLEX.xml:S1:15549:3	O
86%	XIAFLEX.xml:S1:15553:3	O
of	XIAFLEX.xml:S1:15557:2	O
patients	XIAFLEX.xml:S1:15560:8	O
had	XIAFLEX.xml:S1:15569:3	O
antibodies	XIAFLEX.xml:S1:15573:10	O
against	XIAFLEX.xml:S1:15584:7	O
AUX	XIAFLEX.xml:S1:15592:3	O
-	XIAFLEX.xml:S1:15595:1	O
II	XIAFLEX.xml:S1:15596:2	O
detected	XIAFLEX.xml:S1:15599:8	O
.	XIAFLEX.xml:S1:15607:1	O

After	XIAFLEX.xml:S1:15609:5	O
the	XIAFLEX.xml:S1:15615:3	O
fourth	XIAFLEX.xml:S1:15619:6	O
injection	XIAFLEX.xml:S1:15626:9	O
of	XIAFLEX.xml:S1:15636:2	O
XIAFLEX	XIAFLEX.xml:S1:15639:7	O
,	XIAFLEX.xml:S1:15646:1	O
every	XIAFLEX.xml:S1:15648:5	O
XIAFLEX	XIAFLEX.xml:S1:15654:7	O
-	XIAFLEX.xml:S1:15661:1	O
treated	XIAFLEX.xml:S1:15662:7	O
patient	XIAFLEX.xml:S1:15670:7	O
developed	XIAFLEX.xml:S1:15678:9	O
high	XIAFLEX.xml:S1:15688:4	O
titers	XIAFLEX.xml:S1:15693:6	O
of	XIAFLEX.xml:S1:15700:2	O
antibodies	XIAFLEX.xml:S1:15703:10	O
to	XIAFLEX.xml:S1:15714:2	O
both	XIAFLEX.xml:S1:15717:4	O
AUX	XIAFLEX.xml:S1:15722:3	O
-	XIAFLEX.xml:S1:15725:1	O
I	XIAFLEX.xml:S1:15726:1	O
and	XIAFLEX.xml:S1:15728:3	O
AUX	XIAFLEX.xml:S1:15732:3	O
-	XIAFLEX.xml:S1:15735:1	O
II	XIAFLEX.xml:S1:15736:2	O
.	XIAFLEX.xml:S1:15738:1	O

After	XIAFLEX.xml:S1:15741:5	O
five	XIAFLEX.xml:S1:15747:4	O
years	XIAFLEX.xml:S1:15752:5	O
more	XIAFLEX.xml:S1:15758:4	O
than	XIAFLEX.xml:S1:15763:4	O
90	XIAFLEX.xml:S1:15768:2	O
percent	XIAFLEX.xml:S1:15771:7	O
of	XIAFLEX.xml:S1:15779:2	O
patients	XIAFLEX.xml:S1:15782:8	O
remained	XIAFLEX.xml:S1:15791:8	O
seropositive	XIAFLEX.xml:S1:15800:12	O
for	XIAFLEX.xml:S1:15813:3	O
anti	XIAFLEX.xml:S1:15817:4	O
-	XIAFLEX.xml:S1:15821:1	O
AUX	XIAFLEX.xml:S1:15822:3	O
-	XIAFLEX.xml:S1:15825:1	O
I	XIAFLEX.xml:S1:15826:1	O
and	XIAFLEX.xml:S1:15828:3	O
anti	XIAFLEX.xml:S1:15832:4	O
-	XIAFLEX.xml:S1:15836:1	O
AUX	XIAFLEX.xml:S1:15837:3	O
-	XIAFLEX.xml:S1:15840:1	O
II	XIAFLEX.xml:S1:15841:2	O
antibody	XIAFLEX.xml:S1:15844:8	O
(	XIAFLEX.xml:S1:15853:1	O
Study	XIAFLEX.xml:S1:15854:5	O
4	XIAFLEX.xml:S1:15860:1	O
)	XIAFLEX.xml:S1:15861:1	O
.	XIAFLEX.xml:S1:15862:1	O

Neutralizing	XIAFLEX.xml:S1:15865:12	O
antibodies	XIAFLEX.xml:S1:15878:10	O
were	XIAFLEX.xml:S1:15889:4	O
assayed	XIAFLEX.xml:S1:15894:7	O
for	XIAFLEX.xml:S1:15902:3	O
all	XIAFLEX.xml:S1:15906:3	O
patients	XIAFLEX.xml:S1:15910:8	O
(	XIAFLEX.xml:S1:15919:1	O
204	XIAFLEX.xml:S1:15920:3	O
)	XIAFLEX.xml:S1:15923:1	O
in	XIAFLEX.xml:S1:15925:2	O
Study	XIAFLEX.xml:S1:15928:5	O
1	XIAFLEX.xml:S1:15934:1	O
.	XIAFLEX.xml:S1:15935:1	O

Neutralizing	XIAFLEX.xml:S1:15937:12	O
antibodies	XIAFLEX.xml:S1:15950:10	O
to	XIAFLEX.xml:S1:15961:2	O
AUX	XIAFLEX.xml:S1:15964:3	O
-	XIAFLEX.xml:S1:15967:1	O
I	XIAFLEX.xml:S1:15968:1	O
or	XIAFLEX.xml:S1:15970:2	O
AUX	XIAFLEX.xml:S1:15973:3	O
-	XIAFLEX.xml:S1:15976:1	O
II	XIAFLEX.xml:S1:15977:2	O
,	XIAFLEX.xml:S1:15979:1	O
were	XIAFLEX.xml:S1:15981:4	O
detected	XIAFLEX.xml:S1:15986:8	O
in	XIAFLEX.xml:S1:15995:2	O
10%	XIAFLEX.xml:S1:15998:3	O
and	XIAFLEX.xml:S1:16002:3	O
21%	XIAFLEX.xml:S1:16006:3	O
,	XIAFLEX.xml:S1:16009:1	O
respectively	XIAFLEX.xml:S1:16011:12	O
,	XIAFLEX.xml:S1:16023:1	O
of	XIAFLEX.xml:S1:16025:2	O
patients	XIAFLEX.xml:S1:16028:8	O
treated	XIAFLEX.xml:S1:16037:7	O
with	XIAFLEX.xml:S1:16045:4	O
XIAFLEX	XIAFLEX.xml:S1:16050:7	O
.	XIAFLEX.xml:S1:16057:1	O

Among	XIAFLEX.xml:S1:16059:5	O
patients	XIAFLEX.xml:S1:16065:8	O
in	XIAFLEX.xml:S1:16074:2	O
Study	XIAFLEX.xml:S1:16077:5	O
3	XIAFLEX.xml:S1:16083:1	O
who	XIAFLEX.xml:S1:16085:3	O
reported	XIAFLEX.xml:S1:16089:8	O
no	XIAFLEX.xml:S1:16098:2	O
prior	XIAFLEX.xml:S1:16101:5	O
exposure	XIAFLEX.xml:S1:16107:8	O
to	XIAFLEX.xml:S1:16116:2	O
XIAFLEX	XIAFLEX.xml:S1:16119:7	O
,	XIAFLEX.xml:S1:16126:1	O
97%	XIAFLEX.xml:S1:16128:3	O
of	XIAFLEX.xml:S1:16132:2	O
patients	XIAFLEX.xml:S1:16135:8	O
had	XIAFLEX.xml:S1:16144:3	O
antibodies	XIAFLEX.xml:S1:16148:10	O
against	XIAFLEX.xml:S1:16159:7	O
AUX	XIAFLEX.xml:S1:16167:3	O
-	XIAFLEX.xml:S1:16170:1	O
I	XIAFLEX.xml:S1:16171:1	O
and	XIAFLEX.xml:S1:16173:3	O
AUX	XIAFLEX.xml:S1:16177:3	O
-	XIAFLEX.xml:S1:16180:1	O
II	XIAFLEX.xml:S1:16181:2	O
after	XIAFLEX.xml:S1:16184:5	O
two	XIAFLEX.xml:S1:16190:3	O
concurrent	XIAFLEX.xml:S1:16194:10	O
doses	XIAFLEX.xml:S1:16205:5	O
of	XIAFLEX.xml:S1:16211:2	O
XIAFLEX	XIAFLEX.xml:S1:16214:7	O
0.58	XIAFLEX.xml:S1:16222:4	O
mg	XIAFLEX.xml:S1:16227:2	O
(	XIAFLEX.xml:S1:16230:1	O
total	XIAFLEX.xml:S1:16231:5	O
dose	XIAFLEX.xml:S1:16237:4	O
of	XIAFLEX.xml:S1:16242:2	O
1.16	XIAFLEX.xml:S1:16245:4	O
mg	XIAFLEX.xml:S1:16250:2	O
)	XIAFLEX.xml:S1:16252:1	O
in	XIAFLEX.xml:S1:16254:2	O
the	XIAFLEX.xml:S1:16257:3	O
same	XIAFLEX.xml:S1:16261:4	O
hand	XIAFLEX.xml:S1:16266:4	O
.	XIAFLEX.xml:S1:16270:1	O

In	XIAFLEX.xml:S1:16273:2	O
Study	XIAFLEX.xml:S1:16276:5	O
5	XIAFLEX.xml:S1:16282:1	O
,	XIAFLEX.xml:S1:16283:1	O
treatment	XIAFLEX.xml:S1:16285:9	O
of	XIAFLEX.xml:S1:16295:2	O
recurrent	XIAFLEX.xml:S1:16298:9	O
contractures	XIAFLEX.xml:S1:16308:12	O
with	XIAFLEX.xml:S1:16321:4	O
XIAFLEX	XIAFLEX.xml:S1:16326:7	O
resulted	XIAFLEX.xml:S1:16334:8	O
in	XIAFLEX.xml:S1:16343:2	O
similar	XIAFLEX.xml:S1:16346:7	O
immunogenicity	XIAFLEX.xml:S1:16354:14	O
results	XIAFLEX.xml:S1:16369:7	O
as	XIAFLEX.xml:S1:16377:2	O
seen	XIAFLEX.xml:S1:16380:4	O
in	XIAFLEX.xml:S1:16385:2	O
Studies	XIAFLEX.xml:S1:16388:7	O
1	XIAFLEX.xml:S1:16396:1	O
and	XIAFLEX.xml:S1:16398:3	O
2	XIAFLEX.xml:S1:16402:1	O
.	XIAFLEX.xml:S1:16403:1	O

In	XIAFLEX.xml:S1:16409:2	O
the	XIAFLEX.xml:S1:16412:3	O
Peyronie	XIAFLEX.xml:S1:16416:8	O
's	XIAFLEX.xml:S1:16424:2	O
disease	XIAFLEX.xml:S1:16427:7	O
clinical	XIAFLEX.xml:S1:16435:8	O
studies	XIAFLEX.xml:S1:16444:7	O
,	XIAFLEX.xml:S1:16451:1	O
at	XIAFLEX.xml:S1:16453:2	O
6	XIAFLEX.xml:S1:16456:1	O
weeks	XIAFLEX.xml:S1:16458:5	O
after	XIAFLEX.xml:S1:16464:5	O
the	XIAFLEX.xml:S1:16470:3	O
first	XIAFLEX.xml:S1:16474:5	O
treatment	XIAFLEX.xml:S1:16480:9	O
cycle	XIAFLEX.xml:S1:16490:5	O
of	XIAFLEX.xml:S1:16496:2	O
XIAFLEX	XIAFLEX.xml:S1:16499:7	O
0.58	XIAFLEX.xml:S1:16507:4	O
mg	XIAFLEX.xml:S1:16512:2	O
,	XIAFLEX.xml:S1:16514:1	O
approximately	XIAFLEX.xml:S1:16516:13	O
75%	XIAFLEX.xml:S1:16530:3	O
of	XIAFLEX.xml:S1:16534:2	O
patients	XIAFLEX.xml:S1:16537:8	O
had	XIAFLEX.xml:S1:16546:3	O
antibodies	XIAFLEX.xml:S1:16550:10	O
against	XIAFLEX.xml:S1:16561:7	O
AUX	XIAFLEX.xml:S1:16569:3	O
-	XIAFLEX.xml:S1:16572:1	O
I	XIAFLEX.xml:S1:16573:1	O
and	XIAFLEX.xml:S1:16575:3	O
approximately	XIAFLEX.xml:S1:16579:13	O
55%	XIAFLEX.xml:S1:16593:3	O
of	XIAFLEX.xml:S1:16597:2	O
patients	XIAFLEX.xml:S1:16600:8	O
had	XIAFLEX.xml:S1:16609:3	O
antibodies	XIAFLEX.xml:S1:16613:10	O
against	XIAFLEX.xml:S1:16624:7	O
AUX	XIAFLEX.xml:S1:16632:3	O
-	XIAFLEX.xml:S1:16635:1	O
II	XIAFLEX.xml:S1:16636:2	O
.	XIAFLEX.xml:S1:16638:1	O

Six	XIAFLEX.xml:S1:16640:3	O
weeks	XIAFLEX.xml:S1:16644:5	O
after	XIAFLEX.xml:S1:16650:5	O
the	XIAFLEX.xml:S1:16656:3	O
eighth	XIAFLEX.xml:S1:16660:6	O
injection	XIAFLEX.xml:S1:16667:9	O
(	XIAFLEX.xml:S1:16677:1	O
fourth	XIAFLEX.xml:S1:16678:6	O
treatment	XIAFLEX.xml:S1:16685:9	O
cycle	XIAFLEX.xml:S1:16695:5	O
)	XIAFLEX.xml:S1:16700:1	O
of	XIAFLEX.xml:S1:16702:2	O
XIAFLEX	XIAFLEX.xml:S1:16705:7	O
,	XIAFLEX.xml:S1:16712:1	O
99%	XIAFLEX.xml:S1:16715:3	O
of	XIAFLEX.xml:S1:16719:2	O
XIAFLEX	XIAFLEX.xml:S1:16722:7	O
-	XIAFLEX.xml:S1:16729:1	O
treated	XIAFLEX.xml:S1:16730:7	O
patients	XIAFLEX.xml:S1:16738:8	O
developed	XIAFLEX.xml:S1:16747:9	O
high	XIAFLEX.xml:S1:16757:4	O
titers	XIAFLEX.xml:S1:16762:6	O
of	XIAFLEX.xml:S1:16769:2	O
antibodies	XIAFLEX.xml:S1:16772:10	O
to	XIAFLEX.xml:S1:16783:2	O
both	XIAFLEX.xml:S1:16786:4	O
AUX	XIAFLEX.xml:S1:16791:3	O
-	XIAFLEX.xml:S1:16794:1	O
I	XIAFLEX.xml:S1:16795:1	O
and	XIAFLEX.xml:S1:16797:3	O
AUX	XIAFLEX.xml:S1:16801:3	O
-	XIAFLEX.xml:S1:16804:1	O
II	XIAFLEX.xml:S1:16805:2	O
.	XIAFLEX.xml:S1:16807:1	O

Neutralizing	XIAFLEX.xml:S1:16809:12	O
antibodies	XIAFLEX.xml:S1:16822:10	O
were	XIAFLEX.xml:S1:16833:4	O
assayed	XIAFLEX.xml:S1:16838:7	O
for	XIAFLEX.xml:S1:16846:3	O
a	XIAFLEX.xml:S1:16850:1	O
subset	XIAFLEX.xml:S1:16852:6	O
of	XIAFLEX.xml:S1:16859:2	O
70	XIAFLEX.xml:S1:16862:2	O
samples	XIAFLEX.xml:S1:16865:7	O
selected	XIAFLEX.xml:S1:16873:8	O
to	XIAFLEX.xml:S1:16882:2	O
be	XIAFLEX.xml:S1:16885:2	O
representative	XIAFLEX.xml:S1:16888:14	O
of	XIAFLEX.xml:S1:16903:2	O
high	XIAFLEX.xml:S1:16906:4	O
and	XIAFLEX.xml:S1:16911:3	O
low	XIAFLEX.xml:S1:16915:3	O
titer	XIAFLEX.xml:S1:16919:5	O
binding	XIAFLEX.xml:S1:16925:7	O
antibody	XIAFLEX.xml:S1:16933:8	O
responses	XIAFLEX.xml:S1:16942:9	O
at	XIAFLEX.xml:S1:16952:2	O
week	XIAFLEX.xml:S1:16955:4	O
12	XIAFLEX.xml:S1:16960:2	O
of	XIAFLEX.xml:S1:16963:2	O
treatment	XIAFLEX.xml:S1:16966:9	O
.	XIAFLEX.xml:S1:16975:1	O

For	XIAFLEX.xml:S1:16977:3	O
each	XIAFLEX.xml:S1:16981:4	O
subject	XIAFLEX.xml:S1:16986:7	O
in	XIAFLEX.xml:S1:16994:2	O
whom	XIAFLEX.xml:S1:16997:4	O
a	XIAFLEX.xml:S1:17002:1	O
Week	XIAFLEX.xml:S1:17004:4	O
12	XIAFLEX.xml:S1:17009:2	O
sample	XIAFLEX.xml:S1:17012:6	O
was	XIAFLEX.xml:S1:17019:3	O
selected	XIAFLEX.xml:S1:17023:8	O
,	XIAFLEX.xml:S1:17031:1	O
the	XIAFLEX.xml:S1:17033:3	O
corresponding	XIAFLEX.xml:S1:17037:13	O
Week	XIAFLEX.xml:S1:17051:4	O
6	XIAFLEX.xml:S1:17056:1	O
,	XIAFLEX.xml:S1:17057:1	O
18	XIAFLEX.xml:S1:17059:2	O
,	XIAFLEX.xml:S1:17061:1	O
24	XIAFLEX.xml:S1:17063:2	O
,	XIAFLEX.xml:S1:17065:1	O
and	XIAFLEX.xml:S1:17067:3	O
52	XIAFLEX.xml:S1:17071:2	O
samples	XIAFLEX.xml:S1:17074:7	O
were	XIAFLEX.xml:S1:17082:4	O
assayed	XIAFLEX.xml:S1:17087:7	O
if	XIAFLEX.xml:S1:17095:2	O
they	XIAFLEX.xml:S1:17098:4	O
were	XIAFLEX.xml:S1:17103:4	O
also	XIAFLEX.xml:S1:17108:4	O
binding	XIAFLEX.xml:S1:17113:7	O
antibody	XIAFLEX.xml:S1:17121:8	O
positive	XIAFLEX.xml:S1:17130:8	O
.	XIAFLEX.xml:S1:17138:1	O

Neutralizing	XIAFLEX.xml:S1:17140:12	O
antibodies	XIAFLEX.xml:S1:17153:10	O
to	XIAFLEX.xml:S1:17164:2	O
AUX	XIAFLEX.xml:S1:17167:3	O
-	XIAFLEX.xml:S1:17170:1	O
I	XIAFLEX.xml:S1:17171:1	O
or	XIAFLEX.xml:S1:17173:2	O
AUX	XIAFLEX.xml:S1:17176:3	O
-	XIAFLEX.xml:S1:17179:1	O
II	XIAFLEX.xml:S1:17180:2	O
,	XIAFLEX.xml:S1:17182:1	O
were	XIAFLEX.xml:S1:17184:4	O
detected	XIAFLEX.xml:S1:17189:8	O
in	XIAFLEX.xml:S1:17198:2	O
60%	XIAFLEX.xml:S1:17201:3	O
and	XIAFLEX.xml:S1:17205:3	O
51.8%	XIAFLEX.xml:S1:17209:5	O
,	XIAFLEX.xml:S1:17214:1	O
respectively	XIAFLEX.xml:S1:17216:12	O
,	XIAFLEX.xml:S1:17228:1	O
of	XIAFLEX.xml:S1:17230:2	O
patients	XIAFLEX.xml:S1:17233:8	O
tested	XIAFLEX.xml:S1:17242:6	O
.	XIAFLEX.xml:S1:17248:1	O

In	XIAFLEX.xml:S1:17254:2	O
patients	XIAFLEX.xml:S1:17257:8	O
treated	XIAFLEX.xml:S1:17266:7	O
for	XIAFLEX.xml:S1:17274:3	O
these	XIAFLEX.xml:S1:17278:5	O
two	XIAFLEX.xml:S1:17284:3	O
indications	XIAFLEX.xml:S1:17288:11	O
,	XIAFLEX.xml:S1:17299:1	O
there	XIAFLEX.xml:S1:17301:5	O
was	XIAFLEX.xml:S1:17307:3	O
no	XIAFLEX.xml:S1:17311:2	O
apparent	XIAFLEX.xml:S1:17314:8	O
correlation	XIAFLEX.xml:S1:17323:11	O
of	XIAFLEX.xml:S1:17335:2	O
antibody	XIAFLEX.xml:S1:17338:8	O
frequency	XIAFLEX.xml:S1:17347:9	O
,	XIAFLEX.xml:S1:17356:1	O
antibody	XIAFLEX.xml:S1:17358:8	O
titers	XIAFLEX.xml:S1:17367:6	O
,	XIAFLEX.xml:S1:17373:1	O
or	XIAFLEX.xml:S1:17375:2	O
neutralizing	XIAFLEX.xml:S1:17378:12	O
status	XIAFLEX.xml:S1:17391:6	O
to	XIAFLEX.xml:S1:17398:2	O
clinical	XIAFLEX.xml:S1:17401:8	O
response	XIAFLEX.xml:S1:17410:8	O
or	XIAFLEX.xml:S1:17419:2	O
adverse	XIAFLEX.xml:S1:17422:7	O
reactions	XIAFLEX.xml:S1:17430:9	O
.	XIAFLEX.xml:S1:17439:1	O

Since	XIAFLEX.xml:S1:17445:5	O
the	XIAFLEX.xml:S1:17451:3	O
protein	XIAFLEX.xml:S1:17455:7	O
components	XIAFLEX.xml:S1:17463:10	O
in	XIAFLEX.xml:S1:17474:2	O
XIAFLEX	XIAFLEX.xml:S1:17477:7	O
(	XIAFLEX.xml:S1:17485:1	O
AUX	XIAFLEX.xml:S1:17486:3	O
-	XIAFLEX.xml:S1:17489:1	O
I	XIAFLEX.xml:S1:17490:1	O
and	XIAFLEX.xml:S1:17492:3	O
AUX	XIAFLEX.xml:S1:17496:3	O
-	XIAFLEX.xml:S1:17499:1	O
II	XIAFLEX.xml:S1:17500:2	O
)	XIAFLEX.xml:S1:17502:1	O
have	XIAFLEX.xml:S1:17504:4	O
some	XIAFLEX.xml:S1:17509:4	O
sequence	XIAFLEX.xml:S1:17514:8	O
homology	XIAFLEX.xml:S1:17523:8	O
with	XIAFLEX.xml:S1:17532:4	O
human	XIAFLEX.xml:S1:17537:5	O
matrix	XIAFLEX.xml:S1:17543:6	O
metalloproteinases	XIAFLEX.xml:S1:17550:18	O
(	XIAFLEX.xml:S1:17569:1	O
MMPs	XIAFLEX.xml:S1:17570:4	O
)	XIAFLEX.xml:S1:17574:1	O
,	XIAFLEX.xml:S1:17575:1	O
anti	XIAFLEX.xml:S1:17577:4	O
-	XIAFLEX.xml:S1:17581:1	O
product	XIAFLEX.xml:S1:17582:7	O
antibodies	XIAFLEX.xml:S1:17590:10	O
could	XIAFLEX.xml:S1:17601:5	O
theoretically	XIAFLEX.xml:S1:17607:13	O
interfere	XIAFLEX.xml:S1:17621:9	O
with	XIAFLEX.xml:S1:17631:4	O
human	XIAFLEX.xml:S1:17636:5	O
MMPs	XIAFLEX.xml:S1:17642:4	O
.	XIAFLEX.xml:S1:17646:1	O

In	XIAFLEX.xml:S1:17648:2	O
vitro	XIAFLEX.xml:S1:17651:5	O
studies	XIAFLEX.xml:S1:17657:7	O
showed	XIAFLEX.xml:S1:17665:6	O
no	XIAFLEX.xml:S1:17672:2	O
evidence	XIAFLEX.xml:S1:17675:8	O
of	XIAFLEX.xml:S1:17684:2	O
cross	XIAFLEX.xml:S1:17687:5	O
-	XIAFLEX.xml:S1:17692:1	O
reactivity	XIAFLEX.xml:S1:17693:10	O
between	XIAFLEX.xml:S1:17704:7	O
anti	XIAFLEX.xml:S1:17712:4	O
-	XIAFLEX.xml:S1:17716:1	O
drug	XIAFLEX.xml:S1:17717:4	O
-	XIAFLEX.xml:S1:17721:1	O
antibody	XIAFLEX.xml:S1:17722:8	O
positive	XIAFLEX.xml:S1:17731:8	O
patient	XIAFLEX.xml:S1:17740:7	O
sera	XIAFLEX.xml:S1:17748:4	O
and	XIAFLEX.xml:S1:17753:3	O
a	XIAFLEX.xml:S1:17757:1	O
series	XIAFLEX.xml:S1:17759:6	O
of	XIAFLEX.xml:S1:17766:2	O
relevant	XIAFLEX.xml:S1:17769:8	O
MMPs	XIAFLEX.xml:S1:17778:4	O
.	XIAFLEX.xml:S1:17782:1	O

In	XIAFLEX.xml:S1:17784:2	O
addition	XIAFLEX.xml:S1:17787:8	O
,	XIAFLEX.xml:S1:17795:1	O
no	XIAFLEX.xml:S1:17797:2	O
clinical	XIAFLEX.xml:S1:17800:8	O
safety	XIAFLEX.xml:S1:17809:6	O
concerns	XIAFLEX.xml:S1:17816:8	O
related	XIAFLEX.xml:S1:17825:7	O
to	XIAFLEX.xml:S1:17833:2	O
the	XIAFLEX.xml:S1:17836:3	O
inhibition	XIAFLEX.xml:S1:17840:10	O
of	XIAFLEX.xml:S1:17851:2	O
endogenous	XIAFLEX.xml:S1:17854:10	O
MMPs	XIAFLEX.xml:S1:17865:4	O
have	XIAFLEX.xml:S1:17870:4	O
been	XIAFLEX.xml:S1:17875:4	O
observed	XIAFLEX.xml:S1:17880:8	O
.	XIAFLEX.xml:S1:17888:1	O

Immunogenicity	XIAFLEX.xml:S1:17894:14	O
assay	XIAFLEX.xml:S1:17909:5	O
results	XIAFLEX.xml:S1:17915:7	O
are	XIAFLEX.xml:S1:17923:3	O
highly	XIAFLEX.xml:S1:17927:6	O
dependent	XIAFLEX.xml:S1:17934:9	O
on	XIAFLEX.xml:S1:17944:2	O
the	XIAFLEX.xml:S1:17947:3	O
sensitivity	XIAFLEX.xml:S1:17951:11	O
and	XIAFLEX.xml:S1:17963:3	O
specificity	XIAFLEX.xml:S1:17967:11	O
of	XIAFLEX.xml:S1:17979:2	O
the	XIAFLEX.xml:S1:17982:3	O
assay	XIAFLEX.xml:S1:17986:5	O
used	XIAFLEX.xml:S1:17992:4	O
in	XIAFLEX.xml:S1:17997:2	O
detection	XIAFLEX.xml:S1:18000:9	O
and	XIAFLEX.xml:S1:18010:3	O
may	XIAFLEX.xml:S1:18014:3	O
be	XIAFLEX.xml:S1:18018:2	O
influenced	XIAFLEX.xml:S1:18021:10	O
by	XIAFLEX.xml:S1:18032:2	O
several	XIAFLEX.xml:S1:18035:7	O
factors	XIAFLEX.xml:S1:18043:7	O
,	XIAFLEX.xml:S1:18050:1	O
including	XIAFLEX.xml:S1:18052:9	O
sample	XIAFLEX.xml:S1:18062:6	O
handling	XIAFLEX.xml:S1:18069:8	O
,	XIAFLEX.xml:S1:18077:1	O
timing	XIAFLEX.xml:S1:18079:6	O
of	XIAFLEX.xml:S1:18086:2	O
sample	XIAFLEX.xml:S1:18089:6	O
collection	XIAFLEX.xml:S1:18096:10	O
,	XIAFLEX.xml:S1:18106:1	O
concomitant	XIAFLEX.xml:S1:18108:11	O
medications	XIAFLEX.xml:S1:18120:11	O
,	XIAFLEX.xml:S1:18131:1	O
and	XIAFLEX.xml:S1:18133:3	O
underlying	XIAFLEX.xml:S1:18137:10	O
disease	XIAFLEX.xml:S1:18148:7	O
.	XIAFLEX.xml:S1:18155:1	O

For	XIAFLEX.xml:S1:18157:3	O
these	XIAFLEX.xml:S1:18161:5	O
reasons	XIAFLEX.xml:S1:18167:7	O
,	XIAFLEX.xml:S1:18174:1	O
comparison	XIAFLEX.xml:S1:18176:10	O
of	XIAFLEX.xml:S1:18187:2	O
incidence	XIAFLEX.xml:S1:18190:9	O
of	XIAFLEX.xml:S1:18200:2	O
antibodies	XIAFLEX.xml:S1:18203:10	O
to	XIAFLEX.xml:S1:18214:2	O
collagenase	XIAFLEX.xml:S1:18217:11	O
clostridium	XIAFLEX.xml:S1:18229:11	O
histolyticum	XIAFLEX.xml:S1:18241:12	O
with	XIAFLEX.xml:S1:18254:4	O
the	XIAFLEX.xml:S1:18259:3	O
incidence	XIAFLEX.xml:S1:18263:9	O
of	XIAFLEX.xml:S1:18273:2	O
antibodies	XIAFLEX.xml:S1:18276:10	O
to	XIAFLEX.xml:S1:18287:2	O
other	XIAFLEX.xml:S1:18290:5	O
products	XIAFLEX.xml:S1:18296:8	O
may	XIAFLEX.xml:S1:18305:3	O
be	XIAFLEX.xml:S1:18309:2	O
misleading	XIAFLEX.xml:S1:18312:10	O
.	XIAFLEX.xml:S1:18322:1	O
\n\n	XIAFLEX.xml:S2:0:2	O
BOXED	XIAFLEX.xml:S2:6:5	O
WARNING	XIAFLEX.xml:S2:12:7	O
:	XIAFLEX.xml:S2:19:1	O
WARNING	XIAFLEX.xml:S2:21:7	O
:	XIAFLEX.xml:S2:28:1	O
\n\n\n\n	XIAFLEX.xml:S2:30:4	O
CORPORAL	XIAFLEX.xml:S2:34:8	B-AdverseReaction
RUPTURE	XIAFLEX.xml:S2:43:7	I-AdverseReaction
(	XIAFLEX.xml:S2:51:1	O
PENILE	XIAFLEX.xml:S2:52:6	B-AdverseReaction
FRACTURE	XIAFLEX.xml:S2:59:8	I-AdverseReaction
)	XIAFLEX.xml:S2:67:1	O
OR	XIAFLEX.xml:S2:69:2	O
\n\n	XIAFLEX.xml:S2:71:2	O
OTHER	XIAFLEX.xml:S2:73:5	O
SERIOUS	XIAFLEX.xml:S2:79:7	B-Severity
PENILE	XIAFLEX.xml:S2:87:6	B-AdverseReaction
INJURY	XIAFLEX.xml:S2:94:6	I-AdverseReaction
IN	XIAFLEX.xml:S2:101:2	O
THE	XIAFLEX.xml:S2:104:3	O
TREATMENT	XIAFLEX.xml:S2:108:9	O
OF	XIAFLEX.xml:S2:118:2	O
PEYRONIE	XIAFLEX.xml:S2:121:8	O
S	XIAFLEX.xml:S2:130:1	O
DISEASE	XIAFLEX.xml:S2:132:7	O
\n\n	XIAFLEX.xml:S2:139:2	O
WARNING	XIAFLEX.xml:S2:143:7	O
:	XIAFLEX.xml:S2:150:1	O
\n\n\n\n	XIAFLEX.xml:S2:152:4	O
CORPORAL	XIAFLEX.xml:S2:156:8	B-AdverseReaction
RUPTURE	XIAFLEX.xml:S2:165:7	I-AdverseReaction
(	XIAFLEX.xml:S2:173:1	O
PENILE	XIAFLEX.xml:S2:174:6	B-AdverseReaction
FRACTURE	XIAFLEX.xml:S2:181:8	I-AdverseReaction
)	XIAFLEX.xml:S2:189:1	O
OR	XIAFLEX.xml:S2:191:2	O
\n\n	XIAFLEX.xml:S2:193:2	O
OTHER	XIAFLEX.xml:S2:195:5	O
SERIOUS	XIAFLEX.xml:S2:201:7	B-Severity
PENILE	XIAFLEX.xml:S2:209:6	B-AdverseReaction
INJURY	XIAFLEX.xml:S2:216:6	I-AdverseReaction
IN	XIAFLEX.xml:S2:223:2	O
THE	XIAFLEX.xml:S2:226:3	O
TREATMENT	XIAFLEX.xml:S2:230:9	O
OF	XIAFLEX.xml:S2:240:2	O
PEYRONIE	XIAFLEX.xml:S2:243:8	O
S	XIAFLEX.xml:S2:252:1	O
DISEASE	XIAFLEX.xml:S2:254:7	O
\n\n	XIAFLEX.xml:S2:261:2	O
Corporal	XIAFLEX.xml:S2:265:8	B-AdverseReaction
rupture	XIAFLEX.xml:S2:274:7	I-AdverseReaction
(	XIAFLEX.xml:S2:282:1	O
penile	XIAFLEX.xml:S2:283:6	B-AdverseReaction
fracture	XIAFLEX.xml:S2:290:8	I-AdverseReaction
)	XIAFLEX.xml:S2:298:1	O
was	XIAFLEX.xml:S2:300:3	O
reported	XIAFLEX.xml:S2:304:8	O
as	XIAFLEX.xml:S2:313:2	O
an	XIAFLEX.xml:S2:316:2	O
adverse	XIAFLEX.xml:S2:319:7	O
reaction	XIAFLEX.xml:S2:327:8	O
in	XIAFLEX.xml:S2:336:2	O
5	XIAFLEX.xml:S2:339:1	O
of	XIAFLEX.xml:S2:341:2	O
1044	XIAFLEX.xml:S2:344:4	O
(	XIAFLEX.xml:S2:349:1	O
0.5%	XIAFLEX.xml:S2:350:4	O
)	XIAFLEX.xml:S2:354:1	O
XIAFLEX	XIAFLEX.xml:S2:356:7	O
-	XIAFLEX.xml:S2:363:1	O
treated	XIAFLEX.xml:S2:364:7	O
patients	XIAFLEX.xml:S2:372:8	O
in	XIAFLEX.xml:S2:381:2	O
clinical	XIAFLEX.xml:S2:384:8	O
studies	XIAFLEX.xml:S2:393:7	O
.	XIAFLEX.xml:S2:400:1	O

In	XIAFLEX.xml:S2:402:2	O
other	XIAFLEX.xml:S2:405:5	O
XIAFLEX	XIAFLEX.xml:S2:411:7	O
-	XIAFLEX.xml:S2:418:1	O
treated	XIAFLEX.xml:S2:419:7	O
patients	XIAFLEX.xml:S2:427:8	O
(	XIAFLEX.xml:S2:436:1	O
9	XIAFLEX.xml:S2:437:1	O
of	XIAFLEX.xml:S2:439:2	O
1044	XIAFLEX.xml:S2:442:4	O
;	XIAFLEX.xml:S2:446:1	O
0.9%	XIAFLEX.xml:S2:448:4	O
)	XIAFLEX.xml:S2:452:1	O
,	XIAFLEX.xml:S2:453:1	O
a	XIAFLEX.xml:S2:455:1	O
combination	XIAFLEX.xml:S2:457:11	O
of	XIAFLEX.xml:S2:469:2	O
penile	XIAFLEX.xml:S2:472:6	B-AdverseReaction
ecchymoses	XIAFLEX.xml:S2:479:10	I-AdverseReaction
or	XIAFLEX.xml:S2:490:2	O
hematoma	XIAFLEX.xml:S2:493:8	I-AdverseReaction
,	XIAFLEX.xml:S2:501:1	O
sudden	XIAFLEX.xml:S2:503:6	O
penile	XIAFLEX.xml:S2:510:6	B-AdverseReaction
detumescence	XIAFLEX.xml:S2:517:12	I-AdverseReaction
,	XIAFLEX.xml:S2:529:1	O
and	XIAFLEX.xml:S2:531:3	O
or	XIAFLEX.xml:S2:535:2	O
a	XIAFLEX.xml:S2:538:1	O
penile	XIAFLEX.xml:S2:540:6	B-AdverseReaction
"	XIAFLEX.xml:S2:547:1	I-AdverseReaction
popping	XIAFLEX.xml:S2:548:7	I-AdverseReaction
"	XIAFLEX.xml:S2:555:1	I-AdverseReaction
sound	XIAFLEX.xml:S2:557:5	I-AdverseReaction
or	XIAFLEX.xml:S2:563:2	O
sensation	XIAFLEX.xml:S2:566:9	I-AdverseReaction
was	XIAFLEX.xml:S2:576:3	O
reported	XIAFLEX.xml:S2:580:8	O
,	XIAFLEX.xml:S2:588:1	O
and	XIAFLEX.xml:S2:590:3	O
in	XIAFLEX.xml:S2:594:2	O
these	XIAFLEX.xml:S2:597:5	O
cases	XIAFLEX.xml:S2:603:5	O
,	XIAFLEX.xml:S2:608:1	O
a	XIAFLEX.xml:S2:610:1	O
diagnosis	XIAFLEX.xml:S2:612:9	O
of	XIAFLEX.xml:S2:622:2	O
corporal	XIAFLEX.xml:S2:625:8	B-AdverseReaction
rupture	XIAFLEX.xml:S2:634:7	I-AdverseReaction
cannot	XIAFLEX.xml:S2:642:6	B-Factor
be	XIAFLEX.xml:S2:649:2	I-Factor
excluded	XIAFLEX.xml:S2:652:8	I-Factor
.	XIAFLEX.xml:S2:660:1	O

Severe	XIAFLEX.xml:S2:662:6	B-Severity
penile	XIAFLEX.xml:S2:669:6	B-AdverseReaction
hematoma	XIAFLEX.xml:S2:676:8	I-AdverseReaction
was	XIAFLEX.xml:S2:685:3	O
also	XIAFLEX.xml:S2:689:4	O
reported	XIAFLEX.xml:S2:694:8	O
as	XIAFLEX.xml:S2:703:2	O
an	XIAFLEX.xml:S2:706:2	O
adverse	XIAFLEX.xml:S2:709:7	O
reaction	XIAFLEX.xml:S2:717:8	O
in	XIAFLEX.xml:S2:726:2	O
39	XIAFLEX.xml:S2:729:2	O
of	XIAFLEX.xml:S2:732:2	O
1044	XIAFLEX.xml:S2:735:4	O
(	XIAFLEX.xml:S2:740:1	O
3.7%	XIAFLEX.xml:S2:741:4	O
)	XIAFLEX.xml:S2:745:1	O
XIAFLEX	XIAFLEX.xml:S2:747:7	O
-	XIAFLEX.xml:S2:754:1	O
treated	XIAFLEX.xml:S2:755:7	O
patients	XIAFLEX.xml:S2:763:8	O
[	XIAFLEX.xml:S2:774:1	O
see	XIAFLEX.xml:S2:775:3	O
Warnings	XIAFLEX.xml:S2:779:8	O
and	XIAFLEX.xml:S2:788:3	O
Precautions	XIAFLEX.xml:S2:792:11	O
(	XIAFLEX.xml:S2:804:1	O
5.2	XIAFLEX.xml:S2:805:3	O
)]	XIAFLEX.xml:S2:808:2	O
.	XIAFLEX.xml:S2:812:1	O

Signs	XIAFLEX.xml:S2:818:5	O
or	XIAFLEX.xml:S2:824:2	O
symptoms	XIAFLEX.xml:S2:827:8	O
that	XIAFLEX.xml:S2:836:4	O
may	XIAFLEX.xml:S2:841:3	O
reflect	XIAFLEX.xml:S2:845:7	O
serious	XIAFLEX.xml:S2:853:7	O
penile	XIAFLEX.xml:S2:861:6	O
injury	XIAFLEX.xml:S2:868:6	O
should	XIAFLEX.xml:S2:875:6	O
be	XIAFLEX.xml:S2:882:2	O
promptly	XIAFLEX.xml:S2:885:8	O
evaluated	XIAFLEX.xml:S2:894:9	O
to	XIAFLEX.xml:S2:904:2	O
assess	XIAFLEX.xml:S2:907:6	O
for	XIAFLEX.xml:S2:914:3	O
corporal	XIAFLEX.xml:S2:918:8	O
rupture	XIAFLEX.xml:S2:927:7	O
or	XIAFLEX.xml:S2:935:2	O
severe	XIAFLEX.xml:S2:938:6	O
penile	XIAFLEX.xml:S2:945:6	O
hematoma	XIAFLEX.xml:S2:952:8	O
which	XIAFLEX.xml:S2:961:5	O
may	XIAFLEX.xml:S2:967:3	O
require	XIAFLEX.xml:S2:971:7	O
surgical	XIAFLEX.xml:S2:979:8	O
intervention	XIAFLEX.xml:S2:988:12	O
[	XIAFLEX.xml:S2:1003:1	O
see	XIAFLEX.xml:S2:1004:3	O
Warnings	XIAFLEX.xml:S2:1008:8	O
and	XIAFLEX.xml:S2:1017:3	O
Precautions	XIAFLEX.xml:S2:1021:11	O
(	XIAFLEX.xml:S2:1033:1	O
5.2	XIAFLEX.xml:S2:1034:3	O
)]	XIAFLEX.xml:S2:1037:2	O
.	XIAFLEX.xml:S2:1041:1	O

Because	XIAFLEX.xml:S2:1047:7	O
of	XIAFLEX.xml:S2:1055:2	O
the	XIAFLEX.xml:S2:1058:3	O
risks	XIAFLEX.xml:S2:1062:5	B-Factor
of	XIAFLEX.xml:S2:1068:2	O
corporal	XIAFLEX.xml:S2:1071:8	B-AdverseReaction
rupture	XIAFLEX.xml:S2:1080:7	I-AdverseReaction
or	XIAFLEX.xml:S2:1088:2	O
other	XIAFLEX.xml:S2:1091:5	O
serious	XIAFLEX.xml:S2:1097:7	B-Severity
penile	XIAFLEX.xml:S2:1105:6	B-AdverseReaction
injury	XIAFLEX.xml:S2:1112:6	I-AdverseReaction
,	XIAFLEX.xml:S2:1118:1	O
XIAFLEX	XIAFLEX.xml:S2:1120:7	O
is	XIAFLEX.xml:S2:1128:2	O
available	XIAFLEX.xml:S2:1131:9	O
for	XIAFLEX.xml:S2:1141:3	O
the	XIAFLEX.xml:S2:1145:3	O
treatment	XIAFLEX.xml:S2:1149:9	O
of	XIAFLEX.xml:S2:1159:2	O
Peyronie	XIAFLEX.xml:S2:1162:8	O
's	XIAFLEX.xml:S2:1170:2	O
disease	XIAFLEX.xml:S2:1173:7	O
only	XIAFLEX.xml:S2:1181:4	O
through	XIAFLEX.xml:S2:1186:7	O
a	XIAFLEX.xml:S2:1194:1	O
restricted	XIAFLEX.xml:S2:1196:10	O
program	XIAFLEX.xml:S2:1207:7	O
under	XIAFLEX.xml:S2:1215:5	O
a	XIAFLEX.xml:S2:1221:1	O
Risk	XIAFLEX.xml:S2:1223:4	O
Evaluation	XIAFLEX.xml:S2:1228:10	O
and	XIAFLEX.xml:S2:1239:3	O
Mitigation	XIAFLEX.xml:S2:1243:10	O
Strategy	XIAFLEX.xml:S2:1254:8	O
(	XIAFLEX.xml:S2:1263:1	O
REMS	XIAFLEX.xml:S2:1264:4	O
)	XIAFLEX.xml:S2:1268:1	O
called	XIAFLEX.xml:S2:1270:6	O
the	XIAFLEX.xml:S2:1277:3	O
XIAFLEX	XIAFLEX.xml:S2:1281:7	O
REMS	XIAFLEX.xml:S2:1289:4	O
Program	XIAFLEX.xml:S2:1294:7	O
[	XIAFLEX.xml:S2:1304:1	O
see	XIAFLEX.xml:S2:1305:3	O
Warnings	XIAFLEX.xml:S2:1309:8	O
and	XIAFLEX.xml:S2:1318:3	O
Precautions	XIAFLEX.xml:S2:1322:11	O
(	XIAFLEX.xml:S2:1334:1	O
5.3	XIAFLEX.xml:S2:1335:3	O
)]	XIAFLEX.xml:S2:1338:2	O
.	XIAFLEX.xml:S2:1342:1	O

EXCERPT	XIAFLEX.xml:S2:1350:7	O
:	XIAFLEX.xml:S2:1357:1	O
WARNING	XIAFLEX.xml:S2:1361:7	O
:	XIAFLEX.xml:S2:1368:1	O
CORPORAL	XIAFLEX.xml:S2:1370:8	B-AdverseReaction
RUPTURE	XIAFLEX.xml:S2:1379:7	I-AdverseReaction
(	XIAFLEX.xml:S2:1387:1	O
PENILE	XIAFLEX.xml:S2:1388:6	B-AdverseReaction
FRACTURE	XIAFLEX.xml:S2:1395:8	I-AdverseReaction
)	XIAFLEX.xml:S2:1403:1	O
OR	XIAFLEX.xml:S2:1405:2	O
OTHER	XIAFLEX.xml:S2:1408:5	O
SERIOUS	XIAFLEX.xml:S2:1414:7	B-Severity
PENILE	XIAFLEX.xml:S2:1422:6	B-AdverseReaction
INJURY	XIAFLEX.xml:S2:1429:6	I-AdverseReaction
IN	XIAFLEX.xml:S2:1436:2	O
THE	XIAFLEX.xml:S2:1439:3	O
TREATMENT	XIAFLEX.xml:S2:1443:9	O
OF	XIAFLEX.xml:S2:1453:2	O
PEYRONIE	XIAFLEX.xml:S2:1456:8	O
S	XIAFLEX.xml:S2:1465:1	O
DISEASE	XIAFLEX.xml:S2:1467:7	O
\n\n\n\n	XIAFLEX.xml:S2:1474:4	O
See	XIAFLEX.xml:S2:1481:3	O
full	XIAFLEX.xml:S2:1485:4	O
prescribing	XIAFLEX.xml:S2:1490:11	O
information	XIAFLEX.xml:S2:1502:11	O
for	XIAFLEX.xml:S2:1514:3	O
complete	XIAFLEX.xml:S2:1518:8	O
boxed	XIAFLEX.xml:S2:1529:5	O
warning	XIAFLEX.xml:S2:1535:7	O
\n\n\n\n	XIAFLEX.xml:S2:1546:4	O
Corporal	XIAFLEX.xml:S2:1554:8	B-AdverseReaction
rupture	XIAFLEX.xml:S2:1563:7	I-AdverseReaction
(	XIAFLEX.xml:S2:1571:1	O
penile	XIAFLEX.xml:S2:1572:6	B-AdverseReaction
fracture	XIAFLEX.xml:S2:1579:8	I-AdverseReaction
)	XIAFLEX.xml:S2:1587:1	O
was	XIAFLEX.xml:S2:1589:3	O
reported	XIAFLEX.xml:S2:1593:8	O
as	XIAFLEX.xml:S2:1602:2	O
an	XIAFLEX.xml:S2:1605:2	O
adverse	XIAFLEX.xml:S2:1608:7	O
reaction	XIAFLEX.xml:S2:1616:8	O
in	XIAFLEX.xml:S2:1625:2	O
5	XIAFLEX.xml:S2:1628:1	O
of	XIAFLEX.xml:S2:1630:2	O
1044	XIAFLEX.xml:S2:1633:4	O
(	XIAFLEX.xml:S2:1638:1	O
0.5%	XIAFLEX.xml:S2:1639:4	O
)	XIAFLEX.xml:S2:1643:1	O
XIAFLEX	XIAFLEX.xml:S2:1645:7	O
-	XIAFLEX.xml:S2:1652:1	O
treated	XIAFLEX.xml:S2:1653:7	O
patients	XIAFLEX.xml:S2:1661:8	O
in	XIAFLEX.xml:S2:1670:2	O
clinical	XIAFLEX.xml:S2:1673:8	O
studies	XIAFLEX.xml:S2:1682:7	O
.	XIAFLEX.xml:S2:1689:1	O

In	XIAFLEX.xml:S2:1691:2	O
other	XIAFLEX.xml:S2:1694:5	O
XIAFLEX	XIAFLEX.xml:S2:1700:7	O
-	XIAFLEX.xml:S2:1707:1	O
treated	XIAFLEX.xml:S2:1708:7	O
patients	XIAFLEX.xml:S2:1716:8	O
(	XIAFLEX.xml:S2:1725:1	O
9	XIAFLEX.xml:S2:1726:1	O
of	XIAFLEX.xml:S2:1728:2	O
1044	XIAFLEX.xml:S2:1731:4	O
;	XIAFLEX.xml:S2:1735:1	O
0.9%	XIAFLEX.xml:S2:1737:4	O
)	XIAFLEX.xml:S2:1741:1	O
,	XIAFLEX.xml:S2:1742:1	O
a	XIAFLEX.xml:S2:1744:1	O
diagnosis	XIAFLEX.xml:S2:1746:9	O
of	XIAFLEX.xml:S2:1756:2	O
corporal	XIAFLEX.xml:S2:1759:8	B-AdverseReaction
rupture	XIAFLEX.xml:S2:1768:7	I-AdverseReaction
cannot	XIAFLEX.xml:S2:1776:6	B-Factor
be	XIAFLEX.xml:S2:1783:2	I-Factor
excluded	XIAFLEX.xml:S2:1786:8	I-Factor
.	XIAFLEX.xml:S2:1794:1	O

Severe	XIAFLEX.xml:S2:1796:6	B-Severity
penile	XIAFLEX.xml:S2:1803:6	B-AdverseReaction
hematoma	XIAFLEX.xml:S2:1810:8	I-AdverseReaction
was	XIAFLEX.xml:S2:1819:3	O
also	XIAFLEX.xml:S2:1823:4	O
reported	XIAFLEX.xml:S2:1828:8	O
as	XIAFLEX.xml:S2:1837:2	O
an	XIAFLEX.xml:S2:1840:2	O
adverse	XIAFLEX.xml:S2:1843:7	O
reaction	XIAFLEX.xml:S2:1851:8	O
in	XIAFLEX.xml:S2:1860:2	O
39	XIAFLEX.xml:S2:1863:2	O
of	XIAFLEX.xml:S2:1866:2	O
1044	XIAFLEX.xml:S2:1869:4	O
(	XIAFLEX.xml:S2:1874:1	O
3.7%	XIAFLEX.xml:S2:1875:4	O
)	XIAFLEX.xml:S2:1879:1	O
XIAFLEX	XIAFLEX.xml:S2:1881:7	O
-	XIAFLEX.xml:S2:1888:1	O
treated	XIAFLEX.xml:S2:1889:7	O
patients	XIAFLEX.xml:S2:1897:8	O
(	XIAFLEX.xml:S2:1906:1	O
5.2	XIAFLEX.xml:S2:1907:3	O
)	XIAFLEX.xml:S2:1910:1	O
.	XIAFLEX.xml:S2:1911:1	O

XIAFLEX	XIAFLEX.xml:S2:1918:7	O
is	XIAFLEX.xml:S2:1926:2	O
available	XIAFLEX.xml:S2:1929:9	O
for	XIAFLEX.xml:S2:1939:3	O
the	XIAFLEX.xml:S2:1943:3	O
treatment	XIAFLEX.xml:S2:1947:9	O
of	XIAFLEX.xml:S2:1957:2	O
Peyronie	XIAFLEX.xml:S2:1960:8	O
's	XIAFLEX.xml:S2:1968:2	O
disease	XIAFLEX.xml:S2:1971:7	O
only	XIAFLEX.xml:S2:1979:4	O
through	XIAFLEX.xml:S2:1984:7	O
a	XIAFLEX.xml:S2:1992:1	O
restricted	XIAFLEX.xml:S2:1994:10	O
program	XIAFLEX.xml:S2:2005:7	O
called	XIAFLEX.xml:S2:2013:6	O
the	XIAFLEX.xml:S2:2020:3	O
XIAFLEX	XIAFLEX.xml:S2:2024:7	O
REMS	XIAFLEX.xml:S2:2032:4	O
Program	XIAFLEX.xml:S2:2037:7	O
(	XIAFLEX.xml:S2:2045:1	O
5.3	XIAFLEX.xml:S2:2046:3	O
)	XIAFLEX.xml:S2:2049:1	O
.	XIAFLEX.xml:S2:2050:1	O
\n	XIAFLEX.xml:S2:2052:1	O
5	XIAFLEX.xml:S3:4:1	O
WARNINGS	XIAFLEX.xml:S3:6:8	O
AND	XIAFLEX.xml:S3:15:3	O
PRECAUTIONS	XIAFLEX.xml:S3:19:11	O

EXCERPT	XIAFLEX.xml:S3:37:7	O
:	XIAFLEX.xml:S3:44:1	O
Tendon	XIAFLEX.xml:S3:52:6	B-AdverseReaction
rupture	XIAFLEX.xml:S3:59:7	I-AdverseReaction
or	XIAFLEX.xml:S3:67:2	O
serious	XIAFLEX.xml:S3:70:7	B-Severity
injury	XIAFLEX.xml:S3:78:6	B-AdverseReaction
to	XIAFLEX.xml:S3:85:2	I-AdverseReaction
the	XIAFLEX.xml:S3:88:3	I-AdverseReaction
injected	XIAFLEX.xml:S3:92:8	I-AdverseReaction
finger	XIAFLEX.xml:S3:101:6	I-AdverseReaction
hand	XIAFLEX.xml:S3:108:4	I-AdverseReaction
:	XIAFLEX.xml:S3:112:1	O
Avoid	XIAFLEX.xml:S3:114:5	O
injecting	XIAFLEX.xml:S3:120:9	O
XIAFLEX	XIAFLEX.xml:S3:130:7	O
into	XIAFLEX.xml:S3:138:4	O
tendons	XIAFLEX.xml:S3:143:7	O
,	XIAFLEX.xml:S3:150:1	O
nerves	XIAFLEX.xml:S3:152:6	O
,	XIAFLEX.xml:S3:158:1	O
blood	XIAFLEX.xml:S3:160:5	O
vessels	XIAFLEX.xml:S3:166:7	O
,	XIAFLEX.xml:S3:173:1	O
or	XIAFLEX.xml:S3:175:2	O
other	XIAFLEX.xml:S3:178:5	O
collagen	XIAFLEX.xml:S3:184:8	O
-	XIAFLEX.xml:S3:192:1	O
containing	XIAFLEX.xml:S3:193:10	O
structure	XIAFLEX.xml:S3:204:9	O
of	XIAFLEX.xml:S3:214:2	O
the	XIAFLEX.xml:S3:217:3	O
hand	XIAFLEX.xml:S3:221:4	O
.	XIAFLEX.xml:S3:225:1	O

Injection	XIAFLEX.xml:S3:227:9	O
into	XIAFLEX.xml:S3:237:4	O
these	XIAFLEX.xml:S3:242:5	O
structures	XIAFLEX.xml:S3:248:10	O
may	XIAFLEX.xml:S3:259:3	O
result	XIAFLEX.xml:S3:263:6	O
in	XIAFLEX.xml:S3:270:2	O
possible	XIAFLEX.xml:S3:273:8	O
permanent	XIAFLEX.xml:S3:282:9	O
injury	XIAFLEX.xml:S3:292:6	O
,	XIAFLEX.xml:S3:298:1	O
such	XIAFLEX.xml:S3:300:4	O
as	XIAFLEX.xml:S3:305:2	O
tendon	XIAFLEX.xml:S3:308:6	O
rupture	XIAFLEX.xml:S3:315:7	O
or	XIAFLEX.xml:S3:323:2	O
ligament	XIAFLEX.xml:S3:326:8	O
damage	XIAFLEX.xml:S3:335:6	O
,	XIAFLEX.xml:S3:341:1	O
or	XIAFLEX.xml:S3:343:2	O
skin	XIAFLEX.xml:S3:346:4	O
laceration	XIAFLEX.xml:S3:351:10	O
.	XIAFLEX.xml:S3:361:1	O

(	XIAFLEX.xml:S3:363:1	O
5.1	XIAFLEX.xml:S3:366:3	O
)	XIAFLEX.xml:S3:371:1	O

Corporal	XIAFLEX.xml:S3:378:8	B-AdverseReaction
rupture	XIAFLEX.xml:S3:387:7	I-AdverseReaction
(	XIAFLEX.xml:S3:395:1	O
penile	XIAFLEX.xml:S3:396:6	B-AdverseReaction
fracture	XIAFLEX.xml:S3:403:8	I-AdverseReaction
)	XIAFLEX.xml:S3:411:1	O
or	XIAFLEX.xml:S3:413:2	O
other	XIAFLEX.xml:S3:416:5	O
serious	XIAFLEX.xml:S3:422:7	B-Severity
injury	XIAFLEX.xml:S3:430:6	B-AdverseReaction
to	XIAFLEX.xml:S3:437:2	I-AdverseReaction
the	XIAFLEX.xml:S3:440:3	I-AdverseReaction
penis	XIAFLEX.xml:S3:444:5	I-AdverseReaction
:	XIAFLEX.xml:S3:449:1	O
Avoid	XIAFLEX.xml:S3:451:5	O
injecting	XIAFLEX.xml:S3:457:9	O
into	XIAFLEX.xml:S3:467:4	O
the	XIAFLEX.xml:S3:472:3	O
urethra	XIAFLEX.xml:S3:476:7	O
,	XIAFLEX.xml:S3:483:1	O
nerves	XIAFLEX.xml:S3:485:6	O
,	XIAFLEX.xml:S3:491:1	O
blood	XIAFLEX.xml:S3:493:5	O
vessels	XIAFLEX.xml:S3:499:7	O
,	XIAFLEX.xml:S3:506:1	O
corpora	XIAFLEX.xml:S3:508:7	O
cavernosa	XIAFLEX.xml:S3:516:9	O
or	XIAFLEX.xml:S3:526:2	O
other	XIAFLEX.xml:S3:529:5	O
collagen	XIAFLEX.xml:S3:535:8	O
-	XIAFLEX.xml:S3:543:1	O
containing	XIAFLEX.xml:S3:544:10	O
structures	XIAFLEX.xml:S3:555:10	O
of	XIAFLEX.xml:S3:566:2	O
the	XIAFLEX.xml:S3:569:3	O
penis	XIAFLEX.xml:S3:573:5	O
.	XIAFLEX.xml:S3:578:1	O

Injection	XIAFLEX.xml:S3:580:9	O
into	XIAFLEX.xml:S3:590:4	O
these	XIAFLEX.xml:S3:595:5	O
structures	XIAFLEX.xml:S3:601:10	O
may	XIAFLEX.xml:S3:612:3	B-Factor
result	XIAFLEX.xml:S3:616:6	O
in	XIAFLEX.xml:S3:623:2	O
possible	XIAFLEX.xml:S3:626:8	O
permanent	XIAFLEX.xml:S3:635:9	B-AdverseReaction
injury	XIAFLEX.xml:S3:645:6	I-AdverseReaction
such	XIAFLEX.xml:S3:652:4	O
as	XIAFLEX.xml:S3:657:2	O
corporal	XIAFLEX.xml:S3:660:8	B-AdverseReaction
rupture	XIAFLEX.xml:S3:669:7	I-AdverseReaction
(	XIAFLEX.xml:S3:677:1	O
penile	XIAFLEX.xml:S3:678:6	B-AdverseReaction
fracture	XIAFLEX.xml:S3:685:8	I-AdverseReaction
)	XIAFLEX.xml:S3:693:1	O
.	XIAFLEX.xml:S3:694:1	O

(	XIAFLEX.xml:S3:696:1	O
5.2	XIAFLEX.xml:S3:699:3	O
)	XIAFLEX.xml:S3:704:1	O

Hypersensitivity	XIAFLEX.xml:S3:711:16	B-AdverseReaction
reactions	XIAFLEX.xml:S3:728:9	I-AdverseReaction
,	XIAFLEX.xml:S3:737:1	O
including	XIAFLEX.xml:S3:739:9	O
anaphylaxis	XIAFLEX.xml:S3:749:11	B-AdverseReaction
:	XIAFLEX.xml:S3:760:1	O
Healthcare	XIAFLEX.xml:S3:762:10	O
providers	XIAFLEX.xml:S3:773:9	O
should	XIAFLEX.xml:S3:783:6	O
be	XIAFLEX.xml:S3:790:2	O
prepared	XIAFLEX.xml:S3:793:8	O
to	XIAFLEX.xml:S3:802:2	O
address	XIAFLEX.xml:S3:805:7	O
hypersensitivity	XIAFLEX.xml:S3:813:16	O
reactions	XIAFLEX.xml:S3:830:9	O
,	XIAFLEX.xml:S3:839:1	O
including	XIAFLEX.xml:S3:841:9	O
anaphylaxis	XIAFLEX.xml:S3:851:11	O
,	XIAFLEX.xml:S3:862:1	O
following	XIAFLEX.xml:S3:864:9	O
XIAFLEX	XIAFLEX.xml:S3:874:7	O
injections	XIAFLEX.xml:S3:882:10	O
.	XIAFLEX.xml:S3:892:1	O

(	XIAFLEX.xml:S3:894:1	O
5.4	XIAFLEX.xml:S3:897:3	O
)	XIAFLEX.xml:S3:902:1	O

Patients	XIAFLEX.xml:S3:909:8	O
with	XIAFLEX.xml:S3:918:4	O
abnormal	XIAFLEX.xml:S3:923:8	O
coagulation	XIAFLEX.xml:S3:932:11	O
:	XIAFLEX.xml:S3:943:1	O
Use	XIAFLEX.xml:S3:945:3	O
with	XIAFLEX.xml:S3:949:4	O
caution	XIAFLEX.xml:S3:954:7	O
,	XIAFLEX.xml:S3:961:1	O
including	XIAFLEX.xml:S3:963:9	O
in	XIAFLEX.xml:S3:973:2	O
patients	XIAFLEX.xml:S3:976:8	O
who	XIAFLEX.xml:S3:985:3	O
have	XIAFLEX.xml:S3:989:4	O
received	XIAFLEX.xml:S3:994:8	O
anticoagulant	XIAFLEX.xml:S3:1003:13	O
medications	XIAFLEX.xml:S3:1017:11	O
other	XIAFLEX.xml:S3:1029:5	O
than	XIAFLEX.xml:S3:1035:4	O
low	XIAFLEX.xml:S3:1040:3	O
-	XIAFLEX.xml:S3:1043:1	O
dose	XIAFLEX.xml:S3:1044:4	O
aspirin	XIAFLEX.xml:S3:1049:7	O
within	XIAFLEX.xml:S3:1057:6	O
7	XIAFLEX.xml:S3:1064:1	O
days	XIAFLEX.xml:S3:1066:4	O
of	XIAFLEX.xml:S3:1071:2	O
the	XIAFLEX.xml:S3:1074:3	O
injection	XIAFLEX.xml:S3:1078:9	O
.	XIAFLEX.xml:S3:1087:1	O

(	XIAFLEX.xml:S3:1089:1	O
5.5	XIAFLEX.xml:S3:1092:3	O
)	XIAFLEX.xml:S3:1097:1	O

5.1	XIAFLEX.xml:S3:1111:3	O

Tendon	XIAFLEX.xml:S3:1115:6	O

Rupture	XIAFLEX.xml:S3:1122:7	O
or	XIAFLEX.xml:S3:1130:2	O
Other	XIAFLEX.xml:S3:1133:5	O
Serious	XIAFLEX.xml:S3:1139:7	O
Injury	XIAFLEX.xml:S3:1147:6	O
to	XIAFLEX.xml:S3:1154:2	O
the	XIAFLEX.xml:S3:1157:3	O
Injected	XIAFLEX.xml:S3:1161:8	O
Finger	XIAFLEX.xml:S3:1170:6	O
Hand	XIAFLEX.xml:S3:1177:4	O
in	XIAFLEX.xml:S3:1182:2	O
the	XIAFLEX.xml:S3:1185:3	O
Treatment	XIAFLEX.xml:S3:1189:9	O
of	XIAFLEX.xml:S3:1199:2	O
Dupuytren	XIAFLEX.xml:S3:1202:9	O
's	XIAFLEX.xml:S3:1211:2	O
Contracture	XIAFLEX.xml:S3:1214:11	O

In	XIAFLEX.xml:S3:1231:2	O
the	XIAFLEX.xml:S3:1234:3	O
controlled	XIAFLEX.xml:S3:1238:10	O
and	XIAFLEX.xml:S3:1249:3	O
uncontrolled	XIAFLEX.xml:S3:1253:12	O
portions	XIAFLEX.xml:S3:1266:8	O
of	XIAFLEX.xml:S3:1275:2	O
clinical	XIAFLEX.xml:S3:1278:8	O
trials	XIAFLEX.xml:S3:1287:6	O
in	XIAFLEX.xml:S3:1294:2	O
Dupuytren	XIAFLEX.xml:S3:1297:9	O
's	XIAFLEX.xml:S3:1306:2	O
contracture	XIAFLEX.xml:S3:1309:11	O
,	XIAFLEX.xml:S3:1320:1	O
flexor	XIAFLEX.xml:S3:1322:6	B-AdverseReaction
tendon	XIAFLEX.xml:S3:1329:6	I-AdverseReaction
ruptures	XIAFLEX.xml:S3:1336:8	I-AdverseReaction
occurred	XIAFLEX.xml:S3:1345:8	O
after	XIAFLEX.xml:S3:1354:5	O
XIAFLEX	XIAFLEX.xml:S3:1360:7	O
injection	XIAFLEX.xml:S3:1368:9	O
[	XIAFLEX.xml:S3:1380:1	O
see	XIAFLEX.xml:S3:1381:3	O
Adverse	XIAFLEX.xml:S3:1385:7	O
Reactions	XIAFLEX.xml:S3:1393:9	O
(	XIAFLEX.xml:S3:1403:1	O
6.1	XIAFLEX.xml:S3:1404:3	O
)]	XIAFLEX.xml:S3:1407:2	O
.	XIAFLEX.xml:S3:1413:1	O

Injection	XIAFLEX.xml:S3:1415:9	O
of	XIAFLEX.xml:S3:1425:2	O
XIAFLEX	XIAFLEX.xml:S3:1428:7	O
into	XIAFLEX.xml:S3:1436:4	O
collagen	XIAFLEX.xml:S3:1441:8	B-AdverseReaction
-	XIAFLEX.xml:S3:1449:1	I-AdverseReaction
containing	XIAFLEX.xml:S3:1450:10	I-AdverseReaction
structures	XIAFLEX.xml:S3:1461:10	I-AdverseReaction
such	XIAFLEX.xml:S3:1472:4	O
as	XIAFLEX.xml:S3:1477:2	O
tendons	XIAFLEX.xml:S3:1480:7	B-AdverseReaction
or	XIAFLEX.xml:S3:1488:2	O
ligaments	XIAFLEX.xml:S3:1491:9	B-AdverseReaction
of	XIAFLEX.xml:S3:1501:2	I-AdverseReaction
the	XIAFLEX.xml:S3:1504:3	I-AdverseReaction
hand	XIAFLEX.xml:S3:1508:4	I-AdverseReaction
may	XIAFLEX.xml:S3:1513:3	B-Factor
result	XIAFLEX.xml:S3:1517:6	O
in	XIAFLEX.xml:S3:1524:2	O
damage	XIAFLEX.xml:S3:1527:6	I-AdverseReaction
to	XIAFLEX.xml:S3:1534:2	O
those	XIAFLEX.xml:S3:1537:5	O
structures	XIAFLEX.xml:S3:1543:10	O
and	XIAFLEX.xml:S3:1554:3	O
possible	XIAFLEX.xml:S3:1558:8	B-Factor
permanent	XIAFLEX.xml:S3:1567:9	B-AdverseReaction
injury	XIAFLEX.xml:S3:1577:6	I-AdverseReaction
such	XIAFLEX.xml:S3:1584:4	O
as	XIAFLEX.xml:S3:1589:2	O
tendon	XIAFLEX.xml:S3:1592:6	B-AdverseReaction
rupture	XIAFLEX.xml:S3:1599:7	I-AdverseReaction
or	XIAFLEX.xml:S3:1607:2	O
ligament	XIAFLEX.xml:S3:1610:8	B-AdverseReaction
damage	XIAFLEX.xml:S3:1619:6	I-AdverseReaction
.	XIAFLEX.xml:S3:1625:1	O

Therefore	XIAFLEX.xml:S3:1627:9	O
,	XIAFLEX.xml:S3:1636:1	O
XIAFLEX	XIAFLEX.xml:S3:1638:7	O
should	XIAFLEX.xml:S3:1646:6	O
be	XIAFLEX.xml:S3:1653:2	O
injected	XIAFLEX.xml:S3:1656:8	O
only	XIAFLEX.xml:S3:1665:4	O
into	XIAFLEX.xml:S3:1670:4	O
the	XIAFLEX.xml:S3:1675:3	O
collagen	XIAFLEX.xml:S3:1679:8	O
cord	XIAFLEX.xml:S3:1688:4	O
with	XIAFLEX.xml:S3:1693:4	O
a	XIAFLEX.xml:S3:1698:1	O
MP	XIAFLEX.xml:S3:1700:2	O
or	XIAFLEX.xml:S3:1703:2	O
PIP	XIAFLEX.xml:S3:1706:3	O
joint	XIAFLEX.xml:S3:1710:5	O
contracture	XIAFLEX.xml:S3:1716:11	O
,	XIAFLEX.xml:S3:1727:1	O
and	XIAFLEX.xml:S3:1729:3	O
care	XIAFLEX.xml:S3:1733:4	O
should	XIAFLEX.xml:S3:1738:6	O
be	XIAFLEX.xml:S3:1745:2	O
taken	XIAFLEX.xml:S3:1748:5	O
to	XIAFLEX.xml:S3:1754:2	O
avoid	XIAFLEX.xml:S3:1757:5	O
injecting	XIAFLEX.xml:S3:1763:9	O
into	XIAFLEX.xml:S3:1773:4	O
tendons	XIAFLEX.xml:S3:1778:7	O
,	XIAFLEX.xml:S3:1785:1	O
nerves	XIAFLEX.xml:S3:1787:6	O
,	XIAFLEX.xml:S3:1793:1	O
blood	XIAFLEX.xml:S3:1795:5	O
vessels	XIAFLEX.xml:S3:1801:7	O
,	XIAFLEX.xml:S3:1808:1	O
or	XIAFLEX.xml:S3:1810:2	O
other	XIAFLEX.xml:S3:1813:5	O
collagen	XIAFLEX.xml:S3:1819:8	O
-	XIAFLEX.xml:S3:1827:1	O
containing	XIAFLEX.xml:S3:1828:10	O
structures	XIAFLEX.xml:S3:1839:10	O
of	XIAFLEX.xml:S3:1850:2	O
the	XIAFLEX.xml:S3:1853:3	O
hand	XIAFLEX.xml:S3:1857:4	O
.	XIAFLEX.xml:S3:1861:1	O

When	XIAFLEX.xml:S3:1863:4	O
injecting	XIAFLEX.xml:S3:1868:9	O
a	XIAFLEX.xml:S3:1878:1	O
cord	XIAFLEX.xml:S3:1880:4	O
affecting	XIAFLEX.xml:S3:1885:9	O
a	XIAFLEX.xml:S3:1895:1	O
PIP	XIAFLEX.xml:S3:1897:3	O
joint	XIAFLEX.xml:S3:1901:5	O
of	XIAFLEX.xml:S3:1907:2	O
the	XIAFLEX.xml:S3:1910:3	O
fifth	XIAFLEX.xml:S3:1914:5	O
finger	XIAFLEX.xml:S3:1920:6	O
,	XIAFLEX.xml:S3:1926:1	O
the	XIAFLEX.xml:S3:1928:3	O
needle	XIAFLEX.xml:S3:1932:6	O
insertion	XIAFLEX.xml:S3:1939:9	O
should	XIAFLEX.xml:S3:1949:6	O
not	XIAFLEX.xml:S3:1956:3	O
be	XIAFLEX.xml:S3:1960:2	O
more	XIAFLEX.xml:S3:1963:4	O
than	XIAFLEX.xml:S3:1968:4	O
2	XIAFLEX.xml:S3:1973:1	O
to	XIAFLEX.xml:S3:1975:2	O
3	XIAFLEX.xml:S3:1978:1	O
mm	XIAFLEX.xml:S3:1980:2	O
in	XIAFLEX.xml:S3:1983:2	O
depth	XIAFLEX.xml:S3:1986:5	O
and	XIAFLEX.xml:S3:1992:3	O
avoid	XIAFLEX.xml:S3:1996:5	O
injecting	XIAFLEX.xml:S3:2002:9	O
more	XIAFLEX.xml:S3:2012:4	O
than	XIAFLEX.xml:S3:2017:4	O
4	XIAFLEX.xml:S3:2022:1	O
mm	XIAFLEX.xml:S3:2024:2	O
distal	XIAFLEX.xml:S3:2027:6	O
to	XIAFLEX.xml:S3:2034:2	O
the	XIAFLEX.xml:S3:2037:3	O
palmar	XIAFLEX.xml:S3:2041:6	O
digital	XIAFLEX.xml:S3:2048:7	O
crease	XIAFLEX.xml:S3:2056:6	O
[	XIAFLEX.xml:S3:2065:1	O
see	XIAFLEX.xml:S3:2066:3	O
Dosage	XIAFLEX.xml:S3:2070:6	O
and	XIAFLEX.xml:S3:2077:3	O
Administration	XIAFLEX.xml:S3:2081:14	O
(	XIAFLEX.xml:S3:2096:1	O
2.1	XIAFLEX.xml:S3:2097:3	O
)]	XIAFLEX.xml:S3:2100:2	O
.	XIAFLEX.xml:S3:2106:1	O

Other	XIAFLEX.xml:S3:2113:5	O
XIAFLEX	XIAFLEX.xml:S3:2119:7	O
-	XIAFLEX.xml:S3:2126:1	O
associated	XIAFLEX.xml:S3:2127:10	O
serious	XIAFLEX.xml:S3:2138:7	O
local	XIAFLEX.xml:S3:2146:5	O
adverse	XIAFLEX.xml:S3:2152:7	O
reactions	XIAFLEX.xml:S3:2160:9	O
included	XIAFLEX.xml:S3:2170:8	O
pulley	XIAFLEX.xml:S3:2179:6	B-AdverseReaction
rupture	XIAFLEX.xml:S3:2186:7	I-AdverseReaction
,	XIAFLEX.xml:S3:2193:1	O
ligament	XIAFLEX.xml:S3:2195:8	B-AdverseReaction
injury	XIAFLEX.xml:S3:2204:6	I-AdverseReaction
,	XIAFLEX.xml:S3:2210:1	O
complex	XIAFLEX.xml:S3:2212:7	B-AdverseReaction
regional	XIAFLEX.xml:S3:2220:8	I-AdverseReaction
pain	XIAFLEX.xml:S3:2229:4	I-AdverseReaction
syndrome	XIAFLEX.xml:S3:2234:8	I-AdverseReaction
(	XIAFLEX.xml:S3:2243:1	O
CRPS	XIAFLEX.xml:S3:2244:4	B-AdverseReaction
)	XIAFLEX.xml:S3:2248:1	O
,	XIAFLEX.xml:S3:2249:1	O
sensory	XIAFLEX.xml:S3:2251:7	B-AdverseReaction
abnormality	XIAFLEX.xml:S3:2259:11	I-AdverseReaction
of	XIAFLEX.xml:S3:2271:2	I-AdverseReaction
the	XIAFLEX.xml:S3:2274:3	I-AdverseReaction
hand	XIAFLEX.xml:S3:2278:4	I-AdverseReaction
,	XIAFLEX.xml:S3:2282:1	O
and	XIAFLEX.xml:S3:2284:3	O
skin	XIAFLEX.xml:S3:2288:4	B-AdverseReaction
laceration	XIAFLEX.xml:S3:2293:10	I-AdverseReaction
(	XIAFLEX.xml:S3:2304:1	O
tear	XIAFLEX.xml:S3:2305:4	I-AdverseReaction
)	XIAFLEX.xml:S3:2309:1	O
.	XIAFLEX.xml:S3:2310:1	O

In	XIAFLEX.xml:S3:2312:2	O
a	XIAFLEX.xml:S3:2315:1	O
historically	XIAFLEX.xml:S3:2317:12	O
controlled	XIAFLEX.xml:S3:2330:10	O
post	XIAFLEX.xml:S3:2341:4	O
-	XIAFLEX.xml:S3:2345:1	O
marketing	XIAFLEX.xml:S3:2346:9	O
trial	XIAFLEX.xml:S3:2356:5	O
,	XIAFLEX.xml:S3:2361:1	O
the	XIAFLEX.xml:S3:2363:3	O
incidence	XIAFLEX.xml:S3:2367:9	O
of	XIAFLEX.xml:S3:2377:2	O
skin	XIAFLEX.xml:S3:2380:4	B-AdverseReaction
laceration	XIAFLEX.xml:S3:2385:10	I-AdverseReaction
(	XIAFLEX.xml:S3:2396:1	O
22%	XIAFLEX.xml:S3:2397:3	O
)	XIAFLEX.xml:S3:2400:1	O
was	XIAFLEX.xml:S3:2402:3	O
higher	XIAFLEX.xml:S3:2406:6	O
for	XIAFLEX.xml:S3:2413:3	O
subjects	XIAFLEX.xml:S3:2417:8	O
treated	XIAFLEX.xml:S3:2426:7	O
with	XIAFLEX.xml:S3:2434:4	O
two	XIAFLEX.xml:S3:2439:3	O
concurrent	XIAFLEX.xml:S3:2443:10	O
injections	XIAFLEX.xml:S3:2454:10	O
of	XIAFLEX.xml:S3:2465:2	O
XIAFLEX	XIAFLEX.xml:S3:2468:7	O
compared	XIAFLEX.xml:S3:2476:8	O
with	XIAFLEX.xml:S3:2485:4	O
subjects	XIAFLEX.xml:S3:2490:8	O
treated	XIAFLEX.xml:S3:2499:7	O
with	XIAFLEX.xml:S3:2507:4	O
up	XIAFLEX.xml:S3:2512:2	O
to	XIAFLEX.xml:S3:2515:2	O
three	XIAFLEX.xml:S3:2518:5	O
single	XIAFLEX.xml:S3:2524:6	O
injections	XIAFLEX.xml:S3:2531:10	O
in	XIAFLEX.xml:S3:2542:2	O
the	XIAFLEX.xml:S3:2545:3	O
placebo	XIAFLEX.xml:S3:2549:7	O
-	XIAFLEX.xml:S3:2556:1	O
controlled	XIAFLEX.xml:S3:2557:10	O
premarketing	XIAFLEX.xml:S3:2568:12	O
trials	XIAFLEX.xml:S3:2581:6	O
(	XIAFLEX.xml:S3:2588:1	O
9%	XIAFLEX.xml:S3:2589:2	O
)	XIAFLEX.xml:S3:2591:1	O
.	XIAFLEX.xml:S3:2592:1	O

Cases	XIAFLEX.xml:S3:2594:5	O
of	XIAFLEX.xml:S3:2600:2	O
skin	XIAFLEX.xml:S3:2603:4	B-AdverseReaction
laceration	XIAFLEX.xml:S3:2608:10	I-AdverseReaction
requiring	XIAFLEX.xml:S3:2619:9	O
skin	XIAFLEX.xml:S3:2629:4	O
graft	XIAFLEX.xml:S3:2634:5	O
after	XIAFLEX.xml:S3:2640:5	O
finger	XIAFLEX.xml:S3:2646:6	O
extension	XIAFLEX.xml:S3:2653:9	O
procedures	XIAFLEX.xml:S3:2663:10	O
have	XIAFLEX.xml:S3:2674:4	O
been	XIAFLEX.xml:S3:2679:4	O
reported	XIAFLEX.xml:S3:2684:8	O
post	XIAFLEX.xml:S3:2693:4	O
-	XIAFLEX.xml:S3:2697:1	O
marketing	XIAFLEX.xml:S3:2698:9	O
.	XIAFLEX.xml:S3:2707:1	O

Signs	XIAFLEX.xml:S3:2709:5	O
or	XIAFLEX.xml:S3:2715:2	O
symptoms	XIAFLEX.xml:S3:2718:8	O
that	XIAFLEX.xml:S3:2727:4	O
may	XIAFLEX.xml:S3:2732:3	O
reflect	XIAFLEX.xml:S3:2736:7	O
serious	XIAFLEX.xml:S3:2744:7	O
injury	XIAFLEX.xml:S3:2752:6	O
to	XIAFLEX.xml:S3:2759:2	O
the	XIAFLEX.xml:S3:2762:3	O
injected	XIAFLEX.xml:S3:2766:8	O
finger	XIAFLEX.xml:S3:2775:6	O
hand	XIAFLEX.xml:S3:2782:4	O
should	XIAFLEX.xml:S3:2787:6	O
be	XIAFLEX.xml:S3:2794:2	O
promptly	XIAFLEX.xml:S3:2797:8	O
evaluated	XIAFLEX.xml:S3:2806:9	O
because	XIAFLEX.xml:S3:2816:7	O
surgical	XIAFLEX.xml:S3:2824:8	O
intervention	XIAFLEX.xml:S3:2833:12	O
may	XIAFLEX.xml:S3:2846:3	O
be	XIAFLEX.xml:S3:2850:2	O
required	XIAFLEX.xml:S3:2853:8	O
.	XIAFLEX.xml:S3:2861:1	O

5.2	XIAFLEX.xml:S3:2872:3	O
Corporal	XIAFLEX.xml:S3:2876:8	O
Rupture	XIAFLEX.xml:S3:2885:7	O
(	XIAFLEX.xml:S3:2893:1	O
Penile	XIAFLEX.xml:S3:2894:6	O
Fracture	XIAFLEX.xml:S3:2901:8	O
)	XIAFLEX.xml:S3:2909:1	O
or	XIAFLEX.xml:S3:2911:2	O
Other	XIAFLEX.xml:S3:2914:5	O
Serious	XIAFLEX.xml:S3:2920:7	O
Injury	XIAFLEX.xml:S3:2928:6	O
to	XIAFLEX.xml:S3:2935:2	O
the	XIAFLEX.xml:S3:2938:3	O
Penis	XIAFLEX.xml:S3:2942:5	O
in	XIAFLEX.xml:S3:2948:2	O
the	XIAFLEX.xml:S3:2951:3	O
Treatment	XIAFLEX.xml:S3:2955:9	O
of	XIAFLEX.xml:S3:2965:2	O
Peyronie	XIAFLEX.xml:S3:2968:8	O
's	XIAFLEX.xml:S3:2976:2	O
Disease	XIAFLEX.xml:S3:2979:7	O

Corporal	XIAFLEX.xml:S3:2992:8	B-AdverseReaction
rupture	XIAFLEX.xml:S3:3001:7	I-AdverseReaction
was	XIAFLEX.xml:S3:3009:3	O
reported	XIAFLEX.xml:S3:3013:8	O
as	XIAFLEX.xml:S3:3022:2	O
an	XIAFLEX.xml:S3:3025:2	O
adverse	XIAFLEX.xml:S3:3028:7	O
reaction	XIAFLEX.xml:S3:3036:8	O
after	XIAFLEX.xml:S3:3045:5	O
XIAFLEX	XIAFLEX.xml:S3:3051:7	O
injections	XIAFLEX.xml:S3:3059:10	O
in	XIAFLEX.xml:S3:3070:2	O
5	XIAFLEX.xml:S3:3073:1	O
of	XIAFLEX.xml:S3:3075:2	O
1044	XIAFLEX.xml:S3:3078:4	O
(	XIAFLEX.xml:S3:3083:1	O
0.5%	XIAFLEX.xml:S3:3084:4	O
)	XIAFLEX.xml:S3:3088:1	O
XIAFLEX	XIAFLEX.xml:S3:3090:7	O
treated	XIAFLEX.xml:S3:3098:7	O
patients	XIAFLEX.xml:S3:3106:8	O
in	XIAFLEX.xml:S3:3115:2	O
the	XIAFLEX.xml:S3:3118:3	O
controlled	XIAFLEX.xml:S3:3122:10	O
and	XIAFLEX.xml:S3:3133:3	O
uncontrolled	XIAFLEX.xml:S3:3137:12	O
clinical	XIAFLEX.xml:S3:3150:8	O
trials	XIAFLEX.xml:S3:3159:6	O
in	XIAFLEX.xml:S3:3166:2	O
Peyronie	XIAFLEX.xml:S3:3169:8	O
's	XIAFLEX.xml:S3:3177:2	O
disease	XIAFLEX.xml:S3:3180:7	O
.	XIAFLEX.xml:S3:3187:1	O

In	XIAFLEX.xml:S3:3193:2	O
other	XIAFLEX.xml:S3:3196:5	O
XIAFLEX	XIAFLEX.xml:S3:3202:7	O
-	XIAFLEX.xml:S3:3209:1	O
treated	XIAFLEX.xml:S3:3210:7	O
patients	XIAFLEX.xml:S3:3218:8	O
(	XIAFLEX.xml:S3:3227:1	O
9	XIAFLEX.xml:S3:3228:1	O
of	XIAFLEX.xml:S3:3230:2	O
1044	XIAFLEX.xml:S3:3233:4	O
;	XIAFLEX.xml:S3:3237:1	O
0.9%	XIAFLEX.xml:S3:3239:4	O
)	XIAFLEX.xml:S3:3243:1	O
,	XIAFLEX.xml:S3:3244:1	O
a	XIAFLEX.xml:S3:3246:1	O
combination	XIAFLEX.xml:S3:3248:11	O
of	XIAFLEX.xml:S3:3260:2	O
penile	XIAFLEX.xml:S3:3263:6	B-AdverseReaction
ecchymoses	XIAFLEX.xml:S3:3270:10	I-AdverseReaction
or	XIAFLEX.xml:S3:3281:2	O
hematoma	XIAFLEX.xml:S3:3284:8	I-AdverseReaction
,	XIAFLEX.xml:S3:3292:1	O
sudden	XIAFLEX.xml:S3:3294:6	O
penile	XIAFLEX.xml:S3:3301:6	B-AdverseReaction
detumescence	XIAFLEX.xml:S3:3308:12	I-AdverseReaction
,	XIAFLEX.xml:S3:3320:1	O
and	XIAFLEX.xml:S3:3322:3	O
or	XIAFLEX.xml:S3:3326:2	O
a	XIAFLEX.xml:S3:3329:1	O
penile	XIAFLEX.xml:S3:3331:6	B-AdverseReaction
"	XIAFLEX.xml:S3:3338:1	I-AdverseReaction
popping	XIAFLEX.xml:S3:3339:7	I-AdverseReaction
"	XIAFLEX.xml:S3:3346:1	I-AdverseReaction
sound	XIAFLEX.xml:S3:3348:5	I-AdverseReaction
or	XIAFLEX.xml:S3:3354:2	O
sensation	XIAFLEX.xml:S3:3357:9	I-AdverseReaction
was	XIAFLEX.xml:S3:3367:3	O
reported	XIAFLEX.xml:S3:3371:8	O
,	XIAFLEX.xml:S3:3379:1	O
and	XIAFLEX.xml:S3:3381:3	O
in	XIAFLEX.xml:S3:3385:2	O
these	XIAFLEX.xml:S3:3388:5	O
cases	XIAFLEX.xml:S3:3394:5	O
,	XIAFLEX.xml:S3:3399:1	O
a	XIAFLEX.xml:S3:3401:1	O
diagnosis	XIAFLEX.xml:S3:3403:9	O
of	XIAFLEX.xml:S3:3413:2	O
corporal	XIAFLEX.xml:S3:3416:8	B-AdverseReaction
rupture	XIAFLEX.xml:S3:3425:7	I-AdverseReaction
can	XIAFLEX.xml:S3:3433:3	B-Factor
not	XIAFLEX.xml:S3:3437:3	I-Factor
be	XIAFLEX.xml:S3:3441:2	I-Factor
excluded	XIAFLEX.xml:S3:3444:8	I-Factor
.	XIAFLEX.xml:S3:3452:1	O

These	XIAFLEX.xml:S3:3454:5	O
patients	XIAFLEX.xml:S3:3460:8	O
were	XIAFLEX.xml:S3:3469:4	O
managed	XIAFLEX.xml:S3:3474:7	O
without	XIAFLEX.xml:S3:3482:7	O
surgical	XIAFLEX.xml:S3:3490:8	O
intervention	XIAFLEX.xml:S3:3499:12	O
,	XIAFLEX.xml:S3:3511:1	O
but	XIAFLEX.xml:S3:3513:3	O
the	XIAFLEX.xml:S3:3517:3	O
long	XIAFLEX.xml:S3:3521:4	O
-	XIAFLEX.xml:S3:3525:1	O
term	XIAFLEX.xml:S3:3526:4	O
consequences	XIAFLEX.xml:S3:3531:12	O
are	XIAFLEX.xml:S3:3544:3	O
unknown	XIAFLEX.xml:S3:3548:7	O
.	XIAFLEX.xml:S3:3555:1	O

Severe	XIAFLEX.xml:S3:3561:6	B-Severity
penile	XIAFLEX.xml:S3:3568:6	B-AdverseReaction
hematoma	XIAFLEX.xml:S3:3575:8	I-AdverseReaction
was	XIAFLEX.xml:S3:3584:3	O
also	XIAFLEX.xml:S3:3588:4	O
reported	XIAFLEX.xml:S3:3593:8	O
as	XIAFLEX.xml:S3:3602:2	O
an	XIAFLEX.xml:S3:3605:2	O
adverse	XIAFLEX.xml:S3:3608:7	O
reaction	XIAFLEX.xml:S3:3616:8	O
in	XIAFLEX.xml:S3:3625:2	O
39	XIAFLEX.xml:S3:3628:2	O
of	XIAFLEX.xml:S3:3631:2	O
1044	XIAFLEX.xml:S3:3634:4	O
patients	XIAFLEX.xml:S3:3639:8	O
(	XIAFLEX.xml:S3:3648:1	O
3.7%	XIAFLEX.xml:S3:3649:4	O
)	XIAFLEX.xml:S3:3653:1	O
in	XIAFLEX.xml:S3:3655:2	O
the	XIAFLEX.xml:S3:3658:3	O
controlled	XIAFLEX.xml:S3:3662:10	O
and	XIAFLEX.xml:S3:3673:3	O
uncontrolled	XIAFLEX.xml:S3:3677:12	O
clinical	XIAFLEX.xml:S3:3690:8	O
trials	XIAFLEX.xml:S3:3699:6	O
in	XIAFLEX.xml:S3:3706:2	O
Peyronie	XIAFLEX.xml:S3:3709:8	O
's	XIAFLEX.xml:S3:3717:2	O
disease	XIAFLEX.xml:S3:3720:7	O
[	XIAFLEX.xml:S3:3728:1	O
see	XIAFLEX.xml:S3:3730:3	O
Adverse	XIAFLEX.xml:S3:3734:7	O
Reactions	XIAFLEX.xml:S3:3742:9	O
(	XIAFLEX.xml:S3:3752:1	O
6	XIAFLEX.xml:S3:3755:1	O
)	XIAFLEX.xml:S3:3758:1	O
]	XIAFLEX.xml:S3:3761:1	O
.	XIAFLEX.xml:S3:3762:1	O

Signs	XIAFLEX.xml:S3:3768:5	O
or	XIAFLEX.xml:S3:3774:2	O
symptoms	XIAFLEX.xml:S3:3777:8	O
that	XIAFLEX.xml:S3:3786:4	O
may	XIAFLEX.xml:S3:3791:3	O
reflect	XIAFLEX.xml:S3:3795:7	O
serious	XIAFLEX.xml:S3:3803:7	O
injury	XIAFLEX.xml:S3:3811:6	O
to	XIAFLEX.xml:S3:3818:2	O
the	XIAFLEX.xml:S3:3821:3	O
penis	XIAFLEX.xml:S3:3825:5	O
should	XIAFLEX.xml:S3:3831:6	O
be	XIAFLEX.xml:S3:3838:2	O
promptly	XIAFLEX.xml:S3:3841:8	O
evaluated	XIAFLEX.xml:S3:3850:9	O
in	XIAFLEX.xml:S3:3860:2	O
order	XIAFLEX.xml:S3:3863:5	O
to	XIAFLEX.xml:S3:3869:2	O
assess	XIAFLEX.xml:S3:3872:6	O
for	XIAFLEX.xml:S3:3879:3	O
corporal	XIAFLEX.xml:S3:3883:8	O
rupture	XIAFLEX.xml:S3:3892:7	O
or	XIAFLEX.xml:S3:3900:2	O
severe	XIAFLEX.xml:S3:3903:6	O
penile	XIAFLEX.xml:S3:3910:6	O
hematoma	XIAFLEX.xml:S3:3917:8	O
,	XIAFLEX.xml:S3:3925:1	O
which	XIAFLEX.xml:S3:3927:5	O
may	XIAFLEX.xml:S3:3933:3	O
require	XIAFLEX.xml:S3:3937:7	O
surgical	XIAFLEX.xml:S3:3945:8	O
intervention	XIAFLEX.xml:S3:3954:12	O
.	XIAFLEX.xml:S3:3966:1	O

Injection	XIAFLEX.xml:S3:3972:9	O
of	XIAFLEX.xml:S3:3982:2	O
XIAFLEX	XIAFLEX.xml:S3:3985:7	O
into	XIAFLEX.xml:S3:3993:4	O
collagen	XIAFLEX.xml:S3:3998:8	B-AdverseReaction
-	XIAFLEX.xml:S3:4006:1	I-AdverseReaction
containing	XIAFLEX.xml:S3:4007:10	I-AdverseReaction
structures	XIAFLEX.xml:S3:4018:10	I-AdverseReaction
such	XIAFLEX.xml:S3:4029:4	O
as	XIAFLEX.xml:S3:4034:2	O
the	XIAFLEX.xml:S3:4037:3	O
corpora	XIAFLEX.xml:S3:4041:7	B-AdverseReaction
cavernosa	XIAFLEX.xml:S3:4049:9	I-AdverseReaction
of	XIAFLEX.xml:S3:4059:2	I-AdverseReaction
the	XIAFLEX.xml:S3:4062:3	I-AdverseReaction
penis	XIAFLEX.xml:S3:4066:5	I-AdverseReaction
may	XIAFLEX.xml:S3:4072:3	B-Factor
result	XIAFLEX.xml:S3:4076:6	O
in	XIAFLEX.xml:S3:4083:2	O
damage	XIAFLEX.xml:S3:4086:6	I-AdverseReaction
to	XIAFLEX.xml:S3:4093:2	O
those	XIAFLEX.xml:S3:4096:5	O
structures	XIAFLEX.xml:S3:4102:10	O
and	XIAFLEX.xml:S3:4113:3	O
possible	XIAFLEX.xml:S3:4117:8	B-Factor
injury	XIAFLEX.xml:S3:4126:6	O
such	XIAFLEX.xml:S3:4133:4	O
as	XIAFLEX.xml:S3:4138:2	O
corporal	XIAFLEX.xml:S3:4141:8	B-AdverseReaction
rupture	XIAFLEX.xml:S3:4150:7	I-AdverseReaction
(	XIAFLEX.xml:S3:4158:1	O
penile	XIAFLEX.xml:S3:4159:6	B-AdverseReaction
fracture	XIAFLEX.xml:S3:4166:8	I-AdverseReaction
)	XIAFLEX.xml:S3:4174:1	O
.	XIAFLEX.xml:S3:4175:1	O

Therefore	XIAFLEX.xml:S3:4177:9	O
,	XIAFLEX.xml:S3:4186:1	O
XIAFLEX	XIAFLEX.xml:S3:4188:7	O
should	XIAFLEX.xml:S3:4196:6	O
be	XIAFLEX.xml:S3:4203:2	O
injected	XIAFLEX.xml:S3:4206:8	O
only	XIAFLEX.xml:S3:4215:4	O
into	XIAFLEX.xml:S3:4220:4	O
the	XIAFLEX.xml:S3:4225:3	O
Peyronie	XIAFLEX.xml:S3:4229:8	O
's	XIAFLEX.xml:S3:4237:2	O
plaque	XIAFLEX.xml:S3:4240:6	O
and	XIAFLEX.xml:S3:4247:3	O
care	XIAFLEX.xml:S3:4251:4	O
should	XIAFLEX.xml:S3:4256:6	O
be	XIAFLEX.xml:S3:4263:2	O
taken	XIAFLEX.xml:S3:4266:5	O
to	XIAFLEX.xml:S3:4272:2	O
avoid	XIAFLEX.xml:S3:4275:5	O
injecting	XIAFLEX.xml:S3:4281:9	O
into	XIAFLEX.xml:S3:4291:4	O
the	XIAFLEX.xml:S3:4296:3	O
urethra	XIAFLEX.xml:S3:4300:7	O
,	XIAFLEX.xml:S3:4307:1	O
nerves	XIAFLEX.xml:S3:4309:6	O
,	XIAFLEX.xml:S3:4315:1	O
blood	XIAFLEX.xml:S3:4317:5	O
vessels	XIAFLEX.xml:S3:4323:7	O
,	XIAFLEX.xml:S3:4330:1	O
corpora	XIAFLEX.xml:S3:4332:7	O
cavernosa	XIAFLEX.xml:S3:4340:9	O
or	XIAFLEX.xml:S3:4350:2	O
other	XIAFLEX.xml:S3:4353:5	O
collagen	XIAFLEX.xml:S3:4359:8	O
-	XIAFLEX.xml:S3:4367:1	O
containing	XIAFLEX.xml:S3:4368:10	O
structures	XIAFLEX.xml:S3:4379:10	O
of	XIAFLEX.xml:S3:4390:2	O
the	XIAFLEX.xml:S3:4393:3	O
penis	XIAFLEX.xml:S3:4397:5	O
.	XIAFLEX.xml:S3:4402:1	O

5.3	XIAFLEX.xml:S3:4411:3	O
XIAFLEX	XIAFLEX.xml:S3:4415:7	O
REMS	XIAFLEX.xml:S3:4423:4	O
Program	XIAFLEX.xml:S3:4428:7	O

Because	XIAFLEX.xml:S3:4441:7	O
of	XIAFLEX.xml:S3:4449:2	O
the	XIAFLEX.xml:S3:4452:3	O
risks	XIAFLEX.xml:S3:4456:5	O
of	XIAFLEX.xml:S3:4462:2	O
corporal	XIAFLEX.xml:S3:4465:8	O
rupture	XIAFLEX.xml:S3:4474:7	O
(	XIAFLEX.xml:S3:4482:1	O
penile	XIAFLEX.xml:S3:4483:6	O
fracture	XIAFLEX.xml:S3:4490:8	O
)	XIAFLEX.xml:S3:4498:1	O
or	XIAFLEX.xml:S3:4500:2	O
other	XIAFLEX.xml:S3:4503:5	O
serious	XIAFLEX.xml:S3:4509:7	O
penile	XIAFLEX.xml:S3:4517:6	O
injury	XIAFLEX.xml:S3:4524:6	O
in	XIAFLEX.xml:S3:4531:2	O
the	XIAFLEX.xml:S3:4534:3	O
treatment	XIAFLEX.xml:S3:4538:9	O
of	XIAFLEX.xml:S3:4548:2	O
Peyronie	XIAFLEX.xml:S3:4551:8	O
's	XIAFLEX.xml:S3:4559:2	O
disease	XIAFLEX.xml:S3:4562:7	O
,	XIAFLEX.xml:S3:4569:1	O
XIAFLEX	XIAFLEX.xml:S3:4571:7	O
is	XIAFLEX.xml:S3:4579:2	O
available	XIAFLEX.xml:S3:4582:9	O
only	XIAFLEX.xml:S3:4592:4	O
through	XIAFLEX.xml:S3:4597:7	O
the	XIAFLEX.xml:S3:4605:3	O
XIAFLEX	XIAFLEX.xml:S3:4609:7	O
REMS	XIAFLEX.xml:S3:4617:4	O
Program	XIAFLEX.xml:S3:4622:7	O
[	XIAFLEX.xml:S3:4635:1	O
see	XIAFLEX.xml:S3:4636:3	O
Warnings	XIAFLEX.xml:S3:4640:8	O
and	XIAFLEX.xml:S3:4649:3	O
Precautions	XIAFLEX.xml:S3:4653:11	O
(	XIAFLEX.xml:S3:4665:1	O
5.2	XIAFLEX.xml:S3:4666:3	O
)]	XIAFLEX.xml:S3:4669:2	O
.	XIAFLEX.xml:S3:4673:1	O

Required	XIAFLEX.xml:S3:4681:8	O
components	XIAFLEX.xml:S3:4690:10	O
of	XIAFLEX.xml:S3:4701:2	O
the	XIAFLEX.xml:S3:4704:3	O
XIAFLEX	XIAFLEX.xml:S3:4708:7	O
REMS	XIAFLEX.xml:S3:4716:4	O
Program	XIAFLEX.xml:S3:4721:7	O
include	XIAFLEX.xml:S3:4730:7	O
the	XIAFLEX.xml:S3:4738:3	O
following	XIAFLEX.xml:S3:4742:9	O
:	XIAFLEX.xml:S3:4751:1	O

Prescribers	XIAFLEX.xml:S3:4760:11	O
must	XIAFLEX.xml:S3:4772:4	O
be	XIAFLEX.xml:S3:4777:2	O
certified	XIAFLEX.xml:S3:4780:9	O
with	XIAFLEX.xml:S3:4790:4	O
the	XIAFLEX.xml:S3:4795:3	O
program	XIAFLEX.xml:S3:4799:7	O
by	XIAFLEX.xml:S3:4807:2	O
enrolling	XIAFLEX.xml:S3:4810:9	O
and	XIAFLEX.xml:S3:4820:3	O
completing	XIAFLEX.xml:S3:4824:10	O
training	XIAFLEX.xml:S3:4835:8	O
in	XIAFLEX.xml:S3:4844:2	O
the	XIAFLEX.xml:S3:4847:3	O
administration	XIAFLEX.xml:S3:4851:14	O
of	XIAFLEX.xml:S3:4866:2	O
XIAFLEX	XIAFLEX.xml:S3:4869:7	O
treatment	XIAFLEX.xml:S3:4877:9	O
for	XIAFLEX.xml:S3:4887:3	O
Peyronie	XIAFLEX.xml:S3:4891:8	O
's	XIAFLEX.xml:S3:4899:2	O
disease	XIAFLEX.xml:S3:4902:7	O
.	XIAFLEX.xml:S3:4909:1	O

Healthcare	XIAFLEX.xml:S3:4916:10	O
sites	XIAFLEX.xml:S3:4927:5	O
must	XIAFLEX.xml:S3:4933:4	O
be	XIAFLEX.xml:S3:4938:2	O
certified	XIAFLEX.xml:S3:4941:9	O
with	XIAFLEX.xml:S3:4951:4	O
the	XIAFLEX.xml:S3:4956:3	O
program	XIAFLEX.xml:S3:4960:7	O
and	XIAFLEX.xml:S3:4968:3	O
ensure	XIAFLEX.xml:S3:4972:6	O
that	XIAFLEX.xml:S3:4979:4	O
XIAFLEX	XIAFLEX.xml:S3:4984:7	O
is	XIAFLEX.xml:S3:4992:2	O
only	XIAFLEX.xml:S3:4995:4	O
dispensed	XIAFLEX.xml:S3:5000:9	O
for	XIAFLEX.xml:S3:5010:3	O
use	XIAFLEX.xml:S3:5014:3	O
by	XIAFLEX.xml:S3:5018:2	O
certified	XIAFLEX.xml:S3:5021:9	O
prescribers	XIAFLEX.xml:S3:5031:11	O
.	XIAFLEX.xml:S3:5042:1	O

Further	XIAFLEX.xml:S3:5049:7	O
information	XIAFLEX.xml:S3:5057:11	O
is	XIAFLEX.xml:S3:5069:2	O
available	XIAFLEX.xml:S3:5072:9	O
at	XIAFLEX.xml:S3:5082:2	O
www	XIAFLEX.xml:S3:5085:3	O
.	XIAFLEX.xml:S3:5088:1	O
XIAFLEXREMS	XIAFLEX.xml:S3:5089:11	O
.	XIAFLEX.xml:S3:5100:1	O
com	XIAFLEX.xml:S3:5101:3	O
or	XIAFLEX.xml:S3:5105:2	O
1	XIAFLEX.xml:S3:5108:1	O
-	XIAFLEX.xml:S3:5109:1	O
877	XIAFLEX.xml:S3:5110:3	O
-	XIAFLEX.xml:S3:5113:1	O
313	XIAFLEX.xml:S3:5114:3	O
-	XIAFLEX.xml:S3:5117:1	O
1235	XIAFLEX.xml:S3:5118:4	O
.	XIAFLEX.xml:S3:5122:1	O

5.4	XIAFLEX.xml:S3:5131:3	O

Hypersensitivity	XIAFLEX.xml:S3:5135:16	O
Reactions	XIAFLEX.xml:S3:5152:9	O
,	XIAFLEX.xml:S3:5161:1	O
Including	XIAFLEX.xml:S3:5163:9	O
Anaphylaxis	XIAFLEX.xml:S3:5173:11	O

In	XIAFLEX.xml:S3:5190:2	O
the	XIAFLEX.xml:S3:5193:3	O
controlled	XIAFLEX.xml:S3:5197:10	O
portions	XIAFLEX.xml:S3:5208:8	O
of	XIAFLEX.xml:S3:5217:2	O
the	XIAFLEX.xml:S3:5220:3	O
clinical	XIAFLEX.xml:S3:5224:8	O
trials	XIAFLEX.xml:S3:5233:6	O
in	XIAFLEX.xml:S3:5240:2	O
Dupuytren	XIAFLEX.xml:S3:5243:9	O
's	XIAFLEX.xml:S3:5252:2	O
contracture	XIAFLEX.xml:S3:5255:11	O
(	XIAFLEX.xml:S3:5267:1	O
Studies	XIAFLEX.xml:S3:5268:7	O
1	XIAFLEX.xml:S3:5276:1	O
and	XIAFLEX.xml:S3:5278:3	O
2	XIAFLEX.xml:S3:5282:1	O
)	XIAFLEX.xml:S3:5283:1	O
,	XIAFLEX.xml:S3:5284:1	O
a	XIAFLEX.xml:S3:5286:1	O
greater	XIAFLEX.xml:S3:5288:7	O
proportion	XIAFLEX.xml:S3:5296:10	O
of	XIAFLEX.xml:S3:5307:2	O
XIAFLEX	XIAFLEX.xml:S3:5310:7	O
-	XIAFLEX.xml:S3:5317:1	O
treated	XIAFLEX.xml:S3:5318:7	O
patients	XIAFLEX.xml:S3:5326:8	O
(	XIAFLEX.xml:S3:5335:1	O
15%	XIAFLEX.xml:S3:5336:3	O
)	XIAFLEX.xml:S3:5339:1	O
compared	XIAFLEX.xml:S3:5341:8	O
to	XIAFLEX.xml:S3:5350:2	O
placebo	XIAFLEX.xml:S3:5353:7	O
-	XIAFLEX.xml:S3:5360:1	O
treated	XIAFLEX.xml:S3:5361:7	O
patients	XIAFLEX.xml:S3:5369:8	O
(	XIAFLEX.xml:S3:5378:1	O
1%	XIAFLEX.xml:S3:5379:2	O
)	XIAFLEX.xml:S3:5381:1	O
had	XIAFLEX.xml:S3:5383:3	O
mild	XIAFLEX.xml:S3:5387:4	B-Severity
allergic	XIAFLEX.xml:S3:5392:8	B-AdverseReaction
reactions	XIAFLEX.xml:S3:5401:9	I-AdverseReaction
(	XIAFLEX.xml:S3:5411:1	O
pruritus	XIAFLEX.xml:S3:5412:8	B-AdverseReaction
)	XIAFLEX.xml:S3:5420:1	O
after	XIAFLEX.xml:S3:5422:5	O
up	XIAFLEX.xml:S3:5428:2	O
to	XIAFLEX.xml:S3:5431:2	O
3	XIAFLEX.xml:S3:5434:1	O
injections	XIAFLEX.xml:S3:5436:10	O
.	XIAFLEX.xml:S3:5446:1	O

The	XIAFLEX.xml:S3:5448:3	O
incidence	XIAFLEX.xml:S3:5452:9	O
of	XIAFLEX.xml:S3:5462:2	O
XIAFLEX	XIAFLEX.xml:S3:5465:7	O
-	XIAFLEX.xml:S3:5472:1	O
associated	XIAFLEX.xml:S3:5473:10	O
pruritus	XIAFLEX.xml:S3:5484:8	B-AdverseReaction
increased	XIAFLEX.xml:S3:5493:9	O
after	XIAFLEX.xml:S3:5503:5	O
more	XIAFLEX.xml:S3:5509:4	O
XIAFLEX	XIAFLEX.xml:S3:5514:7	O
injections	XIAFLEX.xml:S3:5522:10	O
in	XIAFLEX.xml:S3:5533:2	O
patients	XIAFLEX.xml:S3:5536:8	O
with	XIAFLEX.xml:S3:5545:4	O
Dupuytren	XIAFLEX.xml:S3:5550:9	O
's	XIAFLEX.xml:S3:5559:2	O
contracture	XIAFLEX.xml:S3:5562:11	O
.	XIAFLEX.xml:S3:5573:1	O

In	XIAFLEX.xml:S3:5580:2	O
the	XIAFLEX.xml:S3:5583:3	O
double	XIAFLEX.xml:S3:5587:6	O
-	XIAFLEX.xml:S3:5593:1	O
blind	XIAFLEX.xml:S3:5594:5	O
,	XIAFLEX.xml:S3:5599:1	O
placebo	XIAFLEX.xml:S3:5601:7	O
-	XIAFLEX.xml:S3:5608:1	O
controlled	XIAFLEX.xml:S3:5609:10	O
portions	XIAFLEX.xml:S3:5620:8	O
of	XIAFLEX.xml:S3:5629:2	O
the	XIAFLEX.xml:S3:5632:3	O
clinical	XIAFLEX.xml:S3:5636:8	O
trials	XIAFLEX.xml:S3:5645:6	O
in	XIAFLEX.xml:S3:5652:2	O
Peyronie	XIAFLEX.xml:S3:5655:8	O
's	XIAFLEX.xml:S3:5663:2	O
disease	XIAFLEX.xml:S3:5666:7	O
(	XIAFLEX.xml:S3:5674:1	O
Studies	XIAFLEX.xml:S3:5675:7	O
1	XIAFLEX.xml:S3:5683:1	O
and	XIAFLEX.xml:S3:5685:3	O
2	XIAFLEX.xml:S3:5689:1	O
)	XIAFLEX.xml:S3:5690:1	O
,	XIAFLEX.xml:S3:5691:1	O
a	XIAFLEX.xml:S3:5693:1	O
greater	XIAFLEX.xml:S3:5695:7	O
proportion	XIAFLEX.xml:S3:5703:10	O
of	XIAFLEX.xml:S3:5714:2	O
XIAFLEX	XIAFLEX.xml:S3:5717:7	O
-	XIAFLEX.xml:S3:5724:1	O
treated	XIAFLEX.xml:S3:5725:7	O
patients	XIAFLEX.xml:S3:5733:8	O
(	XIAFLEX.xml:S3:5742:1	O
4%	XIAFLEX.xml:S3:5743:2	O
)	XIAFLEX.xml:S3:5745:1	O
compared	XIAFLEX.xml:S3:5747:8	O
to	XIAFLEX.xml:S3:5756:2	O
placebo	XIAFLEX.xml:S3:5759:7	O
-	XIAFLEX.xml:S3:5766:1	O
treated	XIAFLEX.xml:S3:5767:7	O
patients	XIAFLEX.xml:S3:5775:8	O
(	XIAFLEX.xml:S3:5784:1	O
1%	XIAFLEX.xml:S3:5785:2	O
)	XIAFLEX.xml:S3:5787:1	O
had	XIAFLEX.xml:S3:5789:3	O
localized	XIAFLEX.xml:S3:5793:9	B-AdverseReaction
pruritus	XIAFLEX.xml:S3:5803:8	I-AdverseReaction
after	XIAFLEX.xml:S3:5812:5	O
up	XIAFLEX.xml:S3:5818:2	O
to	XIAFLEX.xml:S3:5821:2	O
4	XIAFLEX.xml:S3:5824:1	O
treatment	XIAFLEX.xml:S3:5826:9	O
cycles	XIAFLEX.xml:S3:5836:6	O
(	XIAFLEX.xml:S3:5843:1	O
involving	XIAFLEX.xml:S3:5844:9	O
up	XIAFLEX.xml:S3:5854:2	O
to	XIAFLEX.xml:S3:5857:2	O
8	XIAFLEX.xml:S3:5860:1	O
XIAFLEX	XIAFLEX.xml:S3:5862:7	O
injection	XIAFLEX.xml:S3:5870:9	O
procedures	XIAFLEX.xml:S3:5880:10	O
)	XIAFLEX.xml:S3:5890:1	O
.	XIAFLEX.xml:S3:5891:1	O

The	XIAFLEX.xml:S3:5893:3	O
incidence	XIAFLEX.xml:S3:5897:9	O
of	XIAFLEX.xml:S3:5907:2	O
XIAFLEX	XIAFLEX.xml:S3:5910:7	O
-	XIAFLEX.xml:S3:5917:1	O
associated	XIAFLEX.xml:S3:5918:10	O
pruritus	XIAFLEX.xml:S3:5929:8	B-AdverseReaction
was	XIAFLEX.xml:S3:5938:3	O
similar	XIAFLEX.xml:S3:5942:7	O
after	XIAFLEX.xml:S3:5950:5	O
each	XIAFLEX.xml:S3:5956:4	O
injection	XIAFLEX.xml:S3:5961:9	O
regardless	XIAFLEX.xml:S3:5971:10	O
of	XIAFLEX.xml:S3:5982:2	O
the	XIAFLEX.xml:S3:5985:3	O
number	XIAFLEX.xml:S3:5989:6	O
of	XIAFLEX.xml:S3:5996:2	O
injections	XIAFLEX.xml:S3:5999:10	O
administered	XIAFLEX.xml:S3:6010:12	O
.	XIAFLEX.xml:S3:6022:1	O

Because	XIAFLEX.xml:S3:6031:7	O
XIAFLEX	XIAFLEX.xml:S3:6039:7	O
contains	XIAFLEX.xml:S3:6047:8	O
foreign	XIAFLEX.xml:S3:6056:7	O
proteins	XIAFLEX.xml:S3:6064:8	O
,	XIAFLEX.xml:S3:6072:1	O
severe	XIAFLEX.xml:S3:6074:6	B-Severity
allergic	XIAFLEX.xml:S3:6081:8	B-AdverseReaction
reactions	XIAFLEX.xml:S3:6090:9	I-AdverseReaction
to	XIAFLEX.xml:S3:6100:2	O
XIAFLEX	XIAFLEX.xml:S3:6103:7	O
can	XIAFLEX.xml:S3:6111:3	B-Factor
occur	XIAFLEX.xml:S3:6115:5	O
.	XIAFLEX.xml:S3:6120:1	O

Anaphylaxis	XIAFLEX.xml:S3:6122:11	B-AdverseReaction
was	XIAFLEX.xml:S3:6134:3	O
reported	XIAFLEX.xml:S3:6138:8	O
in	XIAFLEX.xml:S3:6147:2	O
a	XIAFLEX.xml:S3:6150:1	O
post	XIAFLEX.xml:S3:6152:4	O
-	XIAFLEX.xml:S3:6156:1	O
marketing	XIAFLEX.xml:S3:6157:9	O
clinical	XIAFLEX.xml:S3:6167:8	O
trial	XIAFLEX.xml:S3:6176:5	O
(	XIAFLEX.xml:S3:6182:1	O
Study	XIAFLEX.xml:S3:6183:5	O
3	XIAFLEX.xml:S3:6189:1	O
)	XIAFLEX.xml:S3:6190:1	O
in	XIAFLEX.xml:S3:6192:2	O
one	XIAFLEX.xml:S3:6195:3	O
patient	XIAFLEX.xml:S3:6199:7	O
who	XIAFLEX.xml:S3:6207:3	O
had	XIAFLEX.xml:S3:6211:3	O
previous	XIAFLEX.xml:S3:6215:8	O
exposure	XIAFLEX.xml:S3:6224:8	O
to	XIAFLEX.xml:S3:6233:2	O
XIAFLEX	XIAFLEX.xml:S3:6236:7	O
for	XIAFLEX.xml:S3:6244:3	O
the	XIAFLEX.xml:S3:6248:3	O
treatment	XIAFLEX.xml:S3:6252:9	O
of	XIAFLEX.xml:S3:6262:2	O
Dupuytren	XIAFLEX.xml:S3:6265:9	O
's	XIAFLEX.xml:S3:6274:2	O
contracture	XIAFLEX.xml:S3:6277:11	O
.	XIAFLEX.xml:S3:6288:1	O

Some	XIAFLEX.xml:S3:6290:4	O
patients	XIAFLEX.xml:S3:6295:8	O
with	XIAFLEX.xml:S3:6304:4	O
Dupuytren	XIAFLEX.xml:S3:6309:9	O
's	XIAFLEX.xml:S3:6318:2	O
contracture	XIAFLEX.xml:S3:6321:11	O
developed	XIAFLEX.xml:S3:6333:9	O
IgE	XIAFLEX.xml:S3:6343:3	O
-	XIAFLEX.xml:S3:6346:1	O
anti	XIAFLEX.xml:S3:6347:4	O
-	XIAFLEX.xml:S3:6351:1	O
drug	XIAFLEX.xml:S3:6352:4	O
antibodies	XIAFLEX.xml:S3:6357:10	O
in	XIAFLEX.xml:S3:6368:2	O
greater	XIAFLEX.xml:S3:6371:7	O
proportions	XIAFLEX.xml:S3:6379:11	O
and	XIAFLEX.xml:S3:6391:3	O
higher	XIAFLEX.xml:S3:6395:6	O
titers	XIAFLEX.xml:S3:6402:6	O
with	XIAFLEX.xml:S3:6409:4	O
successive	XIAFLEX.xml:S3:6414:10	O
XIAFLEX	XIAFLEX.xml:S3:6425:7	O
injections	XIAFLEX.xml:S3:6433:10	O
.	XIAFLEX.xml:S3:6443:1	O

Healthcare	XIAFLEX.xml:S3:6445:10	O
providers	XIAFLEX.xml:S3:6456:9	O
should	XIAFLEX.xml:S3:6466:6	O
be	XIAFLEX.xml:S3:6473:2	O
prepared	XIAFLEX.xml:S3:6476:8	O
to	XIAFLEX.xml:S3:6485:2	O
address	XIAFLEX.xml:S3:6488:7	O
severe	XIAFLEX.xml:S3:6496:6	O
allergic	XIAFLEX.xml:S3:6503:8	O
reactions	XIAFLEX.xml:S3:6512:9	O
following	XIAFLEX.xml:S3:6522:9	O
XIAFLEX	XIAFLEX.xml:S3:6532:7	O
injections	XIAFLEX.xml:S3:6540:10	O
.	XIAFLEX.xml:S3:6550:1	O

5.5	XIAFLEX.xml:S3:6561:3	O
Risk	XIAFLEX.xml:S3:6565:4	O
of	XIAFLEX.xml:S3:6570:2	O
bleeding	XIAFLEX.xml:S3:6573:8	O
in	XIAFLEX.xml:S3:6582:2	O
Patients	XIAFLEX.xml:S3:6585:8	O
with	XIAFLEX.xml:S3:6594:4	O
Abnormal	XIAFLEX.xml:S3:6599:8	O
Coagulation	XIAFLEX.xml:S3:6608:11	O

In	XIAFLEX.xml:S3:6625:2	O
the	XIAFLEX.xml:S3:6628:3	O
XIAFLEX	XIAFLEX.xml:S3:6632:7	O
trials	XIAFLEX.xml:S3:6640:6	O
in	XIAFLEX.xml:S3:6647:2	O
Dupuytren	XIAFLEX.xml:S3:6650:9	O
's	XIAFLEX.xml:S3:6659:2	O
contracture	XIAFLEX.xml:S3:6662:11	O
(	XIAFLEX.xml:S3:6674:1	O
Studies	XIAFLEX.xml:S3:6675:7	O
1	XIAFLEX.xml:S3:6683:1	O
and	XIAFLEX.xml:S3:6685:3	O
2	XIAFLEX.xml:S3:6689:1	O
)	XIAFLEX.xml:S3:6690:1	O
,	XIAFLEX.xml:S3:6691:1	O
70%	XIAFLEX.xml:S3:6693:3	O
and	XIAFLEX.xml:S3:6697:3	O
38%	XIAFLEX.xml:S3:6701:3	O
of	XIAFLEX.xml:S3:6705:2	O
XIAFLEX	XIAFLEX.xml:S3:6708:7	O
-	XIAFLEX.xml:S3:6715:1	O
treated	XIAFLEX.xml:S3:6716:7	O
patients	XIAFLEX.xml:S3:6724:8	O
developed	XIAFLEX.xml:S3:6733:9	O
an	XIAFLEX.xml:S3:6743:2	O
ecchymosis	XIAFLEX.xml:S3:6746:10	B-AdverseReaction
contusion	XIAFLEX.xml:S3:6757:9	B-AdverseReaction
or	XIAFLEX.xml:S3:6767:2	O
an	XIAFLEX.xml:S3:6770:2	O
injection	XIAFLEX.xml:S3:6773:9	B-AdverseReaction
site	XIAFLEX.xml:S3:6783:4	I-AdverseReaction
hemorrhage	XIAFLEX.xml:S3:6788:10	I-AdverseReaction
,	XIAFLEX.xml:S3:6798:1	O
respectively	XIAFLEX.xml:S3:6800:12	O
(	XIAFLEX.xml:S3:6813:1	O
see	XIAFLEX.xml:S3:6814:3	O
Table	XIAFLEX.xml:S3:6818:5	O
3	XIAFLEX.xml:S3:6824:1	O
)	XIAFLEX.xml:S3:6825:1	O
.	XIAFLEX.xml:S3:6826:1	O

In	XIAFLEX.xml:S3:6828:2	O
the	XIAFLEX.xml:S3:6831:3	O
XIAFLEX	XIAFLEX.xml:S3:6835:7	O
controlled	XIAFLEX.xml:S3:6843:10	O
trials	XIAFLEX.xml:S3:6854:6	O
in	XIAFLEX.xml:S3:6861:2	O
Peyronie	XIAFLEX.xml:S3:6864:8	O
's	XIAFLEX.xml:S3:6872:2	O
disease	XIAFLEX.xml:S3:6875:7	O
(	XIAFLEX.xml:S3:6883:1	O
Studies	XIAFLEX.xml:S3:6884:7	O
1	XIAFLEX.xml:S3:6892:1	O
and	XIAFLEX.xml:S3:6894:3	O
2	XIAFLEX.xml:S3:6898:1	O
)	XIAFLEX.xml:S3:6899:1	O
,	XIAFLEX.xml:S3:6900:1	O
65.5%	XIAFLEX.xml:S3:6902:5	O
of	XIAFLEX.xml:S3:6908:2	O
XIAFLEX	XIAFLEX.xml:S3:6911:7	O
-	XIAFLEX.xml:S3:6918:1	O
treated	XIAFLEX.xml:S3:6919:7	O
patients	XIAFLEX.xml:S3:6927:8	O
developed	XIAFLEX.xml:S3:6936:9	O
penile	XIAFLEX.xml:S3:6946:6	B-AdverseReaction
hematoma	XIAFLEX.xml:S3:6953:8	I-AdverseReaction
,	XIAFLEX.xml:S3:6961:1	O
and	XIAFLEX.xml:S3:6963:3	O
14.5%	XIAFLEX.xml:S3:6967:5	O
developed	XIAFLEX.xml:S3:6973:9	O
penile	XIAFLEX.xml:S3:6983:6	B-AdverseReaction
ecchymosis	XIAFLEX.xml:S3:6990:10	I-AdverseReaction
(	XIAFLEX.xml:S3:7001:1	O
see	XIAFLEX.xml:S3:7002:3	O
Table	XIAFLEX.xml:S3:7006:5	O
4	XIAFLEX.xml:S3:7012:1	O
)	XIAFLEX.xml:S3:7013:1	O
.	XIAFLEX.xml:S3:7014:1	O

Patients	XIAFLEX.xml:S3:7016:8	O
with	XIAFLEX.xml:S3:7025:4	O
abnormal	XIAFLEX.xml:S3:7030:8	O
coagulation	XIAFLEX.xml:S3:7039:11	O
(	XIAFLEX.xml:S3:7051:1	O
except	XIAFLEX.xml:S3:7052:6	O
for	XIAFLEX.xml:S3:7059:3	O
patients	XIAFLEX.xml:S3:7063:8	O
taking	XIAFLEX.xml:S3:7072:6	O
low	XIAFLEX.xml:S3:7079:3	O
-	XIAFLEX.xml:S3:7082:1	O
dose	XIAFLEX.xml:S3:7083:4	O
aspirin	XIAFLEX.xml:S3:7088:7	O
,	XIAFLEX.xml:S3:7095:1	O
e	XIAFLEX.xml:S3:7097:1	O
.	XIAFLEX.xml:S3:7098:1	O
g	XIAFLEX.xml:S3:7099:1	O
.	XIAFLEX.xml:S3:7100:1	O
,	XIAFLEX.xml:S3:7101:1	O
up	XIAFLEX.xml:S3:7103:2	O
to	XIAFLEX.xml:S3:7106:2	O
150	XIAFLEX.xml:S3:7109:3	O
mg	XIAFLEX.xml:S3:7113:2	O
per	XIAFLEX.xml:S3:7116:3	O
day	XIAFLEX.xml:S3:7120:3	O
)	XIAFLEX.xml:S3:7123:1	O
were	XIAFLEX.xml:S3:7125:4	O
excluded	XIAFLEX.xml:S3:7130:8	O
from	XIAFLEX.xml:S3:7139:4	O
participating	XIAFLEX.xml:S3:7144:13	O
in	XIAFLEX.xml:S3:7158:2	O
these	XIAFLEX.xml:S3:7161:5	O
studies	XIAFLEX.xml:S3:7167:7	O
.	XIAFLEX.xml:S3:7174:1	O

Therefore	XIAFLEX.xml:S3:7180:9	O
,	XIAFLEX.xml:S3:7189:1	O
the	XIAFLEX.xml:S3:7191:3	O
efficacy	XIAFLEX.xml:S3:7195:8	O
and	XIAFLEX.xml:S3:7204:3	O
safety	XIAFLEX.xml:S3:7208:6	O
of	XIAFLEX.xml:S3:7215:2	O
XIAFLEX	XIAFLEX.xml:S3:7218:7	O
in	XIAFLEX.xml:S3:7226:2	O
patients	XIAFLEX.xml:S3:7229:8	O
receiving	XIAFLEX.xml:S3:7238:9	O
anticoagulant	XIAFLEX.xml:S3:7248:13	O
medications	XIAFLEX.xml:S3:7262:11	O
(	XIAFLEX.xml:S3:7274:1	O
other	XIAFLEX.xml:S3:7275:5	O
than	XIAFLEX.xml:S3:7281:4	O
low	XIAFLEX.xml:S3:7286:3	O
-	XIAFLEX.xml:S3:7289:1	O
dose	XIAFLEX.xml:S3:7290:4	O
aspirin	XIAFLEX.xml:S3:7295:7	O
,	XIAFLEX.xml:S3:7302:1	O
e	XIAFLEX.xml:S3:7304:1	O
.	XIAFLEX.xml:S3:7305:1	O
g	XIAFLEX.xml:S3:7306:1	O
.	XIAFLEX.xml:S3:7307:1	O
,	XIAFLEX.xml:S3:7308:1	O
up	XIAFLEX.xml:S3:7310:2	O
to	XIAFLEX.xml:S3:7313:2	O
150	XIAFLEX.xml:S3:7316:3	O
mg	XIAFLEX.xml:S3:7320:2	O
per	XIAFLEX.xml:S3:7323:3	O
day	XIAFLEX.xml:S3:7327:3	O
)	XIAFLEX.xml:S3:7330:1	O
within	XIAFLEX.xml:S3:7332:6	O
7	XIAFLEX.xml:S3:7339:1	O
days	XIAFLEX.xml:S3:7341:4	O
prior	XIAFLEX.xml:S3:7346:5	O
to	XIAFLEX.xml:S3:7352:2	O
XIAFLEX	XIAFLEX.xml:S3:7355:7	O
administration	XIAFLEX.xml:S3:7363:14	O
is	XIAFLEX.xml:S3:7378:2	O
not	XIAFLEX.xml:S3:7381:3	O
known	XIAFLEX.xml:S3:7385:5	O
.	XIAFLEX.xml:S3:7390:1	O

In	XIAFLEX.xml:S3:7392:2	O
addition	XIAFLEX.xml:S3:7395:8	O
,	XIAFLEX.xml:S3:7403:1	O
it	XIAFLEX.xml:S3:7405:2	O
is	XIAFLEX.xml:S3:7408:2	O
recommended	XIAFLEX.xml:S3:7411:11	O
to	XIAFLEX.xml:S3:7423:2	O
avoid	XIAFLEX.xml:S3:7426:5	O
use	XIAFLEX.xml:S3:7432:3	O
of	XIAFLEX.xml:S3:7436:2	O
XIAFLEX	XIAFLEX.xml:S3:7439:7	O
in	XIAFLEX.xml:S3:7447:2	O
patients	XIAFLEX.xml:S3:7450:8	O
with	XIAFLEX.xml:S3:7459:4	O
coagulation	XIAFLEX.xml:S3:7464:11	O
disorders	XIAFLEX.xml:S3:7476:9	O
,	XIAFLEX.xml:S3:7485:1	O
including	XIAFLEX.xml:S3:7487:9	O
patients	XIAFLEX.xml:S3:7497:8	O
receiving	XIAFLEX.xml:S3:7506:9	O
concomitant	XIAFLEX.xml:S3:7516:11	O
anticoagulants	XIAFLEX.xml:S3:7528:14	O
(	XIAFLEX.xml:S3:7543:1	O
except	XIAFLEX.xml:S3:7544:6	O
for	XIAFLEX.xml:S3:7551:3	O
low	XIAFLEX.xml:S3:7555:3	O
-	XIAFLEX.xml:S3:7558:1	O
dose	XIAFLEX.xml:S3:7559:4	O
aspirin	XIAFLEX.xml:S3:7564:7	O
)	XIAFLEX.xml:S3:7571:1	O
.	XIAFLEX.xml:S3:7572:1	O
